Liraglutide Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 8, 2026

The clinical evidence base for Liraglutide comprises 943 peer-reviewed publications across 15 journals, 92 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2, Obesity, Diabetes Mellitus, and Diabetes Mellitus, Type 1. Most recent publication: Response to Comment on Nathan et al. Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial. Diabetes Care 2024;47:2155-2163., Diabetes Care, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Wexler DJ, de Boer IH, Ghosh A, et al. · JAMA Intern Med · 2023
PubMed: PMID 37213109 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U, et al. · JAMA · 2022
PubMed: PMID 35015037 · NCT04074161 (STEP 8) · Obesity
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Rodriguez LA, Finertie H, Neugebauer RS, et al. · Lancet Reg Health Am · 2024
PubMed: PMID 38745886 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.
Neugebauer R, An J, Dombrowski SK, et al. · JAMA Netw Open · 2025
PubMed: PMID 41091469 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial.
Luchsinger JA, Rosin SP, Kazemi EJ, et al. · JAMA Intern Med · 2025
PubMed: PMID 40388190 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM, et al. · Lancet · 2022
PubMed: PMID 34798060 · NCT03856047 · Obesity
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
GRADE Study Research Group, Nathan DM, Lachin JM, et al. · N Engl J Med · 2022
PubMed: PMID 36129997 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
Fox CK, Barrientos-Pérez M, Bomberg EM, et al. · N Engl J Med · 2025
PubMed: PMID 39258838 · NCT04775082 · Obesity

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT00294723 LEAD-3	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104 week 0, week 104	Glimepiride	-0.28 percentage point of total HbA1c (±0.09 Standard Error)
			Lira 1.2	-0.59 percentage point of total HbA1c (±0.09 Standard Error)
			Lira 1.8	-0.88 percentage point of total HbA1c (±0.09 Standard Error)
NCT00294723 LEAD-3	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156 week 0, week 156	Glimepiride	-0.16 percentage point of total HbA1c (±0.08 Standard Error)
			Lira 1.2	-0.44 percentage point of total HbA1c (±0.09 Standard Error)
			Lira 1.8	-0.71 percentage point of total HbA1c (±0.09 Standard Error)
NCT00294723 LEAD-3	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 week 0, week 52	Glimepiride	-0.51 percentage point of total HbA1c (±0.08 Standard Error)
			Lira 1.2	-0.84 percentage point of total HbA1c (±0.08 Standard Error)
			Lira 1.8	-1.14 percentage point of total HbA1c (±0.08 Standard Error)
NCT00318461 LEAD-2	Diabetes Mellitus, Type 2	Change in Glycosylated A1c (HbA1c) at Week 104 week 0, week 104	Lira 0.6 + Met	-0.36 percentage of total haemoglobin (±0.08 Standard Error)
			Lira 1.2 + Met	-0.56 percentage of total haemoglobin (±0.08 Standard Error)
			Lira 1.8 + Met	-0.58 percentage of total haemoglobin (±0.08 Standard Error)
			Met + Glim	-0.50 percentage of total haemoglobin (±0.08 Standard Error)
			Met Mono	0.25 percentage of total haemoglobin (±0.10 Standard Error)
NCT00318461 LEAD-2	Diabetes Mellitus, Type 2	Change in Glycosylated A1c (HbA1c) at Week 26 week 0, week 26	Lira 0.6 + Met	-0.69 Percentage point of total HbA1c (±0.07 Standard Error)
			Lira 1.2 + Met	-0.97 Percentage point of total HbA1c (±0.07 Standard Error)
			Lira 1.8 + Met	-1.00 Percentage point of total HbA1c (±0.07 Standard Error)
			Met + Glim	-0.98 Percentage point of total HbA1c (±0.07 Standard Error)
			Met Mono	0.09 Percentage point of total HbA1c (±0.09 Standard Error)
NCT00393718	Diabetes Mellitus, Type 2	Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment after 24 weeks of treatment	Glibenclamide	7.50 percentage of total haemoglobin (±0.09 Standard Error)
NCT00393718	Diabetes Mellitus, Type 2		Liraglutide	6.99 percentage of total haemoglobin (±0.07 Standard Error)
NCT00395746	Diabetes Mellitus, Type 2	Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment after 24 weeks of treatment	0.6 mg + SU	7.02 percentage of total haemoglobin (±0.10 Standard Error)
			0.9 mg + SU	6.75 percentage of total haemoglobin (±0.11 Standard Error)
			SU Mono	8.02 percentage of total haemoglobin (±0.10 Standard Error)
NCT00518882 LEAD-6	Diabetes Mellitus, Type 2	Change in Glycosylated A1c (HbA1c) at Week 26 week 0, week 26	Exenatide -> Liraglutide -> Liraglutide	-0.79 percentage point of total HbA1c (±0.08 Standard Error)
NCT00518882 LEAD-6	Diabetes Mellitus, Type 2		Liraglutide -> Liraglutide -> Liraglutide	-1.12 percentage point of total HbA1c (±0.08 Standard Error)
NCT00614120	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin A1c (HbA1c) week 0, week 16	Glim + Met	-1.3 percentage point of total HbA1c (±0.98 Standard Deviation)
			Lira 0.6 + Met	-1.0 percentage point of total HbA1c (±1.04 Standard Deviation)
			Lira 1.2 + Met	-1.3 percentage point of total HbA1c (±1.09 Standard Deviation)
			Lira 1.8 + Met	-1.4 percentage point of total HbA1c (±1.23 Standard Deviation)
NCT00620282	Diabetes Mellitus, Type 2	Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF) week 0, week 12	Glimepiride	2.164 mL/100 mL/min (±2.568 Standard Error)
			Lira 1.8	4.244 mL/100 mL/min (±2.551 Standard Error)
			Placebo	-3.187 mL/100 mL/min (±2.758 Standard Error)
NCT00700817	Diabetes Mellitus, Type 2	Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26 Week 0, Week 26	Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg	-1.24 Percentage point of total HbA1c (±0.07 Standard Error)
			Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg	-1.5 Percentage point of total HbA1c (±0.06 Standard Error)
			Sita -> Sita	-0.9 Percentage point of total HbA1c (±0.07 Standard Error)
NCT00700817	Diabetes Mellitus, Type 2	Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 Week 0, Week 52	Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg	-1.29 Percentage point of total HbA1c (±0.07 Standard Error)
			Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg	-1.51 Percentage point of total HbA1c (±0.07 Standard Error)
			Sita -> Sita	-0.88 Percentage point of total HbA1c (±0.07 Standard Error)
NCT00700817	Diabetes Mellitus, Type 2	Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78 Week 0, Week 78	Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg	-0.94 Percentage point of total HbA1c (±0.08 Standard Error)
NCT00700817	Diabetes Mellitus, Type 2		Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg	-1.28 Percentage point of total HbA1c (±0.07 Standard Error)
NCT00700817	Diabetes Mellitus, Type 2	Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78 Week 52, Week 78	Sita -> Sita -> Lira 1.2 mg	-0.24 Percentage point of total HbA1c (±0.7 Standard Deviation)
NCT00700817	Diabetes Mellitus, Type 2		Sita -> Sita -> Lira 1.8 mg	-0.45 Percentage point of total HbA1c (±0.9 Standard Deviation)
NCT00781937	Obesity	Mean Percentage Change in Fasting Body Weight From Baseline Week 0, week 56	Lira 3.0 mg	-6.11 percentage (±0.66 Standard Error)
NCT00781937	Obesity		Placebo	-0.05 percentage (±0.63 Standard Error)
NCT00781937	Obesity	Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 Week 0, week 56	Lira 3.0 mg	50.5 percentage of subjects
NCT00781937	Obesity		Placebo	21.9 percentage of subjects
NCT00781937	Obesity	Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 Week 0, week 56	Lira 3.0 mg	80.8 percentage of subjects
NCT00781937	Obesity		Placebo	47.9 percentage of subjects
NCT00856986	Diabetes Mellitus, Type 2	Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. Week 0 (Randomisation), week 26	Insulin Detemir + Lira 1.8	-0.51 Percentage point of total HbA1c (±0.07 Standard Error)
NCT00856986	Diabetes Mellitus, Type 2		Lira 1.8	0.02 Percentage point of total HbA1c (±0.07 Standard Error)
NCT01029886	Diabetes Mellitus, Type 2	Change in HbA1c From Baseline to Week 26 Baseline, Week 26	Exenatide Once Weekly	-1.28 percentage of total hemoglobin (±0.05 Standard Error)
NCT01029886	Diabetes Mellitus, Type 2	Change in HbA1c From Baseline to Week 26 Baseline, Week 26	Liraglutide Once Daily	-1.48 percentage of total hemoglobin (±0.05 Standard Error)
NCT01128894	Diabetes Mellitus, Type 2	Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32 Baseline and Week 32	Albiglutide 50 mg	-0.78 Percentage of HbA1c in the blood (±0.047 Standard Error)
NCT01128894	Diabetes Mellitus, Type 2		Liraglutide 1.8 mg	-0.99 Percentage of HbA1c in the blood (±0.046 Standard Error)
NCT01179048 LEADER®	Diabetes Mellitus, Type 2	Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)	Liraglutide	13.0 percentage of subjects
NCT01179048 LEADER®	Diabetes Mellitus, Type 2		Placebo	14.9 percentage of subjects
NCT01234649	Diabetes Mellitus, Type 2	Insulin Secretion-Sensitivity Index (IS-SI) 84 weeks of treatment	Metformin XR Plus Liraglutide	418.4 index (±387 Standard Deviation)
NCT01234649	Diabetes Mellitus, Type 2		Metformin XR Plus Placebo	333 index (±206 Standard Deviation)
NCT01272219	Obesity	Change From Baseline in Fasting Body Weight Week 0, Week 56	Liraglutide 3.0 mg (56-Week)	-7.98 percent change (±6.67 Standard Deviation)
NCT01272219	Obesity	Change From Baseline in Fasting Body Weight Week 0, Week 56	Liraglutide Placebo (56-Week)	-2.62 percent change (±5.74 Standard Deviation)
NCT01272219	Obesity	Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight. At Week 56	Liraglutide 3.0 mg (56-Week)	63.2 percentage of subjects
NCT01272219	Obesity		Liraglutide Placebo (56-Week)	27.1 percentage of subjects
NCT01272219	Obesity	Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight At 56 weeks	Liraglutide 3.0 mg (56-Week)	33.1 percentage of subjects
NCT01272219	Obesity		Liraglutide Placebo (56-Week)	10.6 percentage of subjects
NCT01272219	Obesity	Proportion of Subjects With Onset of Type 2 Diabetes At 160 weeks	Liraglutide 3.0 mg (160-Week)	26 Subject
NCT01272219	Obesity		Liraglutide Placebo (160-Week)	46 Subject
NCT01272232	Obesity	Change (%) From Baseline in Body Weight (Fasting) Week 0, week 56	Liraglutide 1.8 mg	-4.6 percent change (±5.5 Standard Deviation)
			Liraglutide 1.8 mg	-3.6 percent change (±5.7 Standard Deviation)
			Liraglutide 3.0 mg	-5.9 percent change (±5.5 Standard Deviation)
			Liraglutide 3.0 mg	-4.7 percent change (±5.0 Standard Deviation)
			Liraglutide Placebo	-2.0 percent change (±4.3 Standard Deviation)
			Liraglutide Placebo	-2.7 percent change (±5.8 Standard Deviation)
NCT01272232	Obesity	Proportion of Subjects Losing at Least 5% of Baseline Body Weight at 56 weeks	Liraglutide 1.8 mg	35.6 percentage of subjects
			Liraglutide 1.8 mg	64.4 percentage of subjects
			Liraglutide 3.0 mg	50.1 percentage of subjects
			Liraglutide 3.0 mg	49.9 percentage of subjects
			Liraglutide Placebo	13.8 percentage of subjects
			Liraglutide Placebo	86.2 percentage of subjects
NCT01272232	Obesity	Proportion of Subjects Losing More Than 10% of Baseline Body Weight at 56 weeks	Liraglutide 1.8 mg	85.6 percentage of subjects
			Liraglutide 1.8 mg	14.4 percentage of subjects
			Liraglutide 3.0 mg	76.6 percentage of subjects
			Liraglutide 3.0 mg	23.4 percentage of subjects
			Liraglutide Placebo	4.3 percentage of subjects
			Liraglutide Placebo	95.7 percentage of subjects
NCT01296412	Diabetes Mellitus, Type 2	Change From Baseline in Hemoglobin A1c (A1C) Baseline and Week 26	Liraglutide	-1.42 percent (±1.04 95% Confidence Interval)
NCT01296412	Diabetes Mellitus, Type 2		Sitagliptin +/- Glimepiride	-1.32 percent (±1.06 95% Confidence Interval)
NCT01336023 DUAL™ I	Diabetes Mellitus, Type 2	Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. Week 0, week 26	IDeg	-1.44 Percentage of glycosylated haemoglobin (±1.03 Standard Deviation)
			IDegLira	-1.91 Percentage of glycosylated haemoglobin (±1.07 Standard Deviation)
			Liraglutide	-1.28 Percentage of glycosylated haemoglobin (±1.13 Standard Deviation)
NCT01388361 BEGIN™	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) week 0, week 26	IDeg	0.10 percentage of glycosylated haemoglobin (±0.40 Standard Deviation)
			IDeg + IAsp OD	-0.39 percentage of glycosylated haemoglobin (±0.72 Standard Deviation)
			IDeg + Liraglutide	-0.74 percentage of glycosylated haemoglobin (±0.73 Standard Deviation)
NCT01392573 DUAL™ II	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c (Glycosylated Haemoglobin) Week 0, week 26	IDeg	-0.89 percentage of glycosylated haemoglobin (±1.18 Standard Deviation)
NCT01392573 DUAL™ II	Diabetes Mellitus, Type 2		IDegLira	-1.90 percentage of glycosylated haemoglobin (±1.09 Standard Deviation)
NCT01512108	Diabetes Mellitus, Type 2	Incidence of Treatment Emergent Adverse Events (AEs) Week 0 to Week 52 + 7 days	Additional OAD	2 Events/100 years of patient exposure
			Additional OAD	9 Events/100 years of patient exposure
			Additional OAD	9 Events/100 years of patient exposure
			Additional OAD	321 Events/100 years of patient exposure
			Additional OAD	331 Events/100 years of patient exposure
			Liraglutide 0.9 mg/Day	345 Events/100 years of patient exposure
			Liraglutide 0.9 mg/Day	14 Events/100 years of patient exposure
			Liraglutide 0.9 mg/Day	361 Events/100 years of patient exposure
			Liraglutide 0.9 mg/Day	5 Events/100 years of patient exposure
			Liraglutide 0.9 mg/Day	2 Events/100 years of patient exposure
NCT01541215 Ellipse™	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) Week 0, week 26	Liraglutide 1.8 mg	-0.643 Percentage of HbA1c (±0.215 Standard Error)
NCT01541215 Ellipse™	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) Week 0, week 26	Placebo	0.415 Percentage of HbA1c (±0.216 Standard Error)
NCT01557166	Obesity	Change From Baseline in Apnoea-hypopnoea Index (AHI) Week 0, Week 32	Liraglutide 3.0 mg	-12.22 events/hour (±23.34 Standard Deviation)
NCT01557166	Obesity		Placebo	-6.08 events/hour (±25.90 Standard Deviation)
NCT01558271	Diabetes Mellitus, Type 2	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks Baseline, 26 weeks	Liraglutide	-1.33 percentage of HbA1c (±0.07 Standard Error)
			LY2189265	-1.43 percentage of HbA1c (±0.05 Standard Error)
			Placebo	0.14 percentage of HbA1c (±0.10 Standard Error)
NCT01572740	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16 Week 0, Week 16	Lira + Insulin	-1.73 percentage of glycosylated haemoglobin (±0.06 Standard Error)
NCT01572740	Diabetes Mellitus, Type 2		Placebo + Insulin	-0.43 percentage of glycosylated haemoglobin (±0.06 Standard Error)
NCT01617434	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 Week 0 to Week 26	Liraglutide	-1.30 percentage of glycosylated haemoglobin (±1.015 Standard Deviation)
NCT01617434	Diabetes Mellitus, Type 2		Placebo	-0.11 percentage of glycosylated haemoglobin (±1.088 Standard Deviation)
NCT01618162 DUAL™IV	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) Week 0, Week 26	IDegLira	-1.45 percentage of glycosylated haemoglobin (±0.84 Standard Deviation)
NCT01618162 DUAL™IV	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) Week 0, Week 26	Placebo	-0.46 percentage of glycosylated haemoglobin (±0.83 Standard Deviation)
NCT01620489	Diabetes Mellitus, Type 2	Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) Week 0, Week 26	Lira 1.8 mg	-1.05 percentage (%) (±0.8944 Standard Deviation)
NCT01620489	Diabetes Mellitus, Type 2		Placebo	-0.38 percentage (%) (±0.8797 Standard Deviation)
NCT01624259 AWARD-6	Diabetes Mellitus, Type 2	Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) Baseline, 26 Weeks	1.5 mg LY2189265	-1.42 percentage of glycosylated hemoglobin (±0.05 Standard Error)
NCT01624259 AWARD-6	Diabetes Mellitus, Type 2		1.8 mg Liraglutide	-1.36 percentage of glycosylated hemoglobin (±0.05 Standard Error)
NCT01664247	Diabetes Mellitus, Type 2	Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) Week 0, week 26	IDeg	-0.99 percentage of glycosylated haemoglobin (±0.08 Standard Error)
NCT01664247	Diabetes Mellitus, Type 2		Placebo	-0.07 percentage of glycosylated haemoglobin (±0.08 Standard Error)
NCT01676116 DUAL™ III	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2) Week 0, week 26	Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs)	-1.32 percentage of glycosylated haemoglobin (±0.05 Standard Error)
NCT01676116 DUAL™ III	Diabetes Mellitus, Type 2		Liraglutide or Exenatide + OADs	-0.37 percentage of glycosylated haemoglobin (±0.07 Standard Error)
NCT01722240 1966	Diabetes Mellitus, Type 1	HbA1c (%) 52 Weeks	Liraglutide	7.45 Percent of Hemoglobin (%) (±0.12 Standard Error)
			Liraglutide	7.92 Percent of Hemoglobin (%) (±0.15 Standard Error)
			Placebo	7.48 Percent of Hemoglobin (%) (±0.18 Standard Error)
			Placebo	7.58 Percent of Hemoglobin (%) (±0.14 Standard Error)
NCT01722266	Diabetes Mellitus, Type 1	Change in Mean Weekly Glucose Concentrations 12 Weeks	Liraglutide 0.6 mg	-0.3 mg/dl (±2 Standard Error)
			Liraglutide 1.2mg	-10 mg/dl (±2 Standard Error)
			Liraglutide 1.8mg	-10 mg/dl (±1 Standard Error)
			Placebo	1 mg/dl (±0 Standard Error)
NCT01733758	Diabetes Mellitus, Type 2	Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24 Baseline and Week 24	Albiglutide 30 mg Weekly	8.06 Percentage of HbA1c in the blood (±0.783 Standard Deviation)
			Albiglutide 30 mg Weekly	6.98 Percentage of HbA1c in the blood (±0.735 Standard Deviation)
			Albiglutide 30 mg Weekly	-1.08 Percentage of HbA1c in the blood (±0.619 Standard Deviation)
			Albiglutide 50 mg Weekly	-1.32 Percentage of HbA1c in the blood (±0.702 Standard Deviation)
			Albiglutide 50 mg Weekly	8.15 Percentage of HbA1c in the blood (±0.825 Standard Deviation)
			Albiglutide 50 mg Weekly	6.83 Percentage of HbA1c in the blood (±0.659 Standard Deviation)
			Open-Label Liraglutide 0.9 mg Daily	6.87 Percentage of HbA1c in the blood (±0.642 Standard Deviation)
			Open-Label Liraglutide 0.9 mg Daily	-1.19 Percentage of HbA1c in the blood (±0.636 Standard Deviation)
			Open-Label Liraglutide 0.9 mg Daily	8.07 Percentage of HbA1c in the blood (±0.787 Standard Deviation)
			Placebo	8.16 Percentage of HbA1c in the blood (±0.877 Standard Deviation)
			Placebo	8.39 Percentage of HbA1c in the blood (±1.066 Standard Deviation)
			Placebo	0.24 Percentage of HbA1c in the blood (±0.715 Standard Deviation)
NCT01733758	Diabetes Mellitus, Type 2	Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 Baseline and Week 24	Albiglutide 30 mg Weekly	-1.10 Percentage of HbA1c in the blood (±0.047 Standard Error)
			Albiglutide 50 mg Weekly	-1.30 Percentage of HbA1c in the blood (±0.049 Standard Error)
			Placebo	0.25 Percentage of HbA1c in the blood (±0.068 Standard Error)
NCT01753362	Diabetes Mellitus, Type 1	HbA1c 26 weeks	Liraglutide	7.94 percent (±1.05 Standard Deviation)
			Liraglutide	7.60 percent (±0.98 Standard Deviation)
			Placebo	7.64 percent (±0.84 Standard Deviation)
			Placebo	7.77 percent (±0.83 Standard Deviation)
NCT01779362 RISE Adult	Diabetes Mellitus, Type 2	Insulin Sensitivity, M/I 3-months after a medication washout	Glargine Followed by Metformin	3.38 x 10-5 mmol/kg/min per pmol/L
			Liraglutide + Metformin	3.49 x 10-5 mmol/kg/min per pmol/L
			Metformin Alone	3.53 x 10-5 mmol/kg/min per pmol/L
			Placebo	3.63 x 10-5 mmol/kg/min per pmol/L
NCT01779362 RISE Adult	Diabetes Mellitus, Type 2	ß-cell Response Measured by Hyperglycemic Clamp 3-months after medication washout (Month 15)	Glargine Followed by Metformin	3.58 nmol/L
			Glargine Followed by Metformin	4.32 nmol/L
			Liraglutide + Metformin	4.58 nmol/L
			Liraglutide + Metformin	3.73 nmol/L
			Metformin Alone	3.65 nmol/L
			Metformin Alone	4.61 nmol/L
			Placebo	4.45 nmol/L
			Placebo	3.60 nmol/L
NCT01784965	Glucose Intolerance	Change in Weight Reported at 14 Weeks Baseline and 14 weeks	Liraglutide	-6.8 kg
NCT01784965	Glucose Intolerance	Change in Weight Reported at 14 Weeks Baseline and 14 weeks	Placebo	-3.3 kg
NCT01794143 GRADE	Diabetes Mellitus, Type 2	HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication Quarterly, 4-7 years	Glargine Insulin U-100	852 Participants
			Glimepiride	908 Participants
			Liraglutide	860 Participants
			Sitagliptin	981 Participants
NCT01794143 GRADE	Diabetes Mellitus, Type 2	Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication Quarterly for 4 to 7 years	Glargine Insulin U-100	1.3 years
			Glimepiride	1.3 years
			Liraglutide	1.5 years
			Sitagliptin	0.8 years
NCT01836523 ADJUNCT ONE™	Diabetes Mellitus	Change From Baseline in Body Weight Week 0, week 52	Liraglutide 0.6 mg	-1.34 kg (±4.183 Standard Deviation)
			Liraglutide 1.2 mg	-2.73 kg (±4.524 Standard Deviation)
			Liraglutide 1.8 mg	-4.02 kg (±4.873 Standard Deviation)
			Placebo	0.94 kg (±3.828 Standard Deviation)
NCT01836523 ADJUNCT ONE™	Diabetes Mellitus	Change From Baseline in HbA1c (Glycosylated Haemoglobin) Week 0, week 52	Liraglutide 0.6 mg	-0.45 percentage of glycosylated haemoglobin (±0.741 Standard Deviation)
			Liraglutide 1.2 mg	-0.50 percentage of glycosylated haemoglobin (±0.767 Standard Deviation)
			Liraglutide 1.8 mg	-0.54 percentage of glycosylated haemoglobin (±0.729 Standard Deviation)
			Placebo	-0.34 percentage of glycosylated haemoglobin (±0.707 Standard Deviation)
NCT01836523 ADJUNCT ONE™	Diabetes Mellitus	Change From Baseline in Total Daily Insulin Dose Week 0, week 52	Liraglutide 0.6 mg	1.04 ratio (±23.75 Geometric Coefficient of Variation)
			Liraglutide 1.2 mg	0.98 ratio (±26.66 Geometric Coefficient of Variation)
			Liraglutide 1.8 mg	0.95 ratio (±24.21 Geometric Coefficient of Variation)
			Placebo	1.04 ratio (±26.69 Geometric Coefficient of Variation)
NCT01847313	Diabetes Mellitus	MCP-1:Creatinine Ratio in Urine Up to 26 weeks	Control	24.3 ng/mmol (±15.4 Standard Deviation)
NCT01847313	Diabetes Mellitus	MCP-1:Creatinine Ratio in Urine Up to 26 weeks	Liraglutide	27.9 ng/mmol (±14.3 Standard Deviation)
NCT01937598	Diabetes Mellitus, Type 2	Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC) 0 to 300 min post mixed meal test	Placebo	5557 [mg*min/dL] (±547 Standard Error)
NCT01937598	Diabetes Mellitus, Type 2		Sitagliptin	5678 [mg*min/dL] (±329 Standard Error)
NCT01952145 DUAL™ V	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c (Glycosylated Haemoglobin) Week 0, week 26	Insulin Degludec/Liraglutide (IDegLira)	-1.81 Percentage (%) (±1.08 Standard Deviation)
NCT01952145 DUAL™ V	Diabetes Mellitus, Type 2		Insulin Glargine (IGlar)	-1.13 Percentage (%) (±0.98 Standard Deviation)
NCT02098395 ADJUNCT TWO™	Diabetes Mellitus	Change From Baseline in Glycosylated Haemoglobin (HbA1c) Week 0, Week 26	Liraglutide 0.6 mg	-0.23 Percent (%) glycosylated haemoglobin (±0.744 Standard Deviation)
			Liraglutide 1.2 mg	-0.23 Percent (%) glycosylated haemoglobin (±0.731 Standard Deviation)
			Liraglutide 1.8 mg	-0.32 Percent (%) glycosylated haemoglobin (±0.73 Standard Deviation)
			Liraglutide Placebo	0.01 Percent (%) glycosylated haemoglobin (±0.674 Standard Deviation)
NCT02100475 DUAL™	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c (Glycosylated Haemoglobin) Week 0, week 26	IDegLira	-0.43 Percentage of glycosylated haemoglobin (±0.94 Standard Deviation)
NCT02100475 DUAL™	Diabetes Mellitus, Type 2		IDegLira + IAsp	-0.14 Percentage of glycosylated haemoglobin (±1.09 Standard Deviation)
NCT02298192 DUAL™ VI	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c Week 0, week 32	IDegLira	-2.02 percentage (±0.98 Standard Deviation)
NCT02298192 DUAL™ VI	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c Week 0, week 32	IDegLira (1WT)	-2.01 percentage (±1.09 Standard Deviation)
NCT02420262	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) Week 0, Week 26	IDegLira	-1.48 Percentage of glycosylated haemoglobin (±0.05 Standard Error)
NCT02420262	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) Week 0, Week 26	IGlar + IAsp	-1.46 Percentage of glycosylated haemoglobin (±0.05 Standard Error)
NCT02501161 DUAL™ VIII	Diabetes Mellitus, Type 2	Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification Weeks 0-104 + 7 days follow-up-1 + 30 days follow-up-2	Insulin Degludec/Liraglutide	NA Weeks
			Insulin Degludec/Liraglutide	104.0 Weeks
			Insulin Degludec/Liraglutide	NA Weeks
			Insulin Degludec/Liraglutide	106.7 Weeks
			Insulin Glargine	104.3 Weeks
			Insulin Glargine	26.6 Weeks
			Insulin Glargine	64.6 Weeks
			Insulin Glargine	90.3 Weeks
NCT02505334	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) (Week 26) Week 0, Week 26	Liraglutide 0.9 mg	0.17 Percentage (%) of HbA1c (±0.06 Standard Error)
NCT02505334	Diabetes Mellitus, Type 2		Liraglutide 1.8 mg	-0.23 Percentage (%) of HbA1c (±0.06 Standard Error)
NCT02516657	Diabetes Mellitus, Type 1	Mean Weekly Blood Glucose Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;	Liraglutide 0.6 mg	178 mg/dL (±42 Standard Deviation)
NCT02516657	Diabetes Mellitus, Type 1		Liraglutide 0.6 mg	187 mg/dL (±35 Standard Deviation)
NCT02518945	Diabetes Mellitus, Type 1	Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. 12 weeks	Active Drugs	-0.66 % HbA1c (±0.1 Standard Error)
NCT02518945	Diabetes Mellitus, Type 1		Placebo	0 % HbA1c (±0.2 Standard Error)
NCT02527200	Obesity	Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks Week 0, Week 16	Part A: Liraglutide	-0.18 SDS score (±0.21 Standard Deviation)
			Part A: Placebo	-0.18 SDS score (±0.23 Standard Deviation)
			Part A+B: Liraglutide	-0.33 SDS score (±0.49 Standard Deviation)
			Part A+B: Placebo	-0.29 SDS score (±0.32 Standard Deviation)
			Part B: Liraglutide	-0.50 SDS score (±0.65 Standard Deviation)
			Part B: Placebo	-0.48 SDS score (±0.39 Standard Deviation)
NCT02527200	Obesity	Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks Week 0, Week 52	Part A: Liraglutide	-0.27 SDS score (±0.37 Standard Deviation)
			Part A: Placebo	-0.13 SDS score (±0.25 Standard Deviation)
			Part A+B: Liraglutide	-0.50 SDS score (±0.88 Standard Deviation)
			Part A+B: Placebo	-0.36 SDS score (±0.53 Standard Deviation)
			Part B: Liraglutide	-0.79 SDS score (±1.21 Standard Deviation)
			Part B: Placebo	-0.71 SDS score (±0.68 Standard Deviation)
NCT02607306 DUAL™ I Japan	Diabetes Mellitus, Type 2	Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira Week 0, Week 52	Insulin Degludec	-1.80 Percentage of HbA1c (±1.02 Standard Deviation)
			Insulin Degludec/Liraglutide	-2.42 Percentage of HbA1c (±1.04 Standard Deviation)
			Liraglutide	-1.80 Percentage of HbA1c (±0.92 Standard Deviation)
NCT02773368 DUALTM IX	Diabetes Mellitus, Type 2	Change in HbA1c (Glycosylated Haemoglobin) Week 0, Week 26	IDegLira	8.20 Percentage of glycosylated haemoglobin (±0.93 Standard Deviation)
			IDegLira	-1.94 Percentage of glycosylated haemoglobin (±0.95 Standard Deviation)
			IGlar	8.36 Percentage of glycosylated haemoglobin (±1.08 Standard Deviation)
			IGlar	-1.68 Percentage of glycosylated haemoglobin (±1.05 Standard Deviation)
NCT02787551 LixiLan-G	Diabetes Mellitus, Type 2	Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period Baseline, Week 26	GLP-1 Receptor Agonist	-0.38 percentage of HbA1c (±0.048 Standard Error)
NCT02787551 LixiLan-G	Diabetes Mellitus, Type 2		Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)	-1.02 percentage of HbA1c (±0.048 Standard Error)
NCT02787551 LixiLan-G	Diabetes Mellitus, Type 2	Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period Baseline, Week 52	Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)	-1.01 percentage of HbA1c (±0.063 Standard Error)
NCT02863419 PIONEER 4	Diabetes Mellitus, Type 2	Change in HbA1c (Week 26) Week 0, week 26	Liraglutide 1.8 mg	-1.2 Percentage of HbA1c (±0.9 Standard Deviation)
			Liraglutide 1.8 mg	-1.1 Percentage of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.2 Percentage of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.4 Percentage of HbA1c (±0.9 Standard Deviation)
			Placebo	-0.1 Percentage of HbA1c (±0.7 Standard Deviation)
			Placebo	-0.1 Percentage of HbA1c (±0.7 Standard Deviation)
NCT02889510	Diabetes Mellitus, Type 2	Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) 7 weeks	Liraglutide	4.1 % (FEV1)
NCT02889510	Diabetes Mellitus, Type 2		Placebo	4.3 % (FEV1)
NCT02911948 DUAL™ II Japan	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) week 0, week 26	Insulin Degludec	-0.65 Percentage of HbA1c (±0.98 Standard Deviation)
NCT02911948 DUAL™ II Japan	Diabetes Mellitus, Type 2	Change in Glycosylated Haemoglobin (HbA1c) week 0, week 26	Insulin Degludec/Liraglutide	-1.95 Percentage of HbA1c (±1.01 Standard Deviation)
NCT02918279	Obesity	Change in BMI SDS (Week 0, Week 56) Week 0, week 56	Liraglutide 3.0 mg	-0.25 SDS score (±0.51 Standard Deviation)
NCT02918279	Obesity	Change in BMI SDS (Week 0, Week 56) Week 0, week 56	Placebo	-0.02 SDS score (±0.54 Standard Deviation)
NCT02963922 SCALE™ Insulin	Obesity	Change in Body Weight (%) Week 0, week 56	Liraglutide 3.0 mg	-6.0 Percentage change (±6.0 Standard Deviation)
			Liraglutide 3.0 mg	-6.5 Percentage change (±5.8 Standard Deviation)
			Placebo	-1.7 Percentage change (±5.2 Standard Deviation)
			Placebo	-1.5 Percentage change (±5.4 Standard Deviation)
NCT02963922 SCALE™ Insulin	Obesity	Participants Losing at Least 5% of Baseline Body Weight Week 56	Liraglutide 3.0 mg	56.92 Percentage of participants
			Liraglutide 3.0 mg	51.80 Percentage of participants
			Placebo	21.83 Percentage of participants
			Placebo	23.98 Percentage of participants
NCT02963935 SCALE™ IBT	Obesity	Change in Body Weight (%) Week 0, week 56	Liraglutide 3.0 mg	-7.4 percent change (±7.9 Standard Deviation)
			Liraglutide 3.0 mg	-9.1 percent change (±7.4 Standard Deviation)
			Placebo	-4.8 percent change (±7.6 Standard Deviation)
			Placebo	-4.0 percent change (±7.4 Standard Deviation)
NCT02963935 SCALE™ IBT	Obesity	Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56 Week 56	Liraglutide 3.0 mg	61.47 percentage of participants
			Liraglutide 3.0 mg	64.08 percentage of participants
			Placebo	38.57 percentage of participants
			Placebo	38.82 percentage of participants
NCT02964247	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, Week 26	Liraglutide	-1.00 Percentage of HbA1c (±0.86 Standard Deviation)
			Liraglutide	-1.05 Percentage of HbA1c (±0.85 Standard Deviation)
			Placebo	-0.35 Percentage of HbA1c (±0.80 Standard Deviation)
			Placebo	-0.32 Percentage of HbA1c (±0.83 Standard Deviation)
NCT03018028 PIONEER 9	Diabetes Mellitus, Type 2	Change in HbA1c (Week 26) Week 0, week 26	Liraglutide 0.9 mg	-1.4 Percentage point of HbA1c (±1.1 Standard Deviation)
			Liraglutide 0.9 mg	-1.4 Percentage point of HbA1c (±1.1 Standard Deviation)
			Oral Semaglutide 14 mg	-1.7 Percentage point of HbA1c (±0.9 Standard Deviation)
			Oral Semaglutide 14 mg	-1.7 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 3 mg	-1.1 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 3 mg	-1.1 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 7 mg	-1.7 Percentage point of HbA1c (±0.8 Standard Deviation)
			Oral Semaglutide 7 mg	-1.6 Percentage point of HbA1c (±0.8 Standard Deviation)
			Placebo	-0.2 Percentage point of HbA1c (±0.7 Standard Deviation)
			Placebo	-0.4 Percentage point of HbA1c (±1.0 Standard Deviation)
NCT03172494 DUAL™ I China	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 26	Insulin Degludec	-1.20 Percentage points of HbA1c (±0.99 Standard Deviation)
			Insulin Degludec/Liraglutide	-1.71 Percentage points of HbA1c (±0.88 Standard Deviation)
			Liraglutide	-1.16 Percentage points of HbA1c (±0.89 Standard Deviation)
NCT03175120 DUAL™ II China	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 26	Insulin Degludec	-1.06 Percentage point of HbA1c (±1.19 Standard Deviation)
NCT03175120 DUAL™ II China	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 26	Insulin Degludec/Liraglutide	-1.93 Percentage point of HbA1c (±1.14 Standard Deviation)
NCT03191396 SUSTAIN 10	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 30	Liraglutide 1.2 mg	-1.1 Percentage of glycosylated haemoglobin (±1.0 Standard Deviation)
NCT03191396 SUSTAIN 10	Diabetes Mellitus, Type 2	Change in HbA1c Week 0, week 30	Semaglutide 1.0 mg	-1.7 Percentage of glycosylated haemoglobin (±0.9 Standard Deviation)
NCT03279731 BELIEVE	Binge-Eating Disorder	Binge Episodes baseline and 17 weeks (or last observation carried forward)	Liraglutide	-3.97 objective binge episodes per week (±0.56 Standard Deviation)
NCT03279731 BELIEVE	Binge-Eating Disorder		Placebo	-2.50 objective binge episodes per week (±.053 Standard Deviation)
NCT03374956	Obesity	Change in Total Body Weight baseline to 12 weeks	Control Group	-6.5 percent change
NCT03374956	Obesity	Change in Total Body Weight baseline to 12 weeks	Intervention Group	-7.7 percent change
NCT03480022 SAXAPCOS	Weight Loss	Absolute Body Weight (BW) 32 weeks of treatment	Liraglutide Pen Injector (Saxenda)	104.7 kilogram (±2.9 Standard Error)
NCT03480022 SAXAPCOS	Weight Loss	Absolute Body Weight (BW) 32 weeks of treatment	Placebo Liraglutide Pen Injector	117.9 kilogram (±5 Standard Error)
NCT03480022 SAXAPCOS	Weight Loss	Free Androgen Index (FAI) 32 weeks of treatment	Liraglutide Pen Injector (Saxenda)	5.98 index score (±0.6 Standard Error)
NCT03480022 SAXAPCOS	Weight Loss	Free Androgen Index (FAI) 32 weeks of treatment	Placebo Liraglutide Pen Injector	6.4 index score (±.75 Standard Error)
NCT04074161 STEP 8	Obesity	Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) Baseline (week 0), week 68	Liraglutide 3.0 mg	-6.4 Percentage of body weight (±7.7 Standard Deviation)
NCT04074161 STEP 8	Obesity		Semaglutide 2.4 mg	-16.4 Percentage of body weight (±10.5 Standard Deviation)

Publications by year

1974–2026: 943 publications.

1974

1979

1980

1982

1987

1989

1990

1993

1994

1995

1996

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Publications by indication

Diabetes Mellitus, Type 2 (490)

Response to Comment on Nathan et al. Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial. Diabetes Care 2024;47:2155-2163.
Diabetes Care · 2026 · PMID 39977640 · NCT01794143
GAD65Abs Are Not Associated With Beta-Cell Dysfunction in Patients With T2D in the GRADE Study.
J Endocr Soc · 2026 · PMID 38333889 · NCT01794143
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.
JAMA Intern Med · 2026 · PMID 41182740 · NCT03948347
Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.
Diabetes Care · 2025 · PMID 40267365 · NCT01794143
Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Diabetes Care · 2025 · PMID 39998948 · NCT01794143

Obesity (184)

Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.
Sports Med · 2026 · PMID 41579235 · NCT04122716
Linkage to HIV care and hypertension and diabetes control in rural South Africa: Results from the population-based Vukuzazi Study.
PLOS Glob Public Health · 2026 · PMID 36962629 · NCT06438146
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
N Engl J Med · 2025 · PMID 39258838 · NCT04775082
Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.
Osteoarthr Cartil Open · 2025 · PMID 39877802 · NCT02905864
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
Nat Med · 2025 · PMID 40555748 · NCT04311411

Diabetes Mellitus (67)

Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.
J Diabetes Sci Technol · 2025 · PMID 39717993 · NCT02098395
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
JAMA Surg · 2023 · PMID 37494014 · NCT03341429
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Metabolism · 2022 · PMID 36375643 · NCT01562678
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Diabetes Endocrinol · 2021 · PMID 33662334 · NCT02443155
Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
Diabetes Care · 2021 · PMID 32647054 · NCT02231658

Diabetes Mellitus, Type 1 (30)

Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
PLoS One · 2023 · PMID 38096190 · NCT03632759
Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.
J Clin Endocrinol Metab · 2022 · PMID 35833597 · NCT02408705
INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).
Diabet Med · 2022 · PMID 35797241 · NCT02908087
Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.
J Ocul Pharmacol Ther · 2022 · PMID 34918951 · NCT02138045
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Diabetes Obes Metab · 2021 · PMID 31696598 · NCT02351232

Metabolic Syndrome (24)

Postexercise improvement in insulin-stimulated glucose uptake occurs concomitant with greater AS160 phosphorylation in muscle from normal and insulin-resistant rats.
Diabetes · 2014 · PMID 24608437 · NCT04575844
Exercise training and cardiometabolic diseases: focus on the vascular system.
Curr Hypertens Rep · 2013 · PMID 23519745 · NCT04575844
Exercise, GLUT4, and skeletal muscle glucose uptake.
Physiol Rev · 2013 · PMID 23899560 · NCT04575844
The vascular endothelium in diabetes and its potential as a therapeutic target.
Rev Endocr Metab Disord · 2013 · PMID 23397463 · NCT04575844
Muscle-specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance.
Diabetes · 2013 · PMID 23002035 · NCT04575844

Microvascular Angina (22)

Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.
Int J Cardiol · 2019 · PMID 30773266 · NCT02602600
A randomised trial comparing weight loss with aerobic exercise in overweight individuals with coronary artery disease: The CUT-IT trial.
Eur J Prev Cardiol · 2016 · PMID 25082954 · NCT02602600
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Cardiovasc Diabetol · 2016 · PMID 25896352 · NCT02602600
Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study.
PLoS One · 2015 · PMID 24705387 · NCT02602600
Correlation between coronary microvascular function and angina status in patients with stable microvascular angina.
Eur Rev Med Pharmacol Sci · 2015 · PMID 24563437 · NCT02602600

Publications by journal

Diabetes Care109 papers
Diabetes Obes Metab77 papers
J Clin Endocrinol Metab33 papers
Diabetes31 papers
Diabetologia30 papers
Circulation25 papers
N Engl J Med23 papers
Lancet19 papers
Cardiovasc Diabetol16 papers
Diabet Med14 papers

Trial-results highlights

For individuals with Type 2 Diabetes Mellitus, studies have evaluated the effects of Liraglutide on Glycosylated Haemoglobin A1c (HbA1c). In NCT00294723, changes in HbA1c were observed at multiple time points. At Week 52, the Lira 1.8 arm showed a change of -1.14 percentage point, the Lira 1.2 arm showed -0.84 percentage point, and the Glimepiride arm showed -0.51 percentage point. At Week 104, the Lira 1.8 arm reported -0.88 percentage point, the Lira 1.2 arm -0.59 percentage point, and the Glimepiride arm -0.28 percentage point. By Week 156, the Lira 1.8 arm showed -0.71 percentage point, the Lira 1.2 arm -0.44 percentage point, and the Glimepiride arm -0.16 percentage point.

Further data from NCT00318461 reported changes in HbA1c at Week 26 and Week 104. At Week 26, the Lira 1.8 + Met arm showed a change of -1.00 Percentage point, the Met + Glim arm showed -0.98 Percentage point, the Lira 1.2 + Met arm showed -0.97 Percentage point, and the Lira 0.6 + Met arm showed -0.69 Percentage point. The Met Mono arm showed a change of 0.09 Percentage point. At Week 104, the Lira 1.8 + Met arm reported -0.58 percentage, the Lira 1.2 + Met arm -0.56 percentage, the Met + Glim arm -0.50 percentage, the Lira 0.6 + Met arm -0.36 percentage, and the Met Mono arm 0.25 percentage. In NCT00393718, after 24 weeks of treatment, the Liraglutide arm reported an HbA1c of 6.99 percentage of total haemoglobin, while the Glibenclamide arm reported 7.50 percentage. In NCT00395746, after 24 weeks, the 0.9 mg + SU arm reported 6.75 percentage of total haemoglobin, the 0.6 mg + SU arm reported 7.02 percentage, and the SU Mono arm reported 8.02 percentage. In NCT00518882 at Week 26, the Liraglutide -> Liraglutide -> Liraglutide arm showed an HbA1c change of -1.12 percentage point, and the Exenatide -> Liraglutide -> Liraglutide arm showed -0.79 percentage point.

All values presented are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Liraglutide publications (943)

2026 (6 papers)

Response to Comment on Nathan et al. Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial. Diabetes Care 2024;47:2155-2163.
Nathan DM · Diabetes Care · 2026 · Trial result
PubMed: PMID 39977640 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
GAD65Abs Are Not Associated With Beta-Cell Dysfunction in Patients With T2D in the GRADE Study.
Hampe CS, Shojaie A, Brooks-Worrell B, et al. · J Endocr Soc · 2026 · Trial result
PubMed: PMID 38333889 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.
Zhu H, Yang B, Lu L, et al. · JAMA Intern Med · 2026 · Derived
PubMed: PMID 41182740 · NCT03948347 (LAMP) · Diabetes Mellitus, Type 2
Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.
Jensen SBK, Fiorenza M, Juhl CR, et al. · Sports Med · 2026 · Derived
PubMed: PMID 41579235 · NCT04122716 (S-LITE) · Obesity
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.
Edison P, Femminella GD, Ritchie C, et al. · Nat Med · 2026 · Derived
PubMed: PMID 41326666 · NCT01843075 (ELAD) · Alzheimer Disease
Linkage to HIV care and hypertension and diabetes control in rural South Africa: Results from the population-based Vukuzazi Study.
Magodoro IM, Olivier S, Gareta D, et al. · PLOS Glob Public Health · 2026 · Background
PubMed: PMID 36962629 · NCT06438146 (LIROH) · Obesity

2025 (22 papers)

Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.
Wexler DJ, Garvey WT, Ghosh A, et al. · Diabetes Care · 2025 · Trial result
PubMed: PMID 40267365 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Utzschneider KM, Tripputi M, Butera NM, et al. · Diabetes Care · 2025 · Trial result
PubMed: PMID 39998948 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Clinical and Demographic Characteristics Associated With Diabetes Remission in Six Integrated Health Care Systems: A Retrospective Cohort Study.
Thapa B, Schmittdiel JA, Arterburn D, et al. · Diabetes Care · 2025 · Trial result
PubMed: PMID 40734551 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
Lack of Association of Emotional Distress With Insulin Initiation in the GRADE Randomized Diabetes Comparative Effectiveness Trial.
Presley CA, Butera NM, Krause-Steinrauf H, et al. · Sci Diabetes Self Manag Care · 2025 · Trial result
PubMed: PMID 40751289 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.
Pop-Busui R, Rosin SP, Butera NM, et al. · Diabetes Care · 2025 · Trial result
PubMed: PMID 40986645 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.
Neugebauer R, An J, Dombrowski SK, et al. · JAMA Netw Open · 2025 · Trial result
PubMed: PMID 41091469 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial.
Luchsinger JA, Rosin SP, Kazemi EJ, et al. · JAMA Intern Med · 2025 · Trial result
PubMed: PMID 40388190 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.
Hsia DS, Younes N, Ghosh A, et al. · Diabetes Care · 2025 · Trial result
PubMed: PMID 40424051 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
Fox CK, Barrientos-Pérez M, Bomberg EM, et al. · N Engl J Med · 2025 · Trial result
PubMed: PMID 39258838 · NCT04775082 · Obesity
Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study.
Ehrmann D, Krause-Steinrauf H, Uschner D, et al. · Diabetologia · 2025 · Trial result
PubMed: PMID 39951058 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.
Yu C, Yang H, Zhang B, et al. · BMJ Open · 2025 · Derived
PubMed: PMID 40840993 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.
Shah VN, Agesen RM, Bardtrum L, et al. · J Diabetes Sci Technol · 2025 · Derived
PubMed: PMID 39717993 · NCT02098395 (ADJUNCT TWO™) · Diabetes Mellitus
Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.
Poulsen AS, Stisen ZR, Skougaard M, et al. · Osteoarthr Cartil Open · 2025 · Derived
PubMed: PMID 39877802 · NCT02905864 (LOSEIT) · Obesity
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, Green SC, Tunnicliffe DJ, et al. · Cochrane Database Syst Rev · 2025 · Derived
PubMed: PMID 39963952 · NCT02545738 (LIRALBU) · Diabetic Nephropathies
Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial.
Myat A, Redwood SR, Arri S, et al. · Diabetol Metab Syndr · 2025 · Derived
PubMed: PMID 33579317 · NCT02315001 (LIONESS) · Coronary Artery Disease
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
Martin CK, Carmichael OT, Carnell S, et al. · Nat Med · 2025 · Derived
PubMed: PMID 40555748 · NCT04311411 · Obesity
Common genetic variants near SLC2A2 and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial.
Li JH, Szczerbinski L, Tripputi M, et al. · medRxiv · 2025 · Derived
PubMed: PMID 41282760 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Weight Loss Induces Changes in Vitamin D Status in Women With Obesity But Not in Men: A Randomized Clinical Trial.
Holt R, Holt J, Jorsal MJ, et al. · J Clin Endocrinol Metab · 2025 · Derived
PubMed: PMID 39530599 · NCT04122716 (S-LITE) · Obesity
One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.
Holt J, Sandsdal RM, Byberg S, et al. · Obesity (Silver Spring) · 2025 · Derived
PubMed: PMID 40998556 · NCT04122716 (S-LITE) · Obesity
Circulating FGF21 is lower in South Asians compared with Europids with type 2 diabetes mellitus.
Hoekx CA, Martinez-Tellez B, Straat ME, et al. · Endocr Connect · 2025 · Derived
PubMed: PMID 39641307 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.
Gómez-Medina AM, Henao-Carillo DC, Villamil-Castañeda LP, et al. · Diabetologia · 2025 · Derived
PubMed: PMID 40760249 · NCT05767255 · Diabetes Mellitus, Type 2
Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.
Glaros SB, Mishra SP, Jain S, et al. · Gut Microbes · 2025 · Derived
PubMed: PMID 41020378 · NCT02960659 · Diabetes Mellitus, Type 2

2024 (34 papers)

Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
Utzschneider KM, Younes N, Butera NM, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38190619 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.
Seaquist ER, Phillips LS, Ghosh A, et al. · PLoS One · 2024 · Trial result
PubMed: PMID 39546502 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Rodriguez LA, Finertie H, Neugebauer RS, et al. · Lancet Reg Health Am · 2024 · Trial result
PubMed: PMID 38745886 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Rasouli N, Younes N, Ghosh A, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38211595 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial.
Nathan DM, Herman WH, Larkin ME, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 39312277 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Kirkman MS, Tripputi M, Krause-Steinrauf H, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38194519 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).
Hsia DS, Younes N, Krause-Steinrauf H, et al. · J Diabetes Complications · 2024 · Trial result
PubMed: PMID 38354481 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Hoogendoorn CJ, Krause-Steinrauf H, Uschner D, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38227900 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Hollander PA, Krause-Steinrauf H, Butera NM, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 37756542 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.
Herfarth H, Long MD, Hansen JJ, et al. · Am J Gastroenterol · 2024 · Trial result
PubMed: PMID 38668926 · NCT04763564 · Pouchitis
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
Green JB, Everett BM, Ghosh A, et al. · Circulation · 2024 · Trial result
PubMed: PMID 38344820 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Gonzalez JS, Bebu I, Krause-Steinrauf H, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38416773 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
Garvey WT, Cohen RM, Butera NM, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38285957 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Cherrington AL, Tripputi MT, Younes N, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38190625 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Does Emotional Distress Predict Worse Glycemic Control Over Time? Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Cherrington AL, Bebu I, Krause-Steinrauf H, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38252848 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Islet Autoimmunity is Highly Prevalent and Associated With Diminished β-Cell Function in Patients With Type 2 Diabetes in the Grade Study.
Brooks-Worrell B, Hampe CS, Hattery EG, et al. · Diabetes · 2024 · Trial result
PubMed: PMID 35061024 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Mortality in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Banerji MA, Buse JB, Younes N, et al. · Diabetes Care · 2024 · Trial result
PubMed: PMID 38252886 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.
Abdalla MA, Deshmukh H, Atkin S, et al. · Ther Adv Endocrinol Metab · 2024 · Trial result
PubMed: PMID 33552465 · NCT05952882 · Obesity
Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol.
Win KZ, Armstrong M, Steeds RP, et al. · Pilot Feasibility Stud · 2024 · Derived
PubMed: PMID 38383462 · NCT05221229 (GOAL-AF) · Obesity
Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes.
Philis-Tsimikas A, Aroda VR, De Block C, et al. · J Diabetes Sci Technol · 2024 · Derived
PubMed: PMID 36710452 · NCT02501161 (DUAL™ VIII) · Diabetes Mellitus, Type 2
Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study.
O'Donnell C, Crilly S, O'Mahony A, et al. · Ann Am Thorac Soc · 2024 · Derived
PubMed: PMID 38096106 · NCT04186494 · Insulin Resistance
Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.
McElroy SL, Guerdjikova AI, Blom TJ, et al. · J Clin Psychopharmacol · 2024 · Derived
PubMed: PMID 38227621 · NCT03158805 · Obesity
The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies.
Kral P, Holst-Hansen T, Olivieri AV, et al. · Adv Ther · 2024 · Derived
PubMed: PMID 39316288 · NCT01272219 · Obesity
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.
Jensen SBK, Blond MB, Sandsdal RM, et al. · EClinicalMedicine · 2024 · Derived
PubMed: PMID 38544798 · NCT04122716 (S-LITE) · Obesity
Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
Freet CS, Evans B, Brick TR, et al. · Addict Sci Clin Pract · 2024 · Derived
PubMed: PMID 39061093 · NCT04199728 · Opioid-Related Disorders
Metformin for preventing the progression of chronic kidney disease.
El-Damanawi R, Stanley IK, Staatz C, et al. · Cochrane Database Syst Rev · 2024 · Derived
PubMed: PMID 38837240 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.
Dogan ADA, Christensen TQ, Jensen TT, et al. · BMC Res Notes · 2024 · Derived
PubMed: PMID 38902794 · NCT03466021 · Weight Loss
Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.
Chowdhary A, Thirunavukarasu S, Joseph T, et al. · J Am Coll Cardiol · 2024 · Derived
PubMed: PMID 39084829 · NCT04657939 (Lean-DM) · Diabetes Mellitus, Type 2
Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial.
Caruso P, Maiorino MI, Longo M, et al. · JAMA Netw Open · 2024 · Derived
PubMed: PMID 38470420 · NCT04881110 (STARDUST) · Diabetes Mellitus, Type 2
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).
Al-Ozairi E, Narula K, Miras AD, et al. · Trials · 2024 · Derived
PubMed: PMID 38365744 · NCT05390307 (OTID) · Obesity
Principles for Stakeholder Engagement in Observational Health Research.
Thomas TW, Hooker SA, Schmittdiel JA, et al. · JAMA Health Forum · 2024 · Background
PubMed: PMID 38488777 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
Perceptions of Health, Body Size, and Nutritional Risk Factors for Obesity in People with HIV in South Africa.
Manne-Goehler J, Rahim N, van Empel E, et al. · AIDS Behav · 2024 · Background
PubMed: PMID 37632604 · NCT06438146 (LIROH) · Obesity
American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease.
Garvey WT, Garber AJ, Mechanick JI, et al. · Endocr Pract · 2024 · Background
PubMed: PMID 25253227 · NCT03038620 · Obesity
Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications.
Chandiwana NC, Siedner MJ, Marconi VC, et al. · J Clin Endocrinol Metab · 2024 · Background
PubMed: PMID 37437159 · NCT06438146 (LIROH) · Obesity

2023 (30 papers)

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Wexler DJ, de Boer IH, Ghosh A, et al. · JAMA Intern Med · 2023 · Trial result
PubMed: PMID 37213109 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Assessment of circulating insulin using liquid chromatography-mass spectrometry during insulin glargine treatment in type 2 diabetes: Implications for estimating insulin sensitivity and β-cell function.
Seegmiller JC, Schmit DJ, Arends VL, et al. · Diabetes Obes Metab · 2023 · Trial result
PubMed: PMID 36999229 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.
Sbraccia P, Aberle J, Olsen AH, et al. · Diabetes Obes Metab · 2023 · Trial result
PubMed: PMID 36514273 · NCT02967757 · Obesity
BMI, insulin sensitivity, and cognition in early type 2 diabetes: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.
Luchsinger JA, Kazemi EJ, Sanchez DL, et al. · Obesity (Silver Spring) · 2023 · Trial result
PubMed: PMID 37368512 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort.
Gulanski BI, Butera NM, Krause-Steinrauf H, et al. · BMJ Open Diabetes Res Care · 2023 · Trial result
PubMed: PMID 37094945 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Emotional distress, self-management, and glycemic control among participants enrolled in the glycemia reduction approaches in diabetes: A comparative effectiveness (GRADE) study.
Gonzalez JS, Krause-Steinrauf H, Bebu I, et al. · Diabetes Res Clin Pract · 2023 · Trial result
PubMed: PMID 36549506 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Emotional distress and cardiovascular disease risk among participants enrolled in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study.
Crespo-Ramos G, Bebu I, Krause-Steinrauf H, et al. · Diabetes Res Clin Pract · 2023 · Trial result
PubMed: PMID 37394014 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Use of comprehensive recruitment strategies in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE) multi-center clinical trial.
Cherrington AL, Krause-Steinrauf H, Aroda V, et al. · Clin Trials · 2023 · Trial result
PubMed: PMID 37329282 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope?
Caruso P, Maiorino MI, Bellastella G, et al. · Diabetes Metab Res Rev · 2023 · Trial result
PubMed: PMID 36812501 · NCT04881110 (STARDUST) · Diabetes Mellitus, Type 2
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
Xu Z, Liu Z, Wang Y, et al. · Expert Rev Clin Pharmacol · 2023 · Derived
PubMed: PMID 36883362 · NCT05029076 · Diabetes Mellitus, Type 2
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.
Wretlind A, Zobel EH, de Zawadzki A, et al. · Front Clin Diabetes Healthc · 2023 · Derived
PubMed: PMID 36992761 · NCT03449654 (LIRAFLAME) · Diabetes Mellitus, Type 2
Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.
Wretlind A, Curovic VR, de Zawadzki A, et al. · Lipids Health Dis · 2023 · Derived
PubMed: PMID 37752566 · NCT02545738 (LIRALBU) · Diabetic Nephropathies
Reproducibility of Glycemic Measures Among Dysglycemic Youth and Adults in the RISE Study.
Tjaden AH, Edelstein SL, Arslanian S, et al. · J Clin Endocrinol Metab · 2023 · Derived
PubMed: PMID 36938582 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Differences in Inflammatory Pathways Between Dutch South Asians vs Dutch Europids With Type 2 Diabetes.
Straat ME, Martinez-Tellez B, van Eyk HJ, et al. · J Clin Endocrinol Metab · 2023 · Derived
PubMed: PMID 36262060 · NCT02660047 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals.
Stefanakis K, Kokkinos A, Simati S, et al. · Clin Nutr · 2023 · Derived
PubMed: PMID 37418844 · NCT04575194 · Obesity
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Scherbak NN, Kruse R, Nyström T, et al. · Diabetes Metab J · 2023 · Derived
PubMed: PMID 37349083 · NCT01425580 · Diabetes Mellitus, Type 2
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
Sandsdal RM, Juhl CR, Jensen SBK, et al. · Cardiovasc Diabetol · 2023 · Derived
PubMed: PMID 36841762 · NCT04122716 (S-LITE) · Obesity
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Ren H, Berry S, Malkin SJP, et al. · BMJ Open · 2023 · Derived
PubMed: PMID 37775297 · NCT02863419 (PIONEER 4) · Diabetes Mellitus, Type 2
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.
Parker VER, Robertson D, Erazo-Tapia E, et al. · Nat Metab · 2023 · Derived
PubMed: PMID 38066113 · NCT03555994 · Diabetes Mellitus, Type 2
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Mok J, Adeleke MO, Brown A, et al. · JAMA Surg · 2023 · Derived
PubMed: PMID 37494014 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
Lord SM, Bahnson HT, Greenbaum CJ, et al. · PLoS One · 2023 · Derived
PubMed: PMID 38096190 · NCT03632759 · Diabetes Mellitus, Type 1
Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
Lee SWH, Chen WS, Sellappans R, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37435938 · NCT01917656 (LIRA-Ramadan™) · Diabetes Mellitus, Type 2
Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM).
Kuruvilla DE, Mann JI, Tepper SJ, et al. · Sci Rep · 2023 · Derived
PubMed: PMID 35332216 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers.
Heinla K, Vasar E, Reppo I, et al. · Diabetes Ther · 2023 · Derived
PubMed: PMID 36800161 · NCT02089256
Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.
Esteghamati A, Zamanzadeh M, Malek M, et al. · Diabetes Ther · 2023 · Derived
PubMed: PMID 37707701 · NCT03421119 · Diabetes Mellitus, Type 2
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.
Denimal D, Bergas V, Pais-de-Barros JP, et al. · Cardiovasc Diabetol · 2023 · Derived
PubMed: PMID 37143040 · NCT02721888 (LIRA-NAFLD/LIP) · Diabetes Mellitus, Type 2
Insufficient sleep predicts poor weight loss maintenance after 1 year.
Bogh AF, Jensen SBK, Juhl CR, et al. · Sleep · 2023 · Derived
PubMed: PMID 36472579 · NCT04122716 (S-LITE) · Obesity
Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.
Bensignor MO, Bramante CT, Bomberg EM, et al. · Pediatr Obes · 2023 · Derived
PubMed: PMID 37264767 · NCT02918279 · Obesity
A Dynamic Risk Model for Multitype Recurrent Events.
Ghosh A, Chan W, Younes N, et al. · Am J Epidemiol · 2023 · Background
PubMed: PMID 36549905 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Modeling longitudinal change in biomarkers using data from a complex survey sampling design: An application to the Hispanic Community Health Study/Study of Latinos.
Butera NM, Zeng D, Heiss G, et al. · Stat Med · 2023 · Background
PubMed: PMID 36631123 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2

2022 (45 papers)

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.
Wharton S, Davies M, Dicker D, et al. · Postgrad Med · 2022 · Trial result
PubMed: PMID 34775881 · NCT04074161 (STEP 8) · Obesity
DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
Wang W, Agner BFR, Luo B, et al. · J Diabetes · 2022 · Trial result
PubMed: PMID 35762390 · NCT03172494 (DUAL™ I China) · Diabetes Mellitus, Type 2
Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone.
Utzschneider KM, Younes N, Rasouli N, et al. · J Diabetes Complications · 2022 · Trial result
PubMed: PMID 33752962 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U, et al. · JAMA · 2022 · Trial result
PubMed: PMID 35015037 · NCT04074161 (STEP 8) · Obesity
Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.
Psota M, Psenkova MB, Racekova N, et al. · Clinicoecon Outcomes Res · 2022 · Trial result
PubMed: PMID 29276398 · NCT01952145 (DUAL™ V) · Diabetes Mellitus, Type 2
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Linjawi S, Bode BW, Chaykin LB, et al. · Diabetes Ther · 2022 · Trial result
PubMed: PMID 27943107 · NCT01676116 (DUAL™ III) · Diabetes Mellitus, Type 2
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM, et al. · Lancet · 2022 · Trial result
PubMed: PMID 34798060 · NCT03856047 · Obesity
Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
Komatsu M, Watada H, Kaneko S, et al. · J Diabetes Investig · 2022 · Trial result
PubMed: PMID 33595901 · NCT02607306 (DUAL™ I Japan) · Diabetes Mellitus, Type 2
The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes.
Jimeno C, Kho S, de Los Santos GK, et al. · J ASEAN Fed Endocr Soc · 2022 · Trial result
PubMed: PMID 33442116 · NCT01345734 (Lead-Ph) · Diabetes Mellitus, Type 2
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
GRADE Study Research Group, Nathan DM, Lachin JM, et al. · N Engl J Med · 2022 · Trial result
PubMed: PMID 36129997 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
GRADE Study Research Group, Nathan DM, Lachin JM, et al. · N Engl J Med · 2022 · Trial result
PubMed: PMID 36129996 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.
Freemantle N, Mamdani M, Vilsbøll T, et al. · Diabetes Ther · 2022 · Trial result
PubMed: PMID 26582052 · NCT01617434 · Diabetes Mellitus, Type 2
Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE).
Florez HJ, Ghosh A, Pop-Busui R, et al. · Diabetes Res Clin Pract · 2022 · Trial result
PubMed: PMID 34971663 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
Diene G, Angulo M, Hale PM, et al. · J Clin Endocrinol Metab · 2022 · Trial result
PubMed: PMID 36181471 · NCT02527200 · Obesity
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Cheng H, Zhang Z, Zhang B, et al. · Diabetes Care · 2022 · Trial result
PubMed: PMID 35263425 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathy-The GRADE study.
Barzilay JI, Ghosh A, Busui RP, et al. · J Diabetes Complications · 2022 · Trial result
PubMed: PMID 34556408 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Aroda VR, Bauer R, Christiansen E, et al. · Diabetes Obes Metab · 2022 · Trial result
PubMed: PMID 35373893 · NCT02863419 (PIONEER 4) · Diabetes Mellitus, Type 2
A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects.
Zhou R, Guo L, Gao X, et al. · Clin Transl Sci · 2022 · Derived
PubMed: PMID 35871497 · NCT05294536 · Diabetes Mellitus, Type 2
Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.
Zenz S, Regittnig W, Boulgaropoulos B, et al. · J Clin Endocrinol Metab · 2022 · Derived
PubMed: PMID 35833597 · NCT02408705 · Diabetes Mellitus, Type 1
Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.
Williams DM, Staff M, Bain SC, et al. · touchREV Endocrinol · 2022 · Derived
PubMed: PMID 35975210 · NCT01272219 · Obesity
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Verma S, Al-Omran M, Leiter LA, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35332654 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Utzschneider KM, Ehrmann DA, Arslanian SA, et al. · Obesity (Silver Spring) · 2022 · Derived
PubMed: PMID 35894078 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
Thomsen RW, Christensen LWB, Kahlert J, et al. · Diabetes Ther · 2022 · Derived
PubMed: PMID 36315384 · NCT03993132 · Diabetes Mellitus, Type 2
Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.
Stier C, Koschker AC, Kim M, et al. · Clin Nutr ESPEN · 2022 · Derived
PubMed: PMID 35871930 · NCT02616003 · Obesity, Morbid
Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
Snitker S, Egebjerg C, Frederiksen M, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35791625 · NCT04074161 (STEP 8) · Obesity
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.
Samson SL, Gu F, Feldt-Rasmussen U, et al. · Pituitary · 2022 · Derived
PubMed: PMID 34275099 · NCT02060383 · Hyperglycemia
Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.
Maselli D, Atieh J, Clark MM, et al. · Obesity (Silver Spring) · 2022 · Derived
PubMed: PMID 35894080 · NCT02647944 · Obesity
Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.
López-Cano C, Ciudin A, Sánchez E, et al. · Diabetes · 2022 · Derived
PubMed: PMID 34737187 · NCT02889510 · Diabetes Mellitus, Type 2
Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.
Lerman JB, Giamberardino SN, Hernandez AF, et al. · Sci Rep · 2022 · Derived
PubMed: PMID 35654972 · NCT01800968 (FIGHT)
INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).
Kero J, Koskenniemi JJ, Karsikas S, et al. · Diabet Med · 2022 · Derived
PubMed: PMID 35797241 · NCT02908087 · Diabetes Mellitus, Type 1
Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
Jensen SBK, Janus C, Lundgren JR, et al. · Nat Commun · 2022 · Derived
PubMed: PMID 35970829 · NCT04122716 (S-LITE) · Obesity
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J, Hyötyläinen T, Orešič M, et al. · Cardiovasc Diabetol · 2022 · Derived
PubMed: PMID 34920733 · NCT01425580 · Diabetes Mellitus, Type 2
Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.
Jendle J, Fang X, Cao Y, et al. · J Am Soc Hypertens · 2022 · Derived
PubMed: PMID 29548934 · NCT01425580 · Diabetes Mellitus, Type 2
A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.
Heller SR, Geybels MS, Iqbal A, et al. · Diabetologia · 2022 · Derived
PubMed: PMID 34704120 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
Guja C, Giorgino F, Blonde L, et al. · Diabetes Ther · 2022 · Derived
PubMed: PMID 34894329 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
Ferrannini E, Niemoeller E, Dex T, et al. · Diabetes Obes Metab · 2022 · Derived
PubMed: PMID 35257461 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.
Elkind-Hirsch KE, Chappell N, Shaler D, et al. · Fertil Steril · 2022 · Derived
PubMed: PMID 35710599 · NCT03480022 (SAXAPCOS) · Weight Loss
The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial.
Dekkers IA, Bizino MB, Paiman EHM, et al. · J Ren Nutr · 2022 · Derived
PubMed: PMID 33293204 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.
Arendt Nielsen T, Sega R, Uggerhøj Andersen C, et al. · J Ocul Pharmacol Ther · 2022 · Derived
PubMed: PMID 34918951 · NCT02138045 (TODINELI) · Diabetes Mellitus, Type 1
Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.
Anholm C, Kumarathurai P, Jürs A, et al. · Diabetol Metab Syndr · 2022 · Derived
PubMed: PMID 31164926 · NCT01595789 (AddHope2) · Diabetes Mellitus, Type 2
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Angelidi AM, Kokkinos A, Sanoudou D, et al. · Metabolism · 2022 · Derived
PubMed: PMID 36375643 · NCT01562678 · Diabetes Mellitus
Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
Andersen E, Juhl CR, Kjøller ET, et al. · Hum Reprod · 2022 · Derived
PubMed: PMID 35580859 · NCT04122716 (S-LITE) · Obesity
Exercise Preserves Lean Mass and Performance during Severe Energy Deficit: The Role of Exercise Volume and Dietary Protein Content.
Calbet JAL, Ponce-González JG, Calle-Herrero J, et al. · Front Physiol · 2022 · Background
PubMed: PMID 28790922 · NCT04122716 (S-LITE) · Obesity
A doubly robust method to handle missing multilevel outcome data with application to the China Health and Nutrition Survey.
Butera NM, Zeng D, Green Howard A, et al. · Stat Med · 2022 · Background
PubMed: PMID 34786739 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Morbidity and mortality associated with obesity.
Abdelaal M, le Roux CW, Docherty NG, et al. · Ann Transl Med · 2022 · Background
PubMed: PMID 28480197 · NCT04122716 (S-LITE) · Obesity

2021 (67 papers)

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, et al. · Lancet Diabetes Endocrinol · 2021 · Trial result
PubMed: PMID 33662334 · NCT02443155 · Diabetes Mellitus
Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin.
Utzschneider KM, Younes N, Rasouli N, et al. · BMJ Open Diabetes Res Care · 2021 · Trial result
PubMed: PMID 34531242 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
Taskinen MR, Björnson E, Matikainen N, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 33502078 · NCT02765399 · Diabetes Mellitus, Type 2
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.
Sivitz WI, Phillips LS, Wexler DJ, et al. · Diabetes Care · 2021 · Trial result
PubMed: PMID 32139384 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort.
Rasouli N, Younes N, Utzschneider KM, et al. · Diabetes Care · 2021 · Trial result
PubMed: PMID 33334808 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Obesity and reproduction: a committee opinion.
Practice Committee of the American Society for Reproductive Medicine. Electronic address: [email protected], Practice Committee of the American Society for Reproductive Medicine · Fertil Steril · 2021 · Trial result
PubMed: PMID 34583840 · NCT05952882 · Obesity
Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies.
Nathan DM, Krause-Steinrauf H, Braffett BH, et al. · PLoS One · 2021 · Trial result
PubMed: PMID 34780485 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Luchsinger JA, Younes N, Manly JJ, et al. · Diabetes Care · 2021 · Trial result
PubMed: PMID 34285097 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
Garvey WT, Birkenfeld AL, Dicker D, et al. · Diabetes Care · 2021 · Trial result
PubMed: PMID 32139381 · NCT02963922 (SCALE™ Insulin) · Obesity
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Dejgaard TF, Schmidt S, Frandsen CS, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 31696598 · NCT02351232 · Diabetes Mellitus, Type 1
Study of emotional distress in a comparative effectiveness trial of diabetes treatments: Rationale and design.
Cherrington AL, Krause-Steinrauf H, Bebu I, et al. · Contemp Clin Trials · 2021 · Trial result
PubMed: PMID 33766761 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Cena H, Chiovato L, Nappi RE, et al. · J Clin Endocrinol Metab · 2021 · Trial result
PubMed: PMID 32442310 · NCT05952882 · Obesity
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS, Catarig AM, Furberg JK, et al. · Diabetes Metab · 2021 · Trial result
PubMed: PMID 31539622 · NCT03191396 (SUSTAIN 10) · Diabetes Mellitus, Type 2
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
Blonde L, Belousova L, Fainberg U, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 31984646 · NCT02964247 · Diabetes Mellitus, Type 2
The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study.
Barzilay JI, Younes N, Pop-Busui R, et al. · J Diabetes Complications · 2021 · Trial result
PubMed: PMID 33288412 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
Araki E, Terauchi Y, Watada H, et al. · Diabetes Obes Metab · 2021 · Trial result
PubMed: PMID 34472698 · NCT02863419 (PIONEER 4) · Diabetes Mellitus, Type 2
Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.
Zobel EH, Wretlind A, Ripa RS, et al. · BMJ Open Diabetes Res Care · 2021 · Derived
PubMed: PMID 34518158 · NCT03449654 (LIRAFLAME) · Diabetes Mellitus, Type 2
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L, Zhang L, Li Y, et al. · J Parkinsons Dis · 2021 · Derived
PubMed: PMID 31958096 · NCT02953665 · Insulin Resistance
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
Verma S, McGuire DK, Bain SC, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32744418 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
Verma S, Bain SC, Honoré JB, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32643857 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
Vergès B, Duvillard L, Pais de Barros JP, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 33531418 · NCT02721888 (LIRA-NAFLD/LIP) · Diabetes Mellitus, Type 2
Differential loss of β-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study.
Utzschneider KM, Tripputi MT, Kozedub A, et al. · Diabetes Res Clin Pract · 2021 · Derived
PubMed: PMID 34274407 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.
Tronieri JS, Wadden TA, Walsh O, et al. · Int J Obes (Lond) · 2021 · Derived
PubMed: PMID 30926955 · NCT02911818 (MODEL) · Obesity
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
Thethi TK, Pratley R, Meier JJ, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32267058 · NCT03018028 (PIONEER 9) · Diabetes Mellitus, Type 2
Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
Smits MM, Fluitman KS, Herrema H, et al. · Diabetes Metab · 2021 · Derived
PubMed: PMID 33429063 · NCT01744236 · Diabetes Mellitus, Type 2
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.
Schiavon M, Visentin R, Göbel B, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 33822469 · NCT02973321 · Diabetes Mellitus, Type 2
Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study.
Sam S, Edelstein SL, Arslanian SA, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 34131048 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Ripa RS, Zobel EH, von Scholten BJ, et al. · Circ Cardiovasc Imaging · 2021 · Derived
PubMed: PMID 34187185 · NCT03449654 (LIRAFLAME) · Diabetes Mellitus, Type 2
Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
Quast DR, Schenker N, Menge BA, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 32647054 · NCT02231658 · Diabetes Mellitus
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.
Pratley RE, Crowley MJ, Gislum M, et al. · Diabetes Ther · 2021 · Derived
PubMed: PMID 33660198 · NCT02863419 (PIONEER 4) · Diabetes Mellitus, Type 2
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.
Persson F, Bain SC, Mosenzon O, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 33504496 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.
Øhrstrøm CC, Worm D, Kielgast UL, et al. · Obes Surg · 2021 · Derived
PubMed: PMID 31907828 · NCT02527993 · Obesity
Peripheral, synaptic and central neuronal transmission is affected in type 1 diabetes.
Nissen TD, Meldgaard T, Nedergaard RW, et al. · J Diabetes Complications · 2021 · Derived
PubMed: PMID 32571684 · NCT02138045 (TODINELI) · Diabetes Mellitus, Type 1
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
Neeland IJ, Marso SP, Ayers CR, et al. · Lancet Diabetes Endocrinol · 2021 · Derived
PubMed: PMID 34358471 · NCT03038620 · Obesity
Diabetic Neuropathy Influences Control of Spinal Mechanisms.
Nedergaard RB, Nissen TD, Mørch CD, et al. · J Clin Neurophysiol · 2021 · Derived
PubMed: PMID 32501945 · NCT02138045 (TODINELI) · Diabetes Mellitus, Type 1
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Nahra R, Wang T, Gadde KM, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 34016612 · NCT03235050 · Diabetes Mellitus, Type 2
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L, Doshi A, Gouet D, et al. · Diabet Med · 2021 · Derived
PubMed: PMID 31705547 · NCT01952145 (DUAL™ V) · Diabetes Mellitus, Type 2
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE, Fonseca VA, Poulter NR, et al. · Clin J Am Soc Nephrol · 2021 · Derived
PubMed: PMID 32132141 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR, Janus C, Jensen SBK, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 33951361 · NCT04122716 (S-LITE) · Obesity
Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Li Q, Jia M, Yan Z, et al. · J Am Heart Assoc · 2021 · Derived
PubMed: PMID 34250817 · NCT03707171 · Diabetes Mellitus, Type 2
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Leiter LA, Bain SC, Bhatt DL, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 32372454 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
Kumarathurai P, Sajadieh A, Anholm C, et al. · Cardiovasc Diabetol · 2021 · Derived
PubMed: PMID 33413428 · NCT01595789 (AddHope2) · Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T, Mizuno A, Takaoka Y, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 34693515 · NCT04146155 · Diabetes Mellitus, Type 2
Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study.
Kahn SE, Mather KJ, Arslanian SA, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 34131047 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study.
Kahn SE, Edelstein SL, Arslanian SA, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 34135015 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H, Chedid V, Halawi H, et al. · J Clin Endocrinol Metab · 2021 · Derived
PubMed: PMID 31665455 · NCT02647944 · Obesity
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Husain M, Bain SC, Jeppesen OK, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 31903692 · NCT03018028 (PIONEER 9) · Diabetes Mellitus, Type 2
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M, Bain SC, Holst AG, et al. · Cardiovasc Diabetol · 2021 · Derived
PubMed: PMID 32998732 · NCT03018028 (PIONEER 9) · Diabetes Mellitus, Type 2
Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial.
Gudbergsen H, Overgaard A, Henriksen M, et al. · Am J Clin Nutr · 2021 · Derived
PubMed: PMID 33471039 · NCT02905864 (LOSEIT) · Obesity
Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
Gaborit B, Julla JB, Besbes S, et al. · J Clin Endocrinol Metab · 2021 · Derived
PubMed: PMID 31589290 · NCT02686177 (ANGIOSAFE 1) · Diabetes Mellitus, Type 2
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
Franklin JM, Patorno E, Desai RJ, et al. · Circulation · 2021 · Derived
PubMed: PMID 33327727 · NCT03936049 · Diabetes Mellitus
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
Elkind-Hirsch KE, Shaler D, Harris R, et al. · J Diabetes Complications · 2021 · Derived
PubMed: PMID 32046931 · NCT01234649 · Diabetes Mellitus, Type 2
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Dejgaard TF, von Scholten BJ, Christiansen E, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 34463425 · NCT01836523 (ADJUNCT ONE™) · Diabetes Mellitus
The impact of a significant weight loss on inflammation assessed on DCE-MRI and static MRI in knee osteoarthritis: a prospective cohort study.
Daugaard CL, Henriksen M, Riis RGC, et al. · Osteoarthritis Cartilage · 2021 · Derived
PubMed: PMID 32165240 · NCT02905864 (LOSEIT) · Obesity
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
Crowley MJ, McGuire DK, Alexopoulos AS, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 32647053 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
Buse JB, Bain SC, Mann JFE, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 32366578 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.
Blonde L, Rosenstock J, Frias J, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 33468520 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
Blonde L, Fainberg U, Kaltoft MS, et al. · Diabetes Obes Metab · 2021 · Derived
PubMed: PMID 34132018 · NCT02964247 · Diabetes Mellitus, Type 2
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK, Agner BFR, Altuntas Y, et al. · J Diabetes Sci Technol · 2021 · Derived
PubMed: PMID 32107930 · NCT02420262 · Diabetes Mellitus, Type 2
Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.
Bensignor MO, Bomberg EM, Bramante CT, et al. · Pediatr Obes · 2021 · Derived
PubMed: PMID 33634589 · NCT01541215 (Ellipse™) · Diabetes Mellitus, Type 2
OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function.
Arslanian SA, El Ghormli L, Kim JY, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 33436401 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes.
Ali AM, Martinez R, Al-Jobori H, et al. · Diabetes Care · 2021 · Derived
PubMed: PMID 32220916 · NCT02324842 · Diabetes Mellitus, Type 2
Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.
Ali AM, Mari A, Martinez R, et al. · J Clin Endocrinol Metab · 2021 · Derived
PubMed: PMID 32745202 · NCT02324842 · Diabetes Mellitus, Type 2
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic.
Acosta A, Camilleri M, Abu Dayyeh B, et al. · Obesity (Silver Spring) · 2021 · Derived
PubMed: PMID 33759389 · NCT03374956 · Obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, et al. · N Engl J Med · 2021 · Background
PubMed: PMID 33567185 · NCT06438146 (LIROH) · Obesity
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Background
PubMed: PMID 33625476 · NCT06438146 (LIROH) · Obesity
Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study.
Thakur U, Bhansali A, Gupta R, et al. · Obes Surg · 2021 · Background
PubMed: PMID 32656729 · NCT05285397 · Obesity, Morbid

2020 (59 papers)

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.
Zobel EH, von Scholten BJ, Goldman B, et al. · Diabetes Obes Metab · 2020 · Trial result
PubMed: PMID 30663196 · NCT01620489 · Diabetes Mellitus, Type 2
Liraglutide and Glycaemic Outcomes in the LEADER Trial.
Zinman B, Nauck MA, Bosch-Traberg H, et al. · Diabetes Ther · 2020 · Trial result
PubMed: PMID 30392095 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Zhang Z, Zhang B, Wang X, et al. · Diabetes Care · 2020 · Trial result
PubMed: PMID 31221697 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Zeng X, Xie YJ, Liu YT, et al. · Clin Chim Acta · 2020 · Trial result
PubMed: PMID 31733195 · NCT05952882 · Obesity
Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Wexler DJ, Krause-Steinrauf H, Crandall JP, et al. · Diabetes Care · 2020 · Trial result
PubMed: PMID 31391203 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Watada H, Kaneko S, Komatsu M, et al. · Diabetes Obes Metab · 2020 · Trial result
PubMed: PMID 31423685 · NCT02911948 (DUAL™ II Japan) · Diabetes Mellitus, Type 2
Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India.
Wangnoo SK, Kumar S, Bhattacharyya A, et al. · Indian J Endocrinol Metab · 2020 · Trial result
PubMed: PMID 27867889 · NCT01212133 (Lead-In) · Diabetes Mellitus, Type 2
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA, Tronieri JS, Sugimoto D, et al. · Obesity (Silver Spring) · 2020 · Trial result
PubMed: PMID 32090517 · NCT02963935 (SCALE™ IBT) · Obesity
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
Philis-Tsimikas A, Billings LK, Busch R, et al. · Diabetes Obes Metab · 2020 · Trial result
PubMed: PMID 30761720 · NCT02773368 (DUALTM IX) · Diabetes Mellitus, Type 2
Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.
Nauck MA, Buse JB, Mann JFE, et al. · Diabetes Obes Metab · 2020 · Trial result
PubMed: PMID 30260088 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort.
Mather KJ, Bebu I, Baker C, et al. · Diabetes Res Clin Pract · 2020 · Trial result
PubMed: PMID 32450102 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.
Lundershausen R, Müller S, Hashim M, et al. · Exp Clin Endocrinol Diabetes · 2020 · Trial result
PubMed: PMID 30157532 · NCT01484262 · Diabetes Mellitus, Type 2
Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring.
Larkin ME, Nathan DM, Bebu I, et al. · Diabetes Technol Ther · 2020 · Trial result
PubMed: PMID 31393176 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
The Discovery and Development of Liraglutide and Semaglutide.
Knudsen LB, Lau J · Front Endocrinol (Lausanne) · 2020 · Trial result
PubMed: PMID 31031702 · NCT05952882 · Obesity
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Kelly AS, Auerbach P, Barrientos-Perez M, et al. · N Engl J Med · 2020 · Trial result
PubMed: PMID 32233338 · NCT02918279 · Obesity
Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K, Araki E, Tanizawa Y, et al. · Diabetes Obes Metab · 2020 · Trial result
PubMed: PMID 31407845 · NCT02607306 (DUAL™ I Japan) · Diabetes Mellitus, Type 2
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Han Y, Li Y, He B, et al. · Reprod Biomed Online · 2020 · Trial result
PubMed: PMID 31229399 · NCT05952882 · Obesity
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
Gilbert MP, Bain SC, Franek E, et al. · Ann Intern Med · 2020 · Trial result
PubMed: PMID 30508430 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients.
Brindisi MC, Brondel L, Meillon S, et al. · Diabetes Metab Syndr · 2020 · Trial result
PubMed: PMID 31405666 · NCT02674893 (GLP1 et Goût) · Diabetes Mellitus, Type 2
Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.
Björnson E, Packard CJ, Adiels M, et al. · J Intern Med · 2020 · Trial result
PubMed: PMID 30779243 · NCT02765399 · Diabetes Mellitus, Type 2
Facilitators and barriers to successful recruitment into a large comparative effectiveness trial: a qualitative study.
Behringer-Massera S, Browne T, George G, et al. · J Comp Eff Res · 2020 · Trial result
PubMed: PMID 31368793 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR, González-Galvez G, Grøn R, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
PubMed: PMID 31189519 · NCT02501161 (DUAL™ VIII) · Diabetes Mellitus, Type 2
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y, Katagiri H, Hamamoto Y, et al. · Lancet Diabetes Endocrinol · 2020 · Derived
PubMed: PMID 32333875 · NCT03018028 (PIONEER 9) · Diabetes Mellitus, Type 2
IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
Watada H, Ross Agner BF, Doshi A, et al. · Diabetes Ther · 2020 · Derived
PubMed: PMID 31760599 · NCT02911948 (DUAL™ II Japan) · Diabetes Mellitus, Type 2
Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.
Wadden TA, Walsh OA, Berkowitz RI, et al. · Obesity (Silver Spring) · 2020 · Derived
PubMed: PMID 30421856 · NCT02911818 (MODEL) · Obesity
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
Verma S, Bain SC, Buse JB, et al. · JAMA Cardiol · 2020 · Derived
PubMed: PMID 31721979 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.
van Eyk HJ, Paiman EHM, Bizino MB, et al. · Nutr Metab Cardiovasc Dis · 2020 · Derived
PubMed: PMID 32127340 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
van Eyk HJ, Paiman EHM, Bizino MB, et al. · Cardiovasc Diabetol · 2020 · Derived
PubMed: PMID 31288820 · NCT02660047 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.
van Eyk HJ, Blauw LL, Bizino MB, et al. · Sci Rep · 2020 · Derived
PubMed: PMID 31292457 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Tronieri JS, Wadden TA, Walsh OA, et al. · Metabolism · 2020 · Derived
PubMed: PMID 30902750 · NCT02911818 (MODEL) · Obesity
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Tack CJ, Jacob S, Desouza C, et al. · Diabetes Obes Metab · 2020 · Derived
PubMed: PMID 31282028 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Rosenstock J, Sorli CH, Trautmann ME, et al. · Diabetes Care · 2020 · Derived
PubMed: PMID 31320446 · NCT02057172 · Diabetes Mellitus, Type 2
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
RISE Consortium, RISE Consortium Investigators · Diabetes · 2020 · Derived
PubMed: PMID 31178433 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Obesity and insulin sensitivity effects on cardiovascular risk factors: Comparisons of obese dysglycemic youth and adults.
RISE Consortium · Pediatr Diabetes · 2020 · Derived
PubMed: PMID 31301210 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
RISE Consortium · Diabetes Care · 2020 · Derived
PubMed: PMID 31178434 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
Redouane B, Greene SJ, Fudim M, et al. · Circ Heart Fail · 2020 · Derived
PubMed: PMID 32362166 · NCT01800968 (FIGHT)
Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.
Peradze N, Farr OM, Perakakis N, et al. · Cardiovasc Diabetol · 2020 · Derived
PubMed: PMID 31672146 · NCT02944500 · Obesity
Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study.
Patel S, Abreu M, Tumyan A, et al. · BMJ Open Diabetes Res Care · 2020 · Derived
PubMed: PMID 31803482 · NCT01966978 (SIMPLE) · Diabetes Mellitus, Type 2
Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.
Nielsen R, Jorsal A, Iversen P, et al. · J Nucl Cardiol · 2020 · Derived
PubMed: PMID 28770459 · NCT01472640 · Diabetes Mellitus
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
Nauck MA, Muus Ghorbani ML, Kreiner E, et al. · Diabetes Care · 2020 · Derived
PubMed: PMID 31399438 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
Nauck MA, Kreiner E, Rasmussen S, et al. · Diabetes Care · 2020 · Derived
PubMed: PMID 31959650 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
Marso SP, Baeres FMM, Bain SC, et al. · J Am Coll Cardiol · 2020 · Derived
PubMed: PMID 32164886 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
Khoo J, Hsiang JC, Taneja R, et al. · Liver Int · 2020 · Derived
PubMed: PMID 30721572 · NCT02654665 (CGH-LiNASH) · Weight Loss
Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.
Iwamoto N, Matsui A, Kazama H, et al. · Diabetes Ther · 2020 · Derived
PubMed: PMID 29264713 · NCT01558271 · Diabetes Mellitus, Type 2
Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Gudbergsen H, Henriksen M, Wæhrens EE, et al. · BMJ Open · 2020 · Derived
PubMed: PMID 31061017 · NCT02905864 (LOSEIT) · Obesity
Metformin monotherapy for adults with type 2 diabetes mellitus.
Gnesin F, Thuesen ACB, Kähler LKA, et al. · Cochrane Database Syst Rev · 2020 · Derived
PubMed: PMID 32501595 · NCT03010683 · Diabetes Mellitus, Type 2
Development and First Use of the Patient's Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit-Harm of Drugs Received During Clinical Studies.
Gater A, Reaney M, Findley A, et al. · Drug Saf · 2020 · Derived
PubMed: PMID 31679129 · NCT02973321 · Diabetes Mellitus, Type 2
Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.
Capehorn M, Ghani Y, Hindsberger C, et al. · Diabetes Ther · 2020 · Derived
PubMed: PMID 32193837 · NCT03191396 (SUSTAIN 10) · Diabetes Mellitus, Type 2
Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.
Brock C, Hansen CS, Karmisholt J, et al. · Br J Clin Pharmacol · 2020 · Derived
PubMed: PMID 31338868 · NCT02138045 (TODINELI) · Diabetes Mellitus, Type 1
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L, Rosenstock J, Del Prato S, et al. · Diabetes Care · 2020 · Derived
PubMed: PMID 31530665 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB, Jazet IM, de Heer P, et al. · Diabetologia · 2020 · Derived
PubMed: PMID 31690988 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
Verma S, Bain SC, Monk Fries T, et al. · Diabetes Obes Metab · 2020 · Background
PubMed: PMID 30851070 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF, Sokhela S, Simmons B, et al. · Lancet HIV · 2020 · Background
PubMed: PMID 33010240 · NCT06438146 (LIROH) · Obesity
Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.
Unger J, Allison DC, Carlton M, et al. · Diabetes Obes Metab · 2020 · Background
PubMed: PMID 30828917 · NCT02730377 (LIRA-PRIME) · Diabetes Mellitus, Type 2
Closed testing of each group versus the others combined in a multiple group analysis.
Lachin JM, Bebu I · Clin Trials · 2020 · Background
PubMed: PMID 31647326 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.
Khunti K, Mohan V, Jain SM, et al. · Diabetes Ther · 2020 · Background
PubMed: PMID 28332144 · NCT01392573 (DUAL™ II) · Diabetes Mellitus, Type 2
Cardiovascular risk factors among ART-experienced people with HIV in South Africa.
Hyle EP, Bekker LG, Martey EB, et al. · J Int AIDS Soc · 2020 · Background
PubMed: PMID 30990252 · NCT06438146 (LIROH) · Obesity
Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network.
Hinton W, Feher M, Munro N, et al. · Diabetes Obes Metab · 2020 · Background
PubMed: PMID 30900349 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Obesity and Weight Gain in Persons with HIV.
Bailin SS, Gabriel CL, Wanjalla CN, et al. · Curr HIV/AIDS Rep · 2020 · Background
PubMed: PMID 32072466 · NCT06438146 (LIROH) · Obesity

2019 (35 papers)

Effect of body mass index on pregnancy outcomes in a freeze-all policy: an analysis of 22,043 first autologous frozen-thawed embryo transfer cycles in China.
Zhang J, Liu H, Mao X, et al. · BMC Med · 2019 · Trial result
PubMed: PMID 31238940 · NCT05952882 · Obesity
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
Verma S, Poulter NR, Bhatt DL, et al. · Circulation · 2019 · Trial result
PubMed: PMID 30566004 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
Verma S, Leiter LA, Mazer CD, et al. · Circulation · 2019 · Trial result
PubMed: PMID 30354517 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
Verma S, Bhatt DL, Bain SC, et al. · Circulation · 2019 · Trial result
PubMed: PMID 29760228 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.
Vergès B, Duvillard L, Pais de Barros JP, et al. · Arterioscler Thromb Vasc Biol · 2019 · Trial result
PubMed: PMID 30026275 · NCT02721888 (LIRA-NAFLD/LIP) · Diabetes Mellitus, Type 2
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
Teede HJ, Misso ML, Costello MF, et al. · Fertil Steril · 2019 · Trial result
PubMed: PMID 30033227 · NCT05952882 · Obesity
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
Price H, Blüher M, Prager R, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29205856 · NCT02754817 · Diabetes Mellitus, Type 2
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R, Amod A, Hoff ST, et al. · Lancet · 2019 · Trial result
PubMed: PMID 31186120 · NCT02863419 (PIONEER 4) · Diabetes Mellitus, Type 2
Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.
Overbeek JA, Heintjes EM, Huisman EL, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29726082 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.
Nexøe-Larsen CC, Sørensen PH, Hausner H, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 29892986 · NCT02717858 · Obesity
Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
Matikainen N, Söderlund S, Björnson E, et al. · Diabetes Obes Metab · 2019 · Trial result
PubMed: PMID 30073766 · NCT02765399 · Diabetes Mellitus, Type 2
Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
Mastrandrea LD, Witten L, Carlsson Petri KC, et al. · Pediatr Obes · 2019 · Trial result
PubMed: PMID 30653847 · NCT02696148 · Obesity
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).
Marso SP, Nauck MA, Monk Fries T, et al. · Am J Cardiol · 2019 · Trial result
PubMed: PMID 29627109 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Mann JFE, Fonseca V, Mosenzon O, et al. · Circulation · 2019 · Trial result
PubMed: PMID 30566006 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
Lingvay I, Handelsman Y, Linjawi S, et al. · Endocr Pract · 2019 · Trial result
PubMed: PMID 30383495 · NCT01676116 (DUAL™ III) · Diabetes Mellitus, Type 2
Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.
le Roux C, Aroda V, Hemmingsson J, et al. · Obes Facts · 2019 · Trial result
PubMed: PMID 29145215 · NCT01272219 · Obesity
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
Lapolla A, Berra C, Boemi M, et al. · Adv Ther · 2019 · Trial result
PubMed: PMID 29270781 · NCT02255266 · Diabetes Mellitus, Type 2
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
Wittbrodt ET, Eudicone JM, Bell KF, et al. · Am J Manag Care · 2019 · Derived
PubMed: PMID 29693361 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.
Suhrs HE, Raft KF, Bové K, et al. · Int J Cardiol · 2019 · Derived
PubMed: PMID 30773266 · NCT02602600 (GAP) · Microvascular Angina
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.
Sharma A, Ambrosy AP, DeVore AD, et al. · ESC Heart Fail · 2019 · Derived
PubMed: PMID 30120812 · NCT01800968 (FIGHT)
Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes.
Nunez Lopez YO, Retnakaran R, Zinman B, et al. · Mol Metab · 2019 · Derived
PubMed: PMID 30503831 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.
Mather KJ, Considine RV, Hamilton L, et al. · J Clin Endocrinol Metab · 2019 · Derived
PubMed: PMID 30020461 · NCT01232946 · Diabetes Mellitus, Type 2
Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V, Pavlidis G, Kousathana F, et al. · Cardiovasc Diabetol · 2019 · Derived
PubMed: PMID 29310645 · NCT03010683 · Diabetes Mellitus, Type 2
Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.
Kim JD, Park CY, Cha BY, et al. · Clin Ther · 2019 · Derived
PubMed: PMID 29729957 · NCT01620489 · Diabetes Mellitus, Type 2
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, et al. · Trials · 2019 · Derived
PubMed: PMID 30944040 · NCT01843075 (ELAD) · Alzheimer Disease
Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB, Jazet IM, Westenberg JJM, et al. · Cardiovasc Diabetol · 2019 · Derived
PubMed: PMID 31039778 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF, Moorhouse M, Sokhela S, et al. · N Engl J Med · 2019 · Background
PubMed: PMID 31339677 · NCT06438146 (LIROH) · Obesity
Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS · Cardiovasc Res · 2019 · Background
PubMed: PMID 30052921 · NCT04122716 (S-LITE) · Obesity
Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. · N Engl J Med · 2019 · Background
PubMed: PMID 31034184 · NCT01541215 (Ellipse™) · Diabetes Mellitus, Type 2
Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH, Jeon SJ, Cho KS, et al. · Mol Neurobiol · 2019 · Background
PubMed: PMID 28456941 · NCT04137328
Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.
Kolotkin RL, Williams VSL, Ervin CM, et al. · Clin Obes · 2019 · Background
PubMed: PMID 30993900 · NCT02453711 · Obesity
Living with painful diabetic neuropathy: insights from focus groups into fears and coping strategies.
Kanera IM, van Laake-Geelen CCM, Ruijgrok JM, et al. · Psychol Health · 2019 · Background
PubMed: PMID 30320508 · NCT04137328
Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential.
Inoue K, Tsuda M · Nat Rev Neurosci · 2019 · Background
PubMed: PMID 29416128 · NCT04137328
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Garvey WT, Mechanick JI, Brett EM, et al. · Endocr Pract · 2019 · Background
PubMed: PMID 27219496 · NCT04122716 (S-LITE) · Obesity
Properties of composite time to first event versus joint marginal analyses of multiple outcomes.
Bebu I, Lachin JM · Stat Med · 2019 · Background
PubMed: PMID 29956365 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2

2018 (45 papers)

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
Zinman B, Marso SP, Christiansen E, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 29903847 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Altered Odor-Induced Brain Activity as an Early Manifestation of Cognitive Decline in Patients With Type 2 Diabetes.
Zhang Z, Zhang B, Wang X, et al. · Diabetes · 2018 · Trial result
PubMed: PMID 29500313 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
von Scholten BJ, Davies MJ, Persson F, et al. · J Diabetes Complications · 2018 · Trial result
PubMed: PMID 28462892 · NCT01272219 · Obesity
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population.
Satman I, R Rea R, Eriksson M, et al. · J Diabetes Complications · 2018 · Trial result
PubMed: PMID 27320184 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Salamun V, Jensterle M, Janez A, et al. · Eur J Endocrinol · 2018 · Trial result
PubMed: PMID 29703793 · NCT05952882 · Obesity
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
Rodbard HW, Bode BW, Harris SB, et al. · Diabet Med · 2018 · Trial result
PubMed: PMID 27589252 · NCT01618162 (DUAL™IV) · Diabetes Mellitus, Type 2
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM, Birkenfeld AL, McGowan B, et al. · Lancet · 2018 · Trial result
PubMed: PMID 30122305 · NCT02453711 · Obesity
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM, Aroda VR, Astrup A, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28386912 · NCT00781937 · Obesity
Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
Nylander M, Frøssing S, Clausen HV, et al. · Reprod Biomed Online · 2018 · Trial result
PubMed: PMID 28479118 · NCT05952882 · Obesity
Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
Norwood P, Chen R, Jaeckel E, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28417535 · NCT01336023 (DUAL™ I) · Diabetes Mellitus, Type 2
Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
Nauck MA, Tornøe K, Rasmussen S, et al. · Diab Vasc Dis Res · 2018 · Trial result
PubMed: PMID 29947247 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.
Nauck MA, Jensen TJ, Rosenkilde C, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 29898902 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Lingvay I, Harris S, Jaeckel E, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28643425 · NCT01952145 (DUAL™ V) · Diabetes Mellitus, Type 2
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Lingvay I, Desouza CV, Lalic KS, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 30026333 · NCT02461589 · Diabetes Mellitus, Type 2
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, et al. · Lancet · 2018 · Trial result
PubMed: PMID 28237263 · NCT01272219 · Obesity
Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
Kolotkin RL, Gabriel Smolarz B, Meincke HH, et al. · Clin Obes · 2018 · Trial result
PubMed: PMID 29045079 · NCT01272219 · Obesity
Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.
Kiyosue A, Seino Y, Nishijima K, et al. · J Diabetes Investig · 2018 · Trial result
PubMed: PMID 28984041 · NCT01512108 · Diabetes Mellitus, Type 2
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial.
Kaneko S, Nishijima K, Bosch-Traberg H, et al. · J Diabetes Investig · 2018 · Trial result
PubMed: PMID 29277968 · NCT01572740 · Diabetes Mellitus, Type 2
Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B, Mocarski M, Valentine WJ, et al. · J Med Econ · 2018 · Trial result
PubMed: PMID 28294641 · NCT01952145 (DUAL™ V) · Diabetes Mellitus, Type 2
Theory of mind predicts severity level in autism.
Hoogenhout M, Malcolm-Smith S · Autism · 2018 · Trial result
PubMed: PMID 27493232 · NCT02098395 (ADJUNCT TWO™) · Diabetes Mellitus
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
Hegedüs L, Sherman SI, Tuttle RM, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 29279300 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
Harris SB, Kocsis G, Prager R, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28124817 · NCT02298192 (DUAL™ VI) · Diabetes Mellitus, Type 2
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S, Nylander M, Chabanova E, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28681988 · NCT05952882 · Obesity
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Frias JP, Bastyr EJ, Vignati L, et al. · Cell Metab · 2018 · Trial result
PubMed: PMID 28768173 · NCT02205528 · Diabetes Mellitus, Type 2
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.
Dhatariya K, Bain SC, Buse JB, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 30072400 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.
Davies MJ, Aronne LJ, Caterson ID, et al. · Diabetes Obes Metab · 2018 · Trial result
PubMed: PMID 28950422 · NCT01272219 · Obesity
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
Blackman A, Foster GD, Zammit G, et al. · Int J Obes (Lond) · 2018 · Trial result
PubMed: PMID 27005405 · NCT01557166 · Obesity
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Billings LK, Doshi A, Gouet D, et al. · Diabetes Care · 2018 · Trial result
PubMed: PMID 29483185 · NCT02420262 · Diabetes Mellitus, Type 2
How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence.
Best D, Avenell A, Bhattacharya S, et al. · Hum Reprod Update · 2018 · Trial result
PubMed: PMID 28961722 · NCT05952882 · Obesity
Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.
Ten Kulve JS, Veltman DJ, Gerdes VEA, et al. · Diabetes Care · 2018 · Derived
PubMed: PMID 29025878 · NCT01363609 (LIBRA) · Diabetes Mellitus, Type 2
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
Shankar SS, Shankar RR, Mixson LA, et al. · Diabetes · 2018 · Derived
PubMed: PMID 29545266 · NCT01373450 · Diabetes Mellitus, Type 2
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test.
RISE Consortium · Diabetes Care · 2018 · Derived
PubMed: PMID 29941498 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp.
RISE Consortium · Diabetes Care · 2018 · Derived
PubMed: PMID 29941497 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
Hunt B, Vega-Hernandez G, Valentine WJ, et al. · Diabetes Obes Metab · 2018 · Derived
PubMed: PMID 28124820 · NCT01973231 (LIRA-LIXI™) · Diabetes Mellitus, Type 2
Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.
Huang M, Wei R, Wang Y, et al. · Ann Med · 2018 · Derived
PubMed: PMID 28286967 · NCT02001363 · Reperfusion Injury
Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).
Heller SR, Pratley RE, Sinclair A, et al. · Diabetes Obes Metab · 2018 · Derived
PubMed: PMID 28671753 · NCT02072096 (IMPERIUM) · Diabetes Mellitus, Type 2
Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Dubé MC, D'Amours M, Weisnagel SJ, et al. · Diabetes Obes Metab · 2018 · Derived
PubMed: PMID 28722271 · NCT01787916 (LIDO) · Diabetes Mellitus, Type 1
The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.
Vinué Á, Navarro J, Herrero-Cervera A, et al. · Diabetologia · 2018 · Background
PubMed: PMID 28608285 · NCT04137328
Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.
Nakatani Y, Maeda M, Matsumura M, et al. · Diabetes Metab · 2018 · Background
PubMed: PMID 28648835 · NCT04046822 · Obesity
Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers.
Jeffcoate WJ, Vileikyte L, Boyko EJ, et al. · Diabetes Care · 2018 · Background
PubMed: PMID 29559450 · NCT04137328
Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds.
Insuela DBR, Carvalho VF · Eur J Pharmacol · 2018 · Background
PubMed: PMID 28688914 · NCT04122716 (S-LITE) · Obesity
Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium.
Hannon TS, Kahn SE, Utzschneider KM, et al. · Diabetes Obes Metab · 2018 · Background
PubMed: PMID 28493515 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H, Khemani D, Eckert D, et al. · Lancet Gastroenterol Hepatol · 2018 · Background
PubMed: PMID 28958851 · NCT02647944 · Obesity
Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation.
Garczorz W, Gallego-Colon E, Kosowska A, et al. · Cardiovasc Ther · 2018 · Background
PubMed: PMID 29283509 · NCT04122716 (S-LITE) · Obesity
Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.
Bruen R, Curley S, Kajani S, et al. · Cardiovasc Diabetol · 2018 · Background
PubMed: PMID 29110715 · NCT04137328

2017 (69 papers)

The International Glossary on Infertility and Fertility Care, 2017.
Zegers-Hochschild F, Adamson GD, Dyer S, et al. · Fertil Steril · 2017 · Trial result
PubMed: PMID 28760517 · NCT05952882 · Obesity
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L, Liu Y, Geng J, et al. · Diabetes Obes Metab · 2017 · Trial result
PubMed: PMID 27060930 · NCT02008682 · Diabetes Mellitus, Type 2
Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP, Overgaard RV, Jacobsen LV, et al. · Diabetes Obes Metab · 2017 · Trial result
PubMed: PMID 26833744 · NCT01272232 · Obesity
Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program.
Steinberg WM, Rosenstock J, Wadden TA, et al. · Diabetes Care · 2017 · Trial result
PubMed: PMID 28473337 · NCT01557166 · Obesity
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
Steinberg WM, Buse JB, Ghorbani MLM, et al. · Diabetes Care · 2017 · Trial result
PubMed: PMID 28476871 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.
Seino Y, Kaneko S, Fukuda S, et al. · J Diabetes Investig · 2017 · Trial result
PubMed: PMID 27182042 · NCT01572740 · Diabetes Mellitus, Type 2
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
Rosenfield RL, Ehrmann DA · Endocr Rev · 2017 · Trial result
PubMed: PMID 27459230 · NCT05952882 · Obesity
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
Petrie JR, Marso SP, Bain SC, et al. · J Hypertens · 2017 · Trial result
PubMed: PMID 26855018 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.
Overgaard RV, Petri KC, Jacobsen LV, et al. · Clin Pharmacokinet · 2017 · Trial result
PubMed: PMID 27193270 · NCT01272232 · Obesity
EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
O'Neil PM, Garvey WT, Gonzalez-Campoy JM, et al. · Endocr Pract · 2017 · Trial result
PubMed: PMID 27482610 · NCT00781937 · Obesity
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
Nauck M, Rizzo M, Johnson A, et al. · Diabetes Care · 2017 · Trial result
PubMed: PMID 27311491 · NCT01973231 (LIRA-LIXI™) · Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Mathieu C, Zinman B, Hemmingsson JU, et al. · Diabetes Care · 2017 · Trial result
PubMed: PMID 27506222 · NCT01836523 (ADJUNCT ONE™) · Diabetes Mellitus
Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.
Martinez L, Penfornis A, Gautier JF, et al. · Adv Ther · 2017 · Trial result
PubMed: PMID 28138803 · NCT01226966 (EVIDENCE) · Diabetes Mellitus, Type 2
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, et al. · N Engl J Med · 2017 · Trial result
PubMed: PMID 28854085 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
Mader JK, Jensen L, Ingwersen SH, et al. · Clin Pharmacokinet · 2017 · Trial result
PubMed: PMID 27282158 · NCT01536665 · Diabetes Mellitus
Obesity and access to kidney transplantation in patients starting dialysis: A prospective cohort study.
Lassalle M, Fezeu LK, Couchoud C, et al. · PLoS One · 2017 · Trial result
PubMed: PMID 28493926 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
Kolotkin RL, Fujioka K, Wolden ML, et al. · Clin Obes · 2017 · Trial result
PubMed: PMID 27198973 · NCT01272219 · Obesity
A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
King AB, Philis-Tsimikas A, Kilpatrick ES, et al. · Diabetes Technol Ther · 2017 · Trial result
PubMed: PMID 28282219 · NCT01392573 (DUAL™ II) · Diabetes Mellitus, Type 2
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
Hunt B, Mocarski M, Valentine WJ, et al. · Adv Ther · 2017 · Trial result
PubMed: PMID 28281218 · NCT01952145 (DUAL™ V) · Diabetes Mellitus, Type 2
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
Fujioka K, O'Neil PM, Davies M, et al. · Obesity (Silver Spring) · 2017 · Trial result
PubMed: PMID 27804269 · NCT01272232 · Obesity
Assessment of a National Diabetes Education Program diabetes management booklet: The GRADE experience.
Devchand R, Nicols C, Gallivan JM, et al. · J Am Assoc Nurse Pract · 2017 · Trial result
PubMed: PMID 28213915 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.
Davidson JA, Ørsted DD, Campos C, et al. · Diabetes Obes Metab · 2017 · Trial result
PubMed: PMID 26936426 · NCT00333151 (LEAD-4) · Diabetes Mellitus, Type 2
Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.
Danne T, Biester T, Kapitzke K, et al. · J Pediatr · 2017 · Trial result
PubMed: PMID 27979579 · NCT01789086 · Obesity
Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
Bays H, Pi-Sunyer X, Hemmingsson JU, et al. · Curr Med Res Opin · 2017 · Trial result
PubMed: PMID 27817208 · NCT01557166 · Obesity
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
Bailey TS, Takács R, Tinahones FJ, et al. · Diabetes Obes Metab · 2017 · Trial result
PubMed: PMID 27381275 · NCT01907854 (LIRA-SWITCH™) · Diabetes Mellitus, Type 2
Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
Azar ST, Echtay A, Wan Bebakar WM, et al. · Diabetes Obes Metab · 2017 · Trial result
PubMed: PMID 27376711 · NCT01917656 (LIRA-Ramadan™) · Diabetes Mellitus, Type 2
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
Aroda VR, Bailey TS, Cariou B, et al. · Diabetes Obes Metab · 2017 · Trial result
PubMed: PMID 26990378 · NCT01664247 · Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Ahrén B, Hirsch IB, Pieber TR, et al. · Diabetes Care · 2017 · Trial result
PubMed: PMID 27493132 · NCT02098395 (ADJUNCT TWO™) · Diabetes Mellitus
The effect of liraglutide on renal function: A randomized clinical trial.
von Scholten BJ, Persson F, Rosenlund S, et al. · Diabetes Obes Metab · 2017 · Derived
PubMed: PMID 27753201 · NCT02545738 (LIRALBU) · Diabetic Nephropathies
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
Vanderheiden A, Harrison LB, Warshauer JT, et al. · J Clin Endocrinol Metab · 2017 · Derived
PubMed: PMID 26909799 · NCT01505673 · Diabetes Mellitus, Type 2
Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Vanderheiden A, Harrison L, Warshauer J, et al. · JAMA Intern Med · 2017 · Derived
PubMed: PMID 27273731 · NCT01505673 · Diabetes Mellitus, Type 2
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Tonneijck L, Smits MM, Muskiet MHA, et al. · Diabetologia · 2017 · Derived
PubMed: PMID 27038451 · NCT01744236 · Diabetes Mellitus, Type 2
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Tonneijck L, Smits MM, Muskiet MH, et al. · Diabetes Care · 2017 · Derived
PubMed: PMID 27585605 · NCT01744236 · Diabetes Mellitus, Type 2
Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
Suzuki S, Oura T, Takeuchi M, et al. · Health Qual Life Outcomes · 2017 · Derived
PubMed: PMID 28606095 · NCT01558271 · Diabetes Mellitus, Type 2
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Smits MM, Tonneijck L, Muskiet MH, et al. · Diabetologia · 2017 · Derived
PubMed: PMID 27627981 · NCT01744236 · Diabetes Mellitus, Type 2
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Smits MM, Tonneijck L, Muskiet MH, et al. · Diabetes Obes Metab · 2017 · Derived
PubMed: PMID 27451030 · NCT01744236 · Diabetes Mellitus, Type 2
Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
Silverstein JM · Pituitary · 2017 · Derived
PubMed: PMID 27405306 · NCT02060383 · Hyperglycemia
Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.
Shankar SS, Shankar RR, Mixson LA, et al. · Am J Physiol Endocrinol Metab · 2017 · Derived
PubMed: PMID 27072496 · NCT01373450 · Diabetes Mellitus, Type 2
Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.
Sedman T, Vasar E, Volke V, et al. · J Clin Endocrinol Metab · 2017 · Derived
PubMed: PMID 28379427 · NCT02089256
Liraglutide Treatment May Affect Renin and Aldosterone Release.
Sedman T, Heinla K, Vasar E, et al. · Horm Metab Res · 2017 · Derived
PubMed: PMID 27300475 · NCT02089256
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.
Muscogiuri G, DeFronzo RA, Gastaldelli A, et al. · Trends Endocrinol Metab · 2017 · Derived
PubMed: PMID 27871675 · NCT01469351 · Alzheimer Disease
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR, Vedtofte L, Jakobsen MSL, et al. · JAMA Psychiatry · 2017 · Derived
PubMed: PMID 28601891 · NCT01845259 (GREAT)
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
Kumarathurai P, Anholm C, Nielsen OW, et al. · Cardiovasc Diabetol · 2017 · Derived
PubMed: PMID 27455835 · NCT01595789 (AddHope2) · Diabetes Mellitus, Type 2
Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
Kumarathurai P, Anholm C, Larsen BS, et al. · Diabetes Care · 2017 · Derived
PubMed: PMID 27797930 · NCT01595789 (AddHope2) · Diabetes Mellitus, Type 2
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Kumarathurai P, Anholm C, Fabricius-Bjerre A, et al. · J Hypertens · 2017 · Derived
PubMed: PMID 28129251 · NCT01595789 (AddHope2) · Diabetes Mellitus, Type 2
Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Kuhadiya ND, Ghanim H, Mehta A, et al. · J Clin Endocrinol Metab · 2017 · Derived
PubMed: PMID 27490915 · NCT02518945 · Diabetes Mellitus, Type 1
Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Kuhadiya ND, Dhindsa S, Ghanim H, et al. · Diabetes Care · 2017 · Derived
PubMed: PMID 27208343 · NCT01722266 · Diabetes Mellitus, Type 1
Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion.
Kramer CK, Zinman B, Choi H, et al. · J Clin Endocrinol Metab · 2017 · Derived
PubMed: PMID 28472325 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Jensterle M, Kravos NA, Goričar K, et al. · BMC Endocr Disord · 2017 · Derived
PubMed: PMID 28143456 · NCT02909933 · Obesity
Liraglutide causes large and rapid epicardial fat reduction.
Iacobellis G, Mohseni M, Bianco SD, et al. · Obesity (Silver Spring) · 2017 · Derived
PubMed: PMID 28124506 · NCT02014740 · Diabetes Mellitus, Type 2
Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).
Htike ZZ, Yates T, Brady EM, et al. · Cardiovasc Diabetol · 2017 · Derived
PubMed: PMID 27440110 · NCT02043054 (LYDIA) · Diabetes Mellitus, Type 2
GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM, Sofopoulos M, Tsoukas MA, et al. · Diabetologia · 2017 · Derived
PubMed: PMID 26831302 · NCT01562678 · Diabetes Mellitus
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF, Frandsen CS, Hansen TS, et al. · Lancet Diabetes Endocrinol · 2017 · Derived
PubMed: PMID 26656289 · NCT01612468 · Diabetes Mellitus
Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.
Chen WR, Chen YD, Tian F, et al. · Circ Cardiovasc Imaging · 2017 · Derived
PubMed: PMID 27940956 · NCT02001363 · Reperfusion Injury
Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.
Boustani MA, Pittman I, Yu M, et al. · Diabetes Obes Metab · 2017 · Derived
PubMed: PMID 27161178 · NCT01624259 (AWARD-6) · Diabetes Mellitus, Type 2
G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.
Zoso A, Serafini P, Lanzoni G, et al. · PLoS One · 2017 · Background
PubMed: PMID 27285580 · NCT03011021 · Diabetes Mellitus, Type 1
Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways.
Zhang Y, Zhou H, Wu W, et al. · Free Radic Biol Med · 2017 · Background
PubMed: PMID 27038735 · NCT02930265
Circulating cytokines as determinants of weight loss-induced improvements in insulin sensitivity.
Weiss EP, Reeds DN, Ezekiel UR, et al. · Endocrine · 2017 · Background
PubMed: PMID 27605038 · NCT04122716 (S-LITE) · Obesity
Effects of matched weight loss from calorie restriction, exercise, or both on cardiovascular disease risk factors: a randomized intervention trial.
Weiss EP, Albert SG, Reeds DN, et al. · Am J Clin Nutr · 2017 · Background
PubMed: PMID 27465384 · NCT04122716 (S-LITE) · Obesity
Substantial Decrease in Comorbidity 5 Years After Gastric Bypass: A Population-based Study From the Scandinavian Obesity Surgery Registry.
Sundbom M, Hedberg J, Marsk R, et al. · Ann Surg · 2017 · Background
PubMed: PMID 27429019 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Gut microbiota, obesity and diabetes.
Patterson E, Ryan PM, Cryan JF, et al. · Postgrad Med J · 2017 · Background
PubMed: PMID 26912499 · NCT04046822 · Obesity
GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E, McCulloch LJ, Ward R, et al. · Clin Sci (Lond) · 2017 · Background
PubMed: PMID 28049736 · NCT04122716 (S-LITE) · Obesity
Fallacies of last observation carried forward analyses.
Lachin JM · Clin Trials · 2017 · Background
PubMed: PMID 26400875 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.
Iepsen EW, Lundgren J, Holst JJ, et al. · Eur J Endocrinol · 2017 · Background
PubMed: PMID 26976129 · NCT04122716 (S-LITE) · Obesity
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
Hirano T, Mori Y · J Diabetes Investig · 2017 · Background
PubMed: PMID 27186361 · NCT04137328
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
Ericsson Å, Lundqvist A · Appl Health Econ Health Policy · 2017 · Background
PubMed: PMID 28063135 · NCT01392573 (DUAL™ II) · Diabetes Mellitus, Type 2
Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.
Chen WR, Shen XQ, Zhang Y, et al. · Endocrine · 2017 · Background
PubMed: PMID 26573925 · NCT02930265
Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation.
Chang TJ, Tseng HC, Liu MW, et al. · Sci Rep · 2017 · Background
PubMed: PMID 26997114 · NCT03011008 · Diabetes Mellitus, Type 1
Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery.
Batterham RL, Cummings DE · Diabetes Care · 2017 · Background
PubMed: PMID 27222547 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus

2016 (65 papers)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
Vilsbøll T, Vora J, Jarlov H, et al. · Clin Drug Investig · 2016 · Trial result
PubMed: PMID 26894800 · NCT01336023 (DUAL™ I) · Diabetes Mellitus, Type 2
LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.
Rutten GE, Tack CJ, Pieber TR, et al. · Diabetol Metab Syndr · 2016 · Trial result
PubMed: PMID 27274772 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
Pieber TR, Deller S, Korsatko S, et al. · Diabetes Obes Metab · 2016 · Trial result
PubMed: PMID 25855340 · NCT01536665 · Diabetes Mellitus
Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.
Petri KC, Jacobsen LV, Klein DJ, et al. · Clin Pharmacokinet · 2016 · Trial result
PubMed: PMID 25603819 · NCT00943501 · Diabetes Mellitus, Type 2
Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis.
Pedroso JA, Zampieri TT, Donato J, et al. · Nutrients · 2016 · Trial result
PubMed: PMID 26007339 · NCT02616003 · Obesity, Morbid
A randomised trial comparing weight loss with aerobic exercise in overweight individuals with coronary artery disease: The CUT-IT trial.
Pedersen LR, Olsen RH, Jürs A, et al. · Eur J Prev Cardiol · 2016 · Trial result
PubMed: PMID 25082954 · NCT02602600 (GAP) · Microvascular Angina
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Meier JJ, Rosenstock J, Hincelin-Méry A, et al. · Diabetes Care · 2016 · Trial result
PubMed: PMID 25887358 · NCT01596504 · Diabetes Mellitus, Type 2
Missing data in clinical trials for weight management.
McEvoy BW · J Biopharm Stat · 2016 · Trial result
PubMed: PMID 26418188 · NCT00781937 · Obesity
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
Masmiquel L, Leiter LA, Vidal J, et al. · Cardiovasc Diabetol · 2016 · Trial result
PubMed: PMID 26864124 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med · 2016 · Trial result
PubMed: PMID 27295427 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.
Malm-Erjefält M, Ekblom M, Vouis J, et al. · Mol Pharm · 2016 · Trial result
PubMed: PMID 26426736 · NCT01518166 · Diabetes Mellitus
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I, Pérez Manghi F, García-Hernández P, et al. · JAMA · 2016 · Trial result
PubMed: PMID 26934259 · NCT01952145 (DUAL™ V) · Diabetes Mellitus, Type 2
Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome.
Legro RS, Dodson WC, Kris-Etherton PM, et al. · J Clin Endocrinol Metab · 2016 · Trial result
PubMed: PMID 26401593 · NCT05952882 · Obesity
Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.
Kapitza C, Bode B, Ingwersen SH, et al. · J Clin Pharmacol · 2016 · Trial result
PubMed: PMID 25998481 · NCT01336023 (DUAL™ I) · Diabetes Mellitus, Type 2
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.
Kaku K, Kiyosue A, Ono Y, et al. · J Diabetes Investig · 2016 · Trial result
PubMed: PMID 26816604 · NCT01512108 · Diabetes Mellitus, Type 2
Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.
Idorn T, Knop FK, Jørgensen MB, et al. · Diabetes Care · 2016 · Trial result
PubMed: PMID 26283739 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
Holst JJ, Buse JB, Rodbard HW, et al. · J Diabetes Sci Technol · 2016 · Trial result
PubMed: PMID 26443290 · NCT01336023 (DUAL™ I) · Diabetes Mellitus, Type 2
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Gough SC, Bode BW, Woo VC, et al. · Diabetes Obes Metab · 2016 · Trial result
PubMed: PMID 25980900 · NCT01336023 (DUAL™ I) · Diabetes Mellitus, Type 2
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.
Gilbert MP, Marre M, Holst JJ, et al. · Endocr Pract · 2016 · Trial result
PubMed: PMID 26574791 · NCT00294723 (LEAD-3) · Diabetes Mellitus, Type 2
Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.
Gautier JF, Martinez L, Penfornis A, et al. · Adv Ther · 2016 · Trial result
PubMed: PMID 26424330 · NCT01226966 (EVIDENCE) · Diabetes Mellitus, Type 2
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Faber R, Zander M, Pena A, et al. · Cardiovasc Diabetol · 2016 · Trial result
PubMed: PMID 25896352 · NCT02602600 (GAP) · Microvascular Angina
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
Davies MJ, Bain SC, Atkin SL, et al. · Diabetes Care · 2016 · Trial result
PubMed: PMID 26681713 · NCT01620489 · Diabetes Mellitus, Type 2
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.
Daniels GH, Hegedüs L, Marso SP, et al. · Diabetes Obes Metab · 2016 · Trial result
PubMed: PMID 25656058 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients.
Buysschaert M, D'Hooge D, Preumont V, et al. · Diabetes Metab Syndr · 2016 · Trial result
PubMed: PMID 26004030 · NCT01288326 (ROOTS) · Diabetes Mellitus, Type 2
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ, Hull D, Guo K, et al. · J Hepatol · 2016 · Trial result
PubMed: PMID 26394161 · NCT01237119 (LEAN) · Non-alcoholic Fatty Liver Disease
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ, Gaunt P, Aithal GP, et al. · Lancet · 2016 · Trial result
PubMed: PMID 26608256 · NCT01237119 (LEAN) · Non-alcoholic Fatty Liver Disease
Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
Ard J, Cannon A, Lewis CE, et al. · Diabetes Obes Metab · 2016 · Trial result
PubMed: PMID 26744025 · NCT01272232 · Obesity
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Ahmann A, Rodbard HW, Rosenstock J, et al. · Diabetes Obes Metab · 2016 · Trial result
PubMed: PMID 26179619 · NCT01617434 · Diabetes Mellitus, Type 2
Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M, Van Brunt K, Varnado OJ, et al. · Diabetes Obes Metab · 2016 · Derived
PubMed: PMID 26691396 · NCT01624259 (AWARD-6) · Diabetes Mellitus, Type 2
Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
von Scholten BJ, Hansen TW, Goetze JP, et al. · J Diabetes Complications · 2016 · Derived
PubMed: PMID 25935863 · NCT01499108 (Liratime) · Diabetes Mellitus, Type 2
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.
ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. · Diabetologia · 2016 · Derived
PubMed: PMID 26385462 · NCT01363609 (LIBRA) · Diabetes Mellitus, Type 2
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
Tang A, Rabasa-Lhoret R, Castel H, et al. · Diabetes Care · 2016 · Derived
PubMed: PMID 25813773 · NCT01399645 (LIRAINS) · Diabetes Mellitus, Type 2
Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes.
Stein CM, Kramer CK, Zinman B, et al. · Diabet Med · 2016 · Derived
PubMed: PMID 25495067 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
Smits MM, Tonneijck L, Muskiet MH, et al. · BMJ Open · 2016 · Derived
PubMed: PMID 26586327 · NCT01744236 · Diabetes Mellitus, Type 2
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.
Sharma AN, Ligade SS, Sharma JN, et al. · Metab Brain Dis · 2016 · Derived
PubMed: PMID 25023888 · NCT01845259 (GREAT)
Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.
Robert SA, Rohana AG, Shah SA, et al. · Obes Res Clin Pract · 2016 · Derived
PubMed: PMID 25870084 · NCT01739049 · Binge-Eating Disorder
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA, Petrie JR, Sesti G, et al. · Diabetes Care · 2016 · Derived
PubMed: PMID 26358288 · NCT00696657 · Diabetes Mellitus, Type 2
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Margulies KB, Hernandez AF, Redfield MM, et al. · JAMA · 2016 · Derived
PubMed: PMID 27483064 · NCT01800968 (FIGHT)
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
Larsen JR, Vedtofte L, Holst JJ, et al. · BMJ Open · 2016 · Derived
PubMed: PMID 24667381 · NCT01845259 (GREAT)
Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes.
Kramer CK, Zinman B, Choi H, et al. · BMJ Open Diabetes Res Care · 2016 · Derived
PubMed: PMID 27547422 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
Kramer CK, Zinman B, Choi H, et al. · J Clin Endocrinol Metab · 2016 · Derived
PubMed: PMID 26230296 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).
Jorsal A, Wiggers H, Holmager P, et al. · BMJ Open · 2016 · Derived
PubMed: PMID 24844271 · NCT01472640 · Diabetes Mellitus
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Jensterle M, Salamun V, Kocjan T, et al. · J Ovarian Res · 2016 · Derived
PubMed: PMID 26032655 · NCT02187250 · Obesity
Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
Jensterle M, Kocjan T, Kravos NA, et al. · Endocr Res · 2016 · Derived
PubMed: PMID 25330463 · NCT01911468 · Obesity
Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.
Hodge RJ, Paulik MA, Walker A, et al. · PLoS One · 2016 · Derived
PubMed: PMID 27093610 · NCT01725126 · Diabetes Mellitus
In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Gejl M, Gjedde A, Egefjord L, et al. · Front Aging Neurosci · 2016 · Derived
PubMed: PMID 27252647 · NCT01469351 · Alzheimer Disease
Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Frandsen CS, Dejgaard TF, Holst JJ, et al. · Diabetes Care · 2016 · Derived
PubMed: PMID 26486191 · NCT02092896 (T1DMLIRA) · Diabetes Mellitus
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
Dejgaard TF, Knop FK, Tarnow L, et al. · BMJ Open · 2016 · Derived
PubMed: PMID 25838513 · NCT01612468 · Diabetes Mellitus
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
Anholm C, Kumarathurai P, Klit MS, et al. · BMJ Open · 2016 · Derived
PubMed: PMID 25031198 · NCT01595789 (AddHope2) · Diabetes Mellitus, Type 2
Microglia in the spinal cord and neuropathic pain.
Tsuda M · J Diabetes Investig · 2016 · Background
PubMed: PMID 26813032 · NCT04137328
Health-Related Quality-of-Life (HRQoL) on an Average of 12 Years After Gastric Bypass Surgery.
Raoof M, Näslund I, Rask E, et al. · Obes Surg · 2016 · Background
PubMed: PMID 25566743 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
Myat A, Arri S, Bhatt DL, et al. · Cardiovasc Diabetol · 2016 · Background
PubMed: PMID 25848859 · NCT02315001 (LIONESS) · Coronary Artery Disease
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, et al. · N Engl J Med · 2016 · Background
PubMed: PMID 27633186 · NCT04122716 (S-LITE) · Obesity
Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass.
Manning S, Pucci A, Carter NC, et al. · Surg Endosc · 2016 · Background
PubMed: PMID 25239175 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity.
Magkos F, Fraterrigo G, Yoshino J, et al. · Cell Metab · 2016 · Background
PubMed: PMID 26916363 · NCT04122716 (S-LITE) · Obesity
Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.
Lind M, Matsson PO, Linder R, et al. · Diabetes Ther · 2016 · Background
PubMed: PMID 27216947 · NCT02077946 · Diabetes Mellitus, Type 2
Predictors of long-term diabetes remission after metabolic surgery.
Lee MH, Lee WJ, Chong K, et al. · J Gastrointest Surg · 2016 · Background
PubMed: PMID 25840670 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes.
Lachin JM, Bebu I · Clin Trials · 2016 · Background
PubMed: PMID 26336199 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Impact of weight regain on metabolic disease risk: a review of human trials.
Kroeger CM, Hoddy KK, Varady KA, et al. · J Obes · 2016 · Background
PubMed: PMID 25197563 · NCT04122716 (S-LITE) · Obesity
Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents.
Inge TH, Courcoulas AP, Jenkins TM, et al. · N Engl J Med · 2016 · Background
PubMed: PMID 26544725 · NCT04883346 · Obesity
Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
Iepsen EW, Lundgren J, Dirksen C, et al. · Int J Obes (Lond) · 2016 · Background
PubMed: PMID 25287751 · NCT04122716 (S-LITE) · Obesity
Mood by microbe: towards clinical translation.
Dinan TG, Cryan JF · Genome Med · 2016 · Background
PubMed: PMID 27048547 · NCT04046822 · Obesity
Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.
Chen WR, Tian F, Chen YD, et al. · Int J Cardiol · 2016 · Background
PubMed: PMID 26849684 · NCT02930265
Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Chen WR, Hu SY, Chen YD, et al. · Am Heart J · 2016 · Background
PubMed: PMID 26542491 · NCT02930265
Validation of a fast method for quantification of intra-abdominal and subcutaneous adipose tissue for large-scale human studies.
Borga M, Thomas EL, Romu T, et al. · NMR Biomed · 2016 · Background
PubMed: PMID 26768490 · NCT03038620 · Obesity

2015 (48 papers)

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
van Can J, Sloth B, Jensen CB, et al. · Int J Obes (Lond) · 2015 · Trial result
PubMed: PMID 23999198 · NCT00978393 · Obesity
LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
Steinberg WM, Nauck MA, Zinman B, et al. · Pancreas · 2015 · Trial result
PubMed: PMID 25275271 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model.
Røge RM, Klim S, Ingwersen SH, et al. · CPT Pharmacometrics Syst Pharmacol · 2015 · Trial result
PubMed: PMID 26225223 · NCT01517555 · Diabetes Mellitus, Type 2
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, et al. · N Engl J Med · 2015 · Trial result
PubMed: PMID 26132939 · NCT02616003 · Obesity, Morbid
Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.
Osonoi T, Saito M, Tamasawa A, et al. · PLoS One · 2015 · Trial result
PubMed: PMID 25526642 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
The effect of liraglutide on endothelial function in patients with type 2 diabetes.
Nandy D, Johnson C, Basu R, et al. · Diab Vasc Dis Res · 2015 · Trial result
PubMed: PMID 25212693 · NCT00620282 · Diabetes Mellitus, Type 2
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C, Rodbard HW, Cariou B, et al. · Diabetes Obes Metab · 2015 · Trial result
PubMed: PMID 24443830 · NCT01388361 (BEGIN™) · Diabetes Mellitus, Type 2
Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
Lüdemann J, Dütting ED, Dworak M, et al. · Ther Adv Endocrinol Metab · 2015 · Trial result
PubMed: PMID 26301063 · NCT01518101 (PREFER) · Diabetes Mellitus, Type 2
Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Lovshin JA, Barnie A, DeAlmeida A, et al. · Diabetes Care · 2015 · Trial result
PubMed: PMID 25414155 · NCT01755572 (BOLT) · Diabetes Mellitus, Type 2
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Lean ME, Carraro R, Finer N, et al. · Int J Obes (Lond) · 2015 · Trial result
PubMed: PMID 23942319 · NCT00422058 · Obesity
Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Klein DJ, Battelino T, Chatterjee DJ, et al. · Diabetes Technol Ther · 2015 · Trial result
PubMed: PMID 25036533 · NCT00943501 · Diabetes Mellitus, Type 2
Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study.
Jespersen L, Abildstrom SZ, Hvelplund A, et al. · PLoS One · 2015 · Trial result
PubMed: PMID 24705387 · NCT02602600 (GAP) · Microvascular Angina
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
Jensen TM, Saha K, Steinberg WM, et al. · Diabetes Care · 2015 · Trial result
PubMed: PMID 25504028 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.
Ingwersen SH, Petri KC, Tandon N, et al. · Diabetes Res Clin Pract · 2015 · Trial result
PubMed: PMID 25684604 · NCT00614120 · Diabetes Mellitus, Type 2
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC, Bode B, Woo V, et al. · Lancet Diabetes Endocrinol · 2015 · Trial result
PubMed: PMID 25190523 · NCT01336023 (DUAL™ I) · Diabetes Mellitus, Type 2
Differential association of body mass index with access to kidney transplantation in men and women.
Gill JS, Hendren E, Dong J, et al. · Clin J Am Soc Nephrol · 2015 · Trial result
PubMed: PMID 24742478 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Correlation between coronary microvascular function and angina status in patients with stable microvascular angina.
Di Franco A, Villano A, Di Monaco A, et al. · Eur Rev Med Pharmacol Sci · 2015 · Trial result
PubMed: PMID 24563437 · NCT02602600 (GAP) · Microvascular Angina
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ, Bergenstal R, Bode B, et al. · JAMA · 2015 · Trial result
PubMed: PMID 26284720 · NCT01272232 · Obesity
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Buse JB, Vilsbøll T, Thurman J, et al. · Diabetes Care · 2015 · Trial result
PubMed: PMID 25114296 · NCT01392573 (DUAL™ II) · Diabetes Mellitus, Type 2
Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB, Peters A, Russell-Jones D, et al. · Diabetes Obes Metab · 2015 · Trial result
PubMed: PMID 25323312 · NCT00331851 (LEAD-5) · Diabetes Mellitus, Type 2
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight.
Baggio LL, Drucker DJ · J Clin Invest · 2015 · Trial result
PubMed: PMID 25202976 · NCT02616003 · Obesity, Morbid
Glucagon-like Peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed.
Alhadeff AL, Baird JP, Swick JC, et al. · Neuropsychopharmacology · 2015 · Trial result
PubMed: PMID 24681814 · NCT02616003 · Obesity, Morbid
Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
Retnakaran R, Kramer CK, Choi H, et al. · Diabetes Care · 2015 · Derived
PubMed: PMID 25249651 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
Polderman JA, Houweling PL, Hollmann MW, et al. · BMC Anesthesiol · 2015 · Derived
PubMed: PMID 25419179 · NCT02036372 (PILGRIM) · Diabetes Mellitus, Type 2
Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
Lind M, Hirsch IB, Tuomilehto J, et al. · Prim Care Diabetes · 2015 · Derived
PubMed: PMID 25175385 · NCT02113332 · Diabetes Mellitus, Type 2
Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes.
Kramer CK, Zinman B, Choi H, et al. · J Clin Endocrinol Metab · 2015 · Derived
PubMed: PMID 26079776 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function.
Kramer CK, Choi H, Zinman B, et al. · Diabetes Care · 2015 · Derived
PubMed: PMID 24550219 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
Kim SH, Liu A, Ariel D, et al. · Diabetologia · 2015 · Derived
PubMed: PMID 24326527 · NCT01784965 · Glucose Intolerance
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.
Fonseca VA, Devries JH, Henry RR, et al. · J Diabetes Complications · 2015 · Derived
PubMed: PMID 24561125 · NCT00318422 (LEAD-1) · Diabetes Mellitus, Type 2
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM, Povedano ST, Forst T, et al. · Lancet · 2015 · Derived
PubMed: PMID 25018121 · NCT01624259 (AWARD-6) · Diabetes Mellitus, Type 2
Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).
de Wit HM, Vervoort GM, Jansen HJ, et al. · Diabetologia · 2015 · Derived
PubMed: PMID 24947583 · NCT01392898 (ELEGANT) · Diabetes Mellitus, Type 2
Test-retest reliability of automated whole body and compartmental muscle volume measurements on a wide bore 3T MR system.
Thomas MS, Newman D, Leinhard OD, et al. · Eur Radiol · 2015 · Background
PubMed: PMID 24871333 · NCT03038620 · Obesity
Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Su B, Sheng H, Zhang M, et al. · Endocrine · 2015 · Background
PubMed: PMID 25074632 · NCT02473809 (LIRABONE) · Diabetes Complications
Predictive accuracy of single- and multi-slice MRI for the estimation of total visceral adipose tissue in overweight to severely obese patients.
Schaudinn A, Linder N, Garnov N, et al. · NMR Biomed · 2015 · Background
PubMed: PMID 25808071 · NCT03038620 · Obesity
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
RISE Consortium · Diabetes Care · 2015 · Background
PubMed: PMID 24194506 · NCT01779362 (RISE Adult) · Diabetes Mellitus, Type 2
Quality of life, weight loss and improvement of co-morbidities after primary and revisional laparoscopic roux Y gastric bypass procedure-comparative match pair study.
Mohos E, Jánó Z, Richter D, et al. · Obes Surg · 2015 · Background
PubMed: PMID 24913243 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Exercise and the cardiovascular system: clinical science and cardiovascular outcomes.
Lavie CJ, Arena R, Swift DL, et al. · Circ Res · 2015 · Background
PubMed: PMID 26139859 · NCT04122716 (S-LITE) · Obesity
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
Lassailly G, Caiazzo R, Buob D, et al. · Gastroenterology · 2015 · Background
PubMed: PMID 25917783 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Applications of the Wei-Lachin multivariate one-sided test for multiple outcomes on possibly different scales.
Lachin JM · PLoS One · 2015 · Background
PubMed: PMID 25329662 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Effect of treadmill training on endothelial function and walking abilities in patients with peripheral arterial disease.
Januszek R, Mika P, Konik A, et al. · J Cardiol · 2015 · Background
PubMed: PMID 24438856 · NCT03883412 (ZQL007)
BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening.
Hsu WC, Araneta MR, Kanaya AM, et al. · Diabetes Care · 2015 · Background
PubMed: PMID 25538311 · NCT03038620 · Obesity
Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF.
Hoier B, Hellsten Y · Microcirculation · 2015 · Background
PubMed: PMID 24450403 · NCT03883412 (ZQL007)
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y, Arima H, Zoungas S, et al. · Diabetes Care · 2015 · Background
PubMed: PMID 24812434 · NCT02879409 · Diabetes Mellitus, Type 2
MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjects.
Dong Z, Luo Y, Zhang Z, et al. · PLoS One · 2015 · Background
PubMed: PMID 25343445 · NCT03038620 · Obesity
Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study.
Caiazzo R, Lassailly G, Leteurtre E, et al. · Ann Surg · 2015 · Background
PubMed: PMID 25379859 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
Barros JI, Fechine FV, Montenegro Júnior RM, et al. · Arq Bras Endocrinol Metabol · 2015 · Background
PubMed: PMID 24936731 · NCT04137328
Corneal confocal microscopy shows an improvement in small-fiber neuropathy in subjects with type 1 diabetes on continuous subcutaneous insulin infusion compared with multiple daily injection.
Azmi S, Ferdousi M, Petropoulos IN, et al. · Diabetes Care · 2015 · Background
PubMed: PMID 25538321 · NCT02879409 · Diabetes Mellitus, Type 2
Increased skeletal muscle capillarization enhances insulin sensitivity.
Akerstrom T, Laub L, Vedel K, et al. · Am J Physiol Endocrinol Metab · 2015 · Background
PubMed: PMID 25352432 · NCT03883412 (ZQL007)

2014 (35 papers)

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
Wadden TA, Hollander P, Klein S, et al. · Int J Obes (Lond) · 2014 · Trial result
PubMed: PMID 23812094 · NCT00781937 · Obesity
Cardiovascular actions of incretin-based therapies.
Ussher JR, Drucker DJ · Circ Res · 2014 · Trial result
PubMed: PMID 24855202 · NCT02602600 (GAP) · Microvascular Angina
The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes.
Seino Y, Rasmussen MF, Clauson P, et al. · J Diabetes Investig · 2014 · Trial result
PubMed: PMID 24843595 · NCT00393718 · Diabetes Mellitus, Type 2
One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
Rosenstock J, Rodbard HW, Bain SC, et al. · J Diabetes Complications · 2014 · Trial result
PubMed: PMID 23746555 · NCT00856986 · Diabetes Mellitus, Type 2
Effects of obesity on kidney transplantation outcomes: a systematic review and meta-analysis.
Nicoletto BB, Fonseca NK, Manfro RC, et al. · Transplantation · 2014 · Trial result
PubMed: PMID 24911038 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Nathan DM, Buse JB, Kahn SE, et al. · Diabetes Care · 2014 · Trial result
PubMed: PMID 23690531 · NCT01794143 (GRADE) · Diabetes Mellitus, Type 2
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM, Kydd AC, Read PA, et al. · Circ Cardiovasc Imaging · 2014 · Trial result
PubMed: PMID 24503784 · NCT02602600 (GAP) · Microvascular Angina
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
Marso SP, Poulter NR, Nissen SE, et al. · Am Heart J · 2014 · Trial result
PubMed: PMID 24176437 · NCT01179048 (LEADER®) · Diabetes Mellitus, Type 2
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.
Legro RS, Arslanian SA, Ehrmann DA, et al. · J Clin Endocrinol Metab · 2014 · Trial result
PubMed: PMID 24151290 · NCT05952882 · Obesity
A retrospective cohort study to evaluate the impact of meaningful weight loss on fertility outcomes in an overweight population with infertility.
Kort JD, Winget C, Kim SH, et al. · Fertil Steril · 2014 · Trial result
PubMed: PMID 24581574 · NCT05952882 · Obesity
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Kapitza C, Forst T, Coester HV, et al. · Diabetes Obes Metab · 2014 · Trial result
PubMed: PMID 23368510 · NCT01175473 · Diabetes Mellitus, Type 2
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Jensterle Sever M, Kocjan T, Pfeifer M, et al. · Eur J Endocrinol · 2014 · Trial result
PubMed: PMID 24362411 · NCT05952882 · Obesity
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K, Bækdal TA, Düring M, et al. · Diabetes Obes Metab · 2014 · Trial result
PubMed: PMID 23683069 · NCT00993304 · Diabetes Mellitus, Type 2
The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
Flint A, Kapitza C, Zdravkovic M, et al. · Diabetes Obes Metab · 2014 · Trial result
PubMed: PMID 23551925 · NCT01517555 · Diabetes Mellitus, Type 2
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Pratley RE, Nauck MA, Barnett AH, et al. · Lancet Diabetes Endocrinol · 2014 · Derived
PubMed: PMID 24703047 · NCT01128894 · Diabetes Mellitus, Type 2
Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH, Bagger JI, Hansen T, et al. · Diabetes Care · 2014 · Derived
PubMed: PMID 24929431 · NCT01610934 · Diabetes Mellitus, Type 2
Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.
Kramer CK, Choi H, Zinman B, et al. · Am J Physiol Endocrinol Metab · 2014 · Derived
PubMed: PMID 24129396 · NCT01270789 (LIBRA) · Diabetes Mellitus, Type 2
Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.
Kim SH, Abbasi F, Lamendola C, et al. · Diabetes Care · 2014 · Derived
PubMed: PMID 23835684 · NCT01784965 · Glucose Intolerance
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B, Steinberg H, Eymard E, et al. · Diabetologia · 2014 · Derived
PubMed: PMID 23604551 · NCT01296412 · Diabetes Mellitus, Type 2
The role of exercise and physical activity in weight loss and maintenance.
Swift DL, Johannsen NM, Lavie CJ, et al. · Prog Cardiovasc Dis · 2014 · Background
PubMed: PMID 24438736 · NCT04122716 (S-LITE) · Obesity
Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study.
Stępień M, Stępień A, Wlazeł RN, et al. · Lipids Health Dis · 2014 · Background
PubMed: PMID 24507240 · NCT04122716 (S-LITE) · Obesity
Glucagon-like peptide-1: modulator of β-cell dysfunction and death.
Rondas D, D'Hertog W, Overbergh L, et al. · Diabetes Obes Metab · 2014 · Background
PubMed: PMID 24003936 · NCT03011021 · Diabetes Mellitus, Type 1
Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery.
Pajecki D, Halpern A, Cercato C, et al. · Rev Col Bras Cir · 2014 · Background
PubMed: PMID 23912365 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.
Neeland IJ, Ayers CR, Rohatgi AK, et al. · Obesity (Silver Spring) · 2014 · Background
PubMed: PMID 23687099 · NCT03038620 · Obesity
Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway.
Mørkedal B, Vatten LJ, Romundstad PR, et al. · J Am Coll Cardiol · 2014 · Background
PubMed: PMID 24345592 · NCT03038620 · Obesity
Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Kuhadiya ND, Malik R, Bellini NJ, et al. · Endocr Pract · 2014 · Background
PubMed: PMID 23807520 · NCT01722266 · Diabetes Mellitus, Type 1
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
Jensen MD, Ryan DH, Apovian CM, et al. · Circulation · 2014 · Background
PubMed: PMID 24222017 · NCT04122716 (S-LITE) · Obesity
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.
Hogan AE, Gaoatswe G, Lynch L, et al. · Diabetologia · 2014 · Background
PubMed: PMID 24362727 · NCT04122716 (S-LITE) · Obesity
The post-prandial pattern of gut hormones is related to magnitude of weight-loss following gastric bypass surgery: a case-control study.
Gerner T, Johansen OE, Olufsen M, et al. · Scand J Clin Lab Invest · 2014 · Background
PubMed: PMID 24472033 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study.
Fenske WK, Dubb S, Bueter M, et al. · Surg Obes Relat Dis · 2014 · Background
PubMed: PMID 22608055 · NCT01847313 · Diabetes Mellitus
Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass.
Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. · Int J Obes (Lond) · 2014 · Background
PubMed: PMID 23419600 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study.
Chandra A, Neeland IJ, Berry JD, et al. · J Am Coll Cardiol · 2014 · Background
PubMed: PMID 25190234 · NCT03038620 · Obesity
A pooled analysis of waist circumference and mortality in 650,000 adults.
Cerhan JR, Moore SC, Jacobs EJ, et al. · Mayo Clin Proc · 2014 · Background
PubMed: PMID 24582192 · NCT03038620 · Obesity
Postexercise improvement in insulin-stimulated glucose uptake occurs concomitant with greater AS160 phosphorylation in muscle from normal and insulin-resistant rats.
Castorena CM, Arias EB, Sharma N, et al. · Diabetes · 2014 · Background
PubMed: PMID 24608437 · NCT04575844 (ZQL008) · Metabolic Syndrome
Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
Ahern T, Tobin AM, Corrigan M, et al. · J Eur Acad Dermatol Venereol · 2014 · Background
PubMed: PMID 22691169 · NCT01847313 · Diabetes Mellitus

2013 (43 papers)

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
Woo JS, Kim W, Ha SJ, et al. · Arterioscler Thromb Vasc Biol · 2013 · Trial result
PubMed: PMID 23868944 · NCT02602600 (GAP) · Microvascular Angina
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Pratley RE, Nauck MA, Bailey T, et al. · Diabetes Care · 2013 · Trial result
PubMed: PMID 22851600 · NCT00700817 · Diabetes Mellitus, Type 2
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Niswender K, Pi-Sunyer X, Buse J, et al. · Diabetes Obes Metab · 2013 · Trial result
PubMed: PMID 22862847 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M, Frid A, Hermansen K, et al. · Diabetes Obes Metab · 2013 · Trial result
PubMed: PMID 22985213 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Nauck M, Frid A, Hermansen K, et al. · Diabetes Care · 2013 · Trial result
PubMed: PMID 18931095 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
Impact of leucine on energy balance.
McAllan L, Cotter PD, Roche HM, et al. · J Physiol Biochem · 2013 · Trial result
PubMed: PMID 22535285 · NCT02616003 · Obesity, Morbid
Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis.
Lim SS, Davies MJ, Norman RJ, et al. · Hum Reprod Update · 2013 · Trial result
PubMed: PMID 22767467 · NCT05952882 · Obesity
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC, Samyshkin Y, Langer J, et al. · J Med Econ · 2013 · Trial result
PubMed: PMID 22834986 · NCT00700817 · Diabetes Mellitus, Type 2
Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB, Montanya E, Pratley RE, et al. · Endocr Pract · 2013 · Trial result
PubMed: PMID 23186975 · NCT00318422 (LEAD-1) · Diabetes Mellitus, Type 2
Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment.
Ingwersen SH, Khurana M, Madabushi R, et al. · J Clin Pharmacol · 2013 · Trial result
PubMed: PMID 22174428 · NCT00294723 (LEAD-3) · Diabetes Mellitus, Type 2
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Alves C, Batel-Marques F, Macedo AF, et al. · Diabetes Res Clin Pract · 2013 · Trial result
PubMed: PMID 23010561 · NCT00395746 · Diabetes Mellitus, Type 2
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Langer J, Hunt B, Valentine WJ, et al. · J Manag Care Pharm · 2013 · Derived
PubMed: PMID 23537458 · NCT00700817 · Diabetes Mellitus, Type 2
Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.
Idorn T, Knop FK, Jørgensen M, et al. · BMJ Open · 2013 · Derived
PubMed: PMID 23624993 · NCT01394341 · Diabetes Mellitus, Type 2
Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M, Han J, Weaver C, et al. · Postgrad Med · 2013 · Derived
PubMed: PMID 23748506 · NCT01029886 · Diabetes Mellitus, Type 2
The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial.
Foghsgaard S, Vedtofte L, Mathiesen ER, et al. · BMJ Open · 2013 · Derived
PubMed: PMID 24176797 · NCT01795248 · Diabetes Mellitus, Type 2
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
Egefjord L, Gejl M, Møller A, et al. · Dan Med J · 2013 · Derived
PubMed: PMID 23158895 · NCT01469351 · Alzheimer Disease
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Buse JB, Nauck M, Forst T, et al. · Lancet · 2013 · Derived
PubMed: PMID 23141817 · NCT01029886 · Diabetes Mellitus, Type 2
Effects of exercise training on chronic inflammation in obesity : current evidence and potential mechanisms.
You T, Arsenis NC, Disanzo BL, et al. · Sports Med · 2013 · Background
PubMed: PMID 23494259 · NCT04122716 (S-LITE) · Obesity
Impact of weight loss with or without exercise on abdominal fat and insulin resistance in obese individuals: a randomised clinical trial.
Trussardi Fayh AP, Lopes AL, Fernandes PR, et al. · Br J Nutr · 2013 · Background
PubMed: PMID 23302544 · NCT04122716 (S-LITE) · Obesity
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Stevens JW, Simpson E, Harnan S, et al. · Br J Surg · 2013 · Background
PubMed: PMID 23034699 · NCT03883412 (ZQL007)
Exercise training and cardiometabolic diseases: focus on the vascular system.
Roque FR, Hernanz R, Salaices M, et al. · Curr Hypertens Rep · 2013 · Background
PubMed: PMID 23519745 · NCT04575844 (ZQL008) · Metabolic Syndrome
Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease.
Robbins JL, Jones WS, Duscha BD, et al. · J Appl Physiol (1985) · 2013 · Background
PubMed: PMID 21512146 · NCT03883412 (ZQL007)
Exercise, GLUT4, and skeletal muscle glucose uptake.
Richter EA, Hargreaves M · Physiol Rev · 2013 · Background
PubMed: PMID 23899560 · NCT04575844 (ZQL008) · Metabolic Syndrome
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Noyan-Ashraf MH, Shikatani EA, Schuiki I, et al. · Circulation · 2013 · Background
PubMed: PMID 23186644 · NCT04122716 (S-LITE) · Obesity
Endurance training per se increases metabolic health in young, moderately overweight men.
Nordby P, Auerbach PL, Rosenkilde M, et al. · Obesity (Silver Spring) · 2013 · Background
PubMed: PMID 22436841 · NCT04122716 (S-LITE) · Obesity
Relation of regional fat distribution to left ventricular structure and function.
Neeland IJ, Gupta S, Ayers CR, et al. · Circ Cardiovasc Imaging · 2013 · Background
PubMed: PMID 23929898 · NCT03038620 · Obesity
Myocardial no-reflow treatment.
Muller O, Trana C, Eeckhout E, et al. · Curr Vasc Pharmacol · 2013 · Background
PubMed: PMID 23506504 · NCT02507128 · ST Elevation Myocardial Infarction
Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes.
Miras AD, Chuah LL, Lascaratos G, et al. · Diabetes Care · 2013 · Background
PubMed: PMID 23173142 · NCT01847313 · Diabetes Mellitus
Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells.
Milward K, Issa F, Hester J, et al. · Transplantation · 2013 · Background
PubMed: PMID 23263503 · NCT03011021 · Diabetes Mellitus, Type 1
The vascular endothelium in diabetes and its potential as a therapeutic target.
Liu Z · Rev Endocr Metab Disord · 2013 · Background
PubMed: PMID 23397463 · NCT04575844 (ZQL008) · Metabolic Syndrome
Incretin therapy and its effect on body weight in patients with diabetes.
Lind M · Prim Care Diabetes · 2013 · Background
PubMed: PMID 22613745 · NCT02113332 · Diabetes Mellitus, Type 2
Inflammation in diabetic nephropathy.
Lim AK, Tesch GH · Mediators Inflamm · 2013 · Background
PubMed: PMID 22969168 · NCT01847313 · Diabetes Mellitus
Type 2 diabetes and bone.
Leslie WD, Rubin MR, Schwartz AV, et al. · J Bone Miner Res · 2013 · Background
PubMed: PMID 23023946 · NCT02473809 (LIRABONE) · Diabetes Complications
Comorbidities remission after Roux-en-Y Gastric Bypass for morbid obesity is sustained in a long-term follow-up and correlates with weight regain.
Laurino Neto RM, Herbella FA, Tauil RM, et al. · Obes Surg · 2013 · Background
PubMed: PMID 22907795 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects.
Jiménez A, Casamitjana R, Flores L, et al. · Ann Surg · 2013 · Background
PubMed: PMID 22968072 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials.
Gloy VL, Briel M, Bhatt DL, et al. · BMJ · 2013 · Background
PubMed: PMID 24149519 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe.
Frühbeck G, Toplak H, Woodward E, et al. · Obes Facts · 2013 · Background
PubMed: PMID 23548858 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Supervised walking therapy in patients with intermittent claudication.
Fakhry F, van de Luijtgaarden KM, Bax L, et al. · J Vasc Surg · 2013 · Background
PubMed: PMID 23026425 · NCT03883412 (ZQL007)
Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality.
Britton KA, Massaro JM, Murabito JM, et al. · J Am Coll Cardiol · 2013 · Background
PubMed: PMID 23850922 · NCT03038620 · Obesity
Muscle-specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance.
Bonner JS, Lantier L, Hasenour CM, et al. · Diabetes · 2013 · Background
PubMed: PMID 23002035 · NCT04575844 (ZQL008) · Metabolic Syndrome
A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass.
Arterburn DE, Bogart A, Sherwood NE, et al. · Obes Surg · 2013 · Background
PubMed: PMID 23161525 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways.
Aronis KN, Chamberland JP, Mantzoros CS, et al. · Metabolism · 2013 · Background
PubMed: PMID 23684008 · NCT04575844 (ZQL008) · Metabolic Syndrome
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.
Armstrong MJ, Barton D, Gaunt P, et al. · BMJ Open · 2013 · Background
PubMed: PMID 24189085 · NCT01237119 (LEAN) · Non-alcoholic Fatty Liver Disease

2012 (34 papers)

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
Zinman B, Schmidt WE, Moses A, et al. · Diabetes Obes Metab · 2012 · Trial result
PubMed: PMID 21883806 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ, Palmer AJ, Lammert M, et al. · Clin Ther · 2012 · Trial result
PubMed: PMID 22018679 · NCT00518882 (LEAD-6) · Diabetes Mellitus, Type 2
The impact of renal function on outcomes of bariatric surgery.
Turgeon NA, Perez S, Mondestin M, et al. · J Am Soc Nephrol · 2012 · Trial result
PubMed: PMID 22383694 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease.
Read PA, Khan FZ, Dutka DP, et al. · Heart · 2012 · Trial result
PubMed: PMID 21561896 · NCT02602600 (GAP) · Microvascular Angina
Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Lønborg J, Kelbæk H, Vejlstrup N, et al. · Circ Cardiovasc Interv · 2012 · Trial result
PubMed: PMID 22496084 · NCT02602600 (GAP) · Microvascular Angina
The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.
Jiang J, Zhang J, Jacobsen LV, et al. · J Clin Pharmacol · 2012 · Trial result
PubMed: PMID 21273395 · NCT00761540 · Diabetes Mellitus
Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events.
Jespersen L, Hvelplund A, Abildstrøm SZ, et al. · Eur Heart J · 2012 · Trial result
PubMed: PMID 21911339 · NCT02602600 (GAP) · Microvascular Angina
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M, Flint A, Jones KL, et al. · Diabetes Res Clin Pract · 2012 · Trial result
PubMed: PMID 22446097 · NCT01511692 · Diabetes Mellitus, Type 2
Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.
Henry RR, Buse JB, Sesti G, et al. · Endocr Pract · 2012 · Trial result
PubMed: PMID 22193143 · NCT00294723 (LEAD-3) · Diabetes Mellitus, Type 2
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
DeVries JH, Bain SC, Rodbard HW, et al. · Diabetes Care · 2012 · Trial result
PubMed: PMID 22584132 · NCT00856986 · Diabetes Mellitus, Type 2
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
Davies MJ, Chubb BD, Smith IC, et al. · Diabet Med · 2012 · Trial result
PubMed: PMID 21883438 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
Bode BW, Brett J, Falahati A, et al. · Am J Geriatr Pharmacother · 2012 · Trial result
PubMed: PMID 22055210 · NCT00518882 (LEAD-6) · Diabetes Mellitus, Type 2
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A, Carraro R, Finer N, et al. · Int J Obes (Lond) · 2012 · Trial result
PubMed: PMID 21844879 · NCT00422058 · Obesity
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
Varanasi A, Patel P, Makdissi A, et al. · Endocr Pract · 2012 · Background
PubMed: PMID 21856595 · NCT01722266 · Diabetes Mellitus, Type 1
MR imaging evaluation of cardiovascular risk in metabolic syndrome.
van der Meer RW, Lamb HJ, Smit JW, et al. · Radiology · 2012 · Background
PubMed: PMID 22723560 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2.
Sugawara A, Kawai K, Motohashi S, et al. · Diabetologia · 2012 · Background
PubMed: PMID 22580991 · NCT02879409 · Diabetes Mellitus, Type 2
Microvascular blood flow responses to muscle contraction are not altered by high-fat feeding in rats.
St-Pierre P, Keith LJ, Richards SM, et al. · Diabetes Obes Metab · 2012 · Background
PubMed: PMID 22429614 · NCT03883412 (ZQL007)
Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: a randomized controlled trial.
Schlager O, Giurgea A, Schuhfried O, et al. · Atherosclerosis · 2012 · Background
PubMed: PMID 21481871 · NCT03883412 (ZQL007)
Hemodynamic monitoring by transpulmonary thermodilution and pulse contour analysis in critically ill children.
Proulx F, Lemson J, Choker G, et al. · Pediatr Crit Care Med · 2012 · Background
PubMed: PMID 21263372 · NCT02490176 · Heart Failure
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults.
Neeland IJ, Turer AT, Ayers CR, et al. · JAMA · 2012 · Background
PubMed: PMID 22990274 · NCT03038620 · Obesity
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.
Nathanson D, Ullman B, Löfström U, et al. · Diabetologia · 2012 · Background
PubMed: PMID 22246377 · NCT02655770 · Diabetes Mellitus, Type 2
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Lønborg J, Vejlstrup N, Kelbæk H, et al. · Eur Heart J · 2012 · Background
PubMed: PMID 21920963 · NCT02490176 · Heart Failure
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.
Lind M, Jendle J, Torffvit O, et al. · Prim Care Diabetes · 2012 · Background
PubMed: PMID 22015237 · NCT02113332 · Diabetes Mellitus, Type 2
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.
Lee YS, Park MS, Choung JS, et al. · Diabetologia · 2012 · Background
PubMed: PMID 22722451 · NCT04122716 (S-LITE) · Obesity
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Inzucchi SE, Bergenstal RM, Buse JB, et al. · Diabetes Care · 2012 · Background
PubMed: PMID 22517736 · NCT01847313 · Diabetes Mellitus
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
Hogan AE, Tobin AM, Ahern T, et al. · Diabetologia · 2012 · Background
PubMed: PMID 21744074 · NCT01847313 · Diabetes Mellitus
Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.
Gejl M, Søndergaard HM, Stecher C, et al. · J Clin Endocrinol Metab · 2012 · Background
PubMed: PMID 22544917 · NCT02930265
Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood.
Fan H, Yang J, Hao J, et al. · Immunology · 2012 · Background
PubMed: PMID 22348606 · NCT03011021 · Diabetes Mellitus, Type 1
Body fat distribution and risk of cardiovascular disease: an update.
Després JP · Circulation · 2012 · Background
PubMed: PMID 22949540 · NCT03038620 · Obesity
Oocyte morphological abnormalities in overweight women undergoing in vitro fertilization cycles.
Depalo R, Garruti G, Totaro I, et al. · Gynecol Endocrinol · 2012 · Background
PubMed: PMID 21500991 · NCT03034941 · Obesity
Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure.
Chokshi A, Drosatos K, Cheema FH, et al. · Circulation · 2012 · Background
PubMed: PMID 22586279 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Exenatide exerts a potent antiinflammatory effect.
Chaudhuri A, Ghanim H, Vora M, et al. · J Clin Endocrinol Metab · 2012 · Background
PubMed: PMID 22013105 · NCT04122716 (S-LITE) · Obesity
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.
Bunck MC, Diamant M, Eliasson B, et al. · Diabetes Care · 2012 · Background
PubMed: PMID 20424219 · NCT04122716 (S-LITE) · Obesity
Cause-specific mortality in diabetes: recent changes in trend mortality.
Abi Khalil C, Roussel R, Mohammedi K, et al. · Eur J Prev Cardiol · 2012 · Background
PubMed: PMID 22991697 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2

2011 (43 papers)

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).
Yang W, Chen L, Ji Q, et al. · Diabetes Obes Metab · 2011 · Trial result
PubMed: PMID 21114607 · NCT00614120 · Diabetes Mellitus, Type 2
Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.
Schmidt WE, Christiansen JS, Hammer M, et al. · Diabet Med · 2011 · Trial result
PubMed: PMID 21388442 · NCT00518882 (LEAD-6) · Diabetes Mellitus, Type 2
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.
Read PA, Hoole SP, White PA, et al. · Circ Cardiovasc Interv · 2011 · Trial result
PubMed: PMID 21586690 · NCT02602600 (GAP) · Microvascular Angina
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Pratley R, Nauck M, Bailey T, et al. · Int J Clin Pract · 2011 · Trial result
PubMed: PMID 21355967 · NCT00700817 · Diabetes Mellitus, Type 2
Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
Morrow L, Hompesch M, Guthrie H, et al. · Diabetes Obes Metab · 2011 · Trial result
PubMed: PMID 21114606 · NCT00873223 · Diabetes Mellitus, Type 2
Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, et al. · Drug Metab Dispos · 2011 · Trial result
PubMed: PMID 20709939 · NCT01517568 · Diabetes Mellitus
Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
Kapitza C, Zdravkovic M, Zijlstra E, et al. · J Clin Pharmacol · 2011 · Trial result
PubMed: PMID 20671294 · NCT01513525 · Diabetes Mellitus
The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.
Kapitza C, Zdravkovic M, Hindsberger C, et al. · Adv Ther · 2011 · Trial result
PubMed: PMID 21792552 · NCT01517555 · Diabetes Mellitus, Type 2
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
Kaku K, Rasmussen MF, Clauson P, et al. · Diabetes Obes Metab · 2011 · Trial result
PubMed: PMID 20380655 · NCT00395746 · Diabetes Mellitus, Type 2
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J, Nauck MA, Matthews DR, et al. · Diabetes Obes Metab · 2011 · Trial result
PubMed: PMID 19930006 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
Hegedüs L, Moses AC, Zdravkovic M, et al. · J Clin Endocrinol Metab · 2011 · Trial result
PubMed: PMID 21209033 · NCT00318422 (LEAD-1) · Diabetes Mellitus, Type 2
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A, Kapitza C, Hindsberger C, et al. · Adv Ther · 2011 · Trial result
PubMed: PMID 21340616 · NCT01517555 · Diabetes Mellitus, Type 2
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Davies M, Pratley R, Hammer M, et al. · Diabet Med · 2011 · Trial result
PubMed: PMID 21309842 · NCT00700817 · Diabetes Mellitus, Type 2
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
Buse JB, Garber A, Rosenstock J, et al. · J Clin Endocrinol Metab · 2011 · Trial result
PubMed: PMID 21450987 · NCT00331851 (LEAD-5) · Diabetes Mellitus, Type 2
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW, Testa MA, Magwire M, et al. · Diabetes Obes Metab · 2011 · Trial result
PubMed: PMID 20590735 · NCT00294723 (LEAD-3) · Diabetes Mellitus, Type 2
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.
Blonde L, Russell-Jones D · Diabetes Obes Metab · 2011 · Trial result
PubMed: PMID 19878259 · NCT00331851 (LEAD-5) · Diabetes Mellitus, Type 2
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
Kielgast U, Krarup T, Holst JJ, et al. · Diabetes Care · 2011 · Derived
PubMed: PMID 21593296 · NCT00993720 · Diabetes Mellitus
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. · Diabetes Obes Metab · 2011 · Background
PubMed: PMID 20092585 · NCT02113332 · Diabetes Mellitus, Type 2
Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.
Varanasi A, Chaudhuri A, Dhindsa S, et al. · Endocr Pract · 2011 · Background
PubMed: PMID 20841306 · NCT01722266 · Diabetes Mellitus, Type 1
Liraglutide as additional treatment for type 1 diabetes.
Varanasi A, Bellini N, Rawal D, et al. · Eur J Endocrinol · 2011 · Background
PubMed: PMID 21646283 · NCT01722266 · Diabetes Mellitus, Type 1
Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
Sze L, Purtell L, Jenkins A, et al. · J Clin Endocrinol Metab · 2011 · Background
PubMed: PMID 21632815 · NCT01542242 · Diabetes Mellitus, Type 2
Progressive hyperglycemia across the glucose tolerance continuum in older obese adults is related to skeletal muscle capillarization and nitric oxide bioavailability.
Solomon TP, Haus JM, Li Y, et al. · J Clin Endocrinol Metab · 2011 · Background
PubMed: PMID 21289242 · NCT04575844 (ZQL008) · Metabolic Syndrome
Glucagon-like peptide analogues for type 2 diabetes mellitus.
Shyangdan DS, Royle P, Clar C, et al. · Cochrane Database Syst Rev · 2011 · Background
PubMed: PMID 21975753 · NCT01847313 · Diabetes Mellitus
Adaptive thermogenesis in humans.
Rosenbaum M, Leibel RL · Int J Obes (Lond) · 2011 · Background
PubMed: PMID 20935667 · NCT04122716 (S-LITE) · Obesity
Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.
Pinkney J, Fox T, Ranganath L, et al. · Ther Clin Risk Manag · 2011 · Background
PubMed: PMID 20856686 · NCT01847313 · Diabetes Mellitus
GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia.
Nuche-Berenguer B, Lozano D, Gutiérrez-Rojas I, et al. · J Endocrinol · 2011 · Background
PubMed: PMID 21372151 · NCT02473809 (LIRABONE) · Diabetes Complications
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.
Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. · Nat Rev Nephrol · 2011 · Background
PubMed: PMID 21537349 · NCT01847313 · Diabetes Mellitus
Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity.
McLaughlin T, Lamendola C, Liu A, et al. · J Clin Endocrinol Metab · 2011 · Background
PubMed: PMID 21865361 · NCT03038620 · Obesity
Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury.
Matsubara M, Kanemoto S, Leshnower BG, et al. · J Surg Res · 2011 · Background
PubMed: PMID 19552923 · NCT02930265
Arresting type 1 diabetes after diagnosis: GAD is not enough.
Mathieu C, Gillard P · Lancet · 2011 · Background
PubMed: PMID 21715000 · NCT03011008 · Diabetes Mellitus, Type 1
Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans.
Liu J, Jahn LA, Fowler DE, et al. · J Clin Endocrinol Metab · 2011 · Background
PubMed: PMID 21047922 · NCT03883412 (ZQL007)
Insulin resistance is related to impaired lung function in morbidly obese women: a case-control study.
Lecube A, Sampol G, Muñoz X, et al. · Diabetes Metab Res Rev · 2011 · Background
PubMed: PMID 20882512 · NCT02889510 · Diabetes Mellitus, Type 2
Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
Kodera R, Shikata K, Kataoka HU, et al. · Diabetologia · 2011 · Background
PubMed: PMID 21253697 · NCT01847313 · Diabetes Mellitus
Sitagliptin reduces albuminuria in patients with type 2 diabetes.
Hattori S · Endocr J · 2011 · Background
PubMed: PMID 21206136 · NCT01847313 · Diabetes Mellitus
Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits.
Hamburg NM, Balady GJ · Circulation · 2011 · Background
PubMed: PMID 21200015 · NCT03883412 (ZQL007)
The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease.
Gleeson M, Bishop NC, Stensel DJ, et al. · Nat Rev Immunol · 2011 · Background
PubMed: PMID 21818123 · NCT04122716 (S-LITE) · Obesity
Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies.
Genser B, Dias KC, Siekmeier R, et al. · Clin Lab · 2011 · Background
PubMed: PMID 21500721 · NCT02501850 (EGLIPA) · Diabetes Mellitus, Type 2
Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes.
Forbes S, Taylor-Robinson SD, Patel N, et al. · Diabetologia · 2011 · Background
PubMed: PMID 21153530 · NCT01795248 · Diabetes Mellitus, Type 2
Liraglutide therapy in Prader-Willi syndrome.
Cyganek K, Koblik T, Kozek E, et al. · Diabet Med · 2011 · Background
PubMed: PMID 21388446 · NCT01542242 · Diabetes Mellitus, Type 2
Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans.
Chai W, Liu J, Jahn LA, et al. · Diabetes Care · 2011 · Background
PubMed: PMID 21617098 · NCT03883412 (ZQL007)
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.
Brunstein CG, Miller JS, Cao Q, et al. · Blood · 2011 · Background
PubMed: PMID 20952687 · NCT03011021 · Diabetes Mellitus, Type 1
Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review.
Barte JC, ter Bogt NC, Bogers RP, et al. · Obes Rev · 2011 · Background
PubMed: PMID 20345430 · NCT04122716 (S-LITE) · Obesity
Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature.
Barrett EJ, Wang H, Upchurch CT, et al. · Am J Physiol Endocrinol Metab · 2011 · Background
PubMed: PMID 21610226 · NCT04575844 (ZQL008) · Metabolic Syndrome

2010 (34 papers)

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
Seino Y, Rasmussen MF, Nishida T, et al. · Curr Med Res Opin · 2010 · Trial result
PubMed: PMID 20199137 · NCT00393718 · Diabetes Mellitus, Type 2
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Read PA, Khan FZ, Heck PM, et al. · Circ Cardiovasc Imaging · 2010 · Trial result
PubMed: PMID 20075143 · NCT02602600 (GAP) · Microvascular Angina
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE, Nauck M, Bailey T, et al. · Lancet · 2010 · Trial result
PubMed: PMID 20417856 · NCT00700817 · Diabetes Mellitus, Type 2
Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.
Pepine CJ, Anderson RD, Sharaf BL, et al. · J Am Coll Cardiol · 2010 · Trial result
PubMed: PMID 20579539 · NCT02602600 (GAP) · Microvascular Angina
Low diagnostic yield of elective coronary angiography.
Patel MR, Peterson ED, Dai D, et al. · N Engl J Med · 2010 · Trial result
PubMed: PMID 20220183 · NCT02602600 (GAP) · Microvascular Angina
Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
MacLaughlin HL, Cook SA, Kariyawasam D, et al. · Am J Kidney Dis · 2010 · Trial result
PubMed: PMID 19926371 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.
Jacobsen LV, Hindsberger C, Robson R, et al. · Br J Clin Pharmacol · 2010 · Trial result
PubMed: PMID 20002084 · NCT01508806 · Diabetes Mellitus, Type 2
Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.
Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. · Eur J Endocrinol · 2010 · Trial result
PubMed: PMID 19841045 · NCT05952882 · Obesity
Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.
Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. · J Clin Pharmacol · 2010 · Trial result
PubMed: PMID 19737980 · NCT01516255 · Diabetes Mellitus, Type 2
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
Buse JB, Sesti G, Schmidt WE, et al. · Diabetes Care · 2010 · Trial result
PubMed: PMID 20332351 · NCT00518882 (LEAD-6) · Diabetes Mellitus, Type 2
Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus.
Xiang AH, Kjos SL, Takayanagi M, et al. · Diabetes · 2010 · Background
PubMed: PMID 20682697 · NCT01795248 · Diabetes Mellitus, Type 2
A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.
Wadén J, Forsblom C, Thorn LM, et al. · Diabetes · 2010 · Background
PubMed: PMID 19651819 · NCT02879409 · Diabetes Mellitus, Type 2
Exercise and the metabolic syndrome with weight regain.
Thomas TR, Warner SO, Dellsperger KC, et al. · J Appl Physiol (1985) · 2010 · Background
PubMed: PMID 20167668 · NCT04122716 (S-LITE) · Obesity
Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Rother KI, Spain LM, Wesley RA, et al. · Diabetes Care · 2010 · Background
PubMed: PMID 19808924 · NCT01722266 · Diabetes Mellitus, Type 1
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
Okerson T, Yan P, Stonehouse A, et al. · Am J Hypertens · 2010 · Background
PubMed: PMID 20019672 · NCT01722266 · Diabetes Mellitus, Type 1
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E, Sesti G · Clin Ther · 2010 · Background
PubMed: PMID 20109994 · NCT01722266 · Diabetes Mellitus, Type 1
Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.
Mangravite LM, Medina MW, Cui J, et al. · Arterioscler Thromb Vasc Biol · 2010 · Background
PubMed: PMID 20413733 · NCT02488057 · Glucose Intolerance
High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown.
Lu B, Yang Z, Wang M, et al. · Diabetes Res Clin Pract · 2010 · Background
PubMed: PMID 20359765 · NCT04137328
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
Look AHEAD Research Group, Wing RR · Arch Intern Med · 2010 · Background
PubMed: PMID 20876408 · NCT02488057 · Glucose Intolerance
The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review.
Lenz M, Richter T, Mühlhauser I, et al. · Dtsch Arztebl Int · 2010 · Background
PubMed: PMID 19890430 · NCT03341429 (BARIOPTIMISE) · Diabetes Mellitus
Type 2 diabetes impairs pulmonary function in morbidly obese women: a case-control study.
Lecube A, Sampol G, Muñoz X, et al. · Diabetologia · 2010 · Background
PubMed: PMID 20217039 · NCT02889510 · Diabetes Mellitus, Type 2
Adjunct therapy for type 1 diabetes mellitus.
Lebovitz HE · Nat Rev Endocrinol · 2010 · Background
PubMed: PMID 20404854 · NCT01722266 · Diabetes Mellitus, Type 1
Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Kielgast U, Asmar M, Madsbad S, et al. · J Clin Endocrinol Metab · 2010 · Background
PubMed: PMID 20207828 · NCT01722266 · Diabetes Mellitus, Type 1
Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus.
Jonker JT, Lamb HJ, van der Meer RW, et al. · J Clin Endocrinol Metab · 2010 · Background
PubMed: PMID 19915017 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Prediabetes: the importance of early identification and intervention.
Hsueh WA, Orloski L, Wyne K, et al. · Postgrad Med · 2010 · Background
PubMed: PMID 20675976 · NCT02488057 · Glucose Intolerance
The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study.
From AM, Scott CG, Chen HH, et al. · J Am Coll Cardiol · 2010 · Background
PubMed: PMID 20117433 · NCT02655770 · Diabetes Mellitus, Type 2
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. · Lancet · 2010 · Background
PubMed: PMID 20609967 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.
Cummings BP, Stanhope KL, Graham JL, et al. · Diabetes · 2010 · Background
PubMed: PMID 20622169 · NCT01847313 · Diabetes Mellitus
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Chai W, Wang W, Liu J, et al. · Hypertension · 2010 · Background
PubMed: PMID 19996061 · NCT04575844 (ZQL008) · Metabolic Syndrome
Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy.
Bhashyam S, Fields AV, Patterson B, et al. · Circ Heart Fail · 2010 · Background
PubMed: PMID 20466848 · NCT02655770 · Diabetes Mellitus, Type 2
Body-mass index and mortality among 1.46 million white adults.
Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 21121834 · NCT03038620 · Obesity
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Arakawa M, Mita T, Azuma K, et al. · Diabetes · 2010 · Background
PubMed: PMID 20068138 · NCT04122716 (S-LITE) · Obesity
Standards of medical care in diabetes--2010.
American Diabetes Association · Diabetes Care · 2010 · Background
PubMed: PMID 20042772 · NCT02113332 · Diabetes Mellitus, Type 2
Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.
Abbas T, Faivre E, Hölscher C, et al. · Behav Brain Res · 2010 · Background
PubMed: PMID 19573562 · NCT01469351 · Alzheimer Disease

2009 (43 papers)

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Zinman B, Gerich J, Buse JB, et al. · Diabetes Care · 2009 · Trial result
PubMed: PMID 19289857 · NCT00333151 (LEAD-4) · Diabetes Mellitus, Type 2
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
Sullivan SD, Alfonso-Cristancho R, Conner C, et al. · Cardiovasc Diabetol · 2009 · Trial result
PubMed: PMID 19245711 · NCT00331851 (LEAD-5) · Diabetes Mellitus, Type 2
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Russell-Jones D, Vaag A, Schmitz O, et al. · Diabetologia · 2009 · Trial result
PubMed: PMID 19688338 · NCT00331851 (LEAD-5) · Diabetes Mellitus, Type 2
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Palomba S, Falbo A, Zullo F, et al. · Endocr Rev · 2009 · Trial result
PubMed: PMID 19056992 · NCT05952882 · Obesity
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Noyan-Ashraf MH, Momen MA, Ban K, et al. · Diabetes · 2009 · Trial result
PubMed: PMID 19151200 · NCT02001363 · Reperfusion Injury
Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.
Nauck M, Marre M · Postgrad Med · 2009 · Trial result
PubMed: PMID 19491535 · NCT00318461 (LEAD-2) · Diabetes Mellitus, Type 2
Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies.
McGill JB · Postgrad Med · 2009 · Trial result
PubMed: PMID 19491536 · NCT00518882 (LEAD-6) · Diabetes Mellitus, Type 2
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M, Shaw J, Brändle M, et al. · Diabet Med · 2009 · Trial result
PubMed: PMID 19317822 · NCT00318422 (LEAD-1) · Diabetes Mellitus, Type 2
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project.
Gulati M, Cooper-DeHoff RM, McClure C, et al. · Arch Intern Med · 2009 · Trial result
PubMed: PMID 19433695 · NCT02602600 (GAP) · Microvascular Angina
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Garber A, Henry R, Ratner R, et al. · Lancet · 2009 · Trial result
PubMed: PMID 18819705 · NCT00294723 (LEAD-3) · Diabetes Mellitus, Type 2
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
Courrèges JP, Vilsbøll T, Zdravkovic M, et al. · Diabet Med · 2009 · Trial result
PubMed: PMID 19183322 · NCT00154401 · Diabetes Mellitus, Type 2
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB, Rosenstock J, Sesti G, et al. · Lancet · 2009 · Trial result
PubMed: PMID 19515413 · NCT00518882 (LEAD-6) · Diabetes Mellitus, Type 2
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A, Rössner S, Van Gaal L, et al. · Lancet · 2009 · Trial result
PubMed: PMID 19853906 · NCT04529278 (LIRADIAL) · Diabetes Mellitus, Type 2
Glycemia and cardiovascular disease in type 1 diabetes mellitus.
Wajchenberg BL, Feitosa AC, Rassi N, et al. · Endocr Pract · 2009 · Background
PubMed: PMID 18996824 · NCT01722266 · Diabetes Mellitus, Type 1
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
van der Meer RW, Rijzewijk LJ, de Jong HW, et al. · Circulation · 2009 · Background
PubMed: PMID 19349323 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Timmers L, Henriques JP, de Kleijn DP, et al. · J Am Coll Cardiol · 2009 · Background
PubMed: PMID 19195607 · NCT02930265
Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.
Tarabra E, Giunti S, Barutta F, et al. · Diabetes · 2009 · Background
PubMed: PMID 19587356 · NCT01847313 · Diabetes Mellitus
Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT.
Siegelaar SE, Kilpatrick ES, Rigby AS, et al. · Diabetologia · 2009 · Background
PubMed: PMID 19672575 · NCT02879409 · Diabetes Mellitus, Type 2
Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging.
Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. · J Am Coll Cardiol · 2009 · Background
PubMed: PMID 19815124 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.
Rezkalla SH, Kloner RA · Catheter Cardiovasc Interv · 2009 · Background
PubMed: PMID 19021281 · NCT02507128 · ST Elevation Myocardial Infarction
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
Raz I, Wilson PW, Strojek K, et al. · Diabetes Care · 2009 · Background
PubMed: PMID 19246588 · NCT02879409 · Diabetes Mellitus, Type 2
The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.
Pi-Sunyer FX · Postgrad Med · 2009 · Background
PubMed: PMID 19820278 · NCT02113332 · Diabetes Mellitus, Type 2
The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart.
Ossum A, van Deurs U, Engstrøm T, et al. · Pharmacol Res · 2009 · Background
PubMed: PMID 19540343 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice.
Olfert IM, Howlett RA, Tang K, et al. · J Physiol · 2009 · Background
PubMed: PMID 19237429 · NCT04575844 (ZQL008) · Metabolic Syndrome
Status and rationale of renoprotection studies in adolescents with type 1 diabetes.
Marcovecchio ML, Tossavainen PH, Dunger DB, et al. · Pediatr Diabetes · 2009 · Background
PubMed: PMID 19496962 · NCT02879409 · Diabetes Mellitus, Type 2
Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.
Mannino DM, Thorn D, Swensen A, et al. · Eur Respir J · 2009 · Background
PubMed: PMID 18579551 · NCT02889510 · Diabetes Mellitus, Type 2
Are natural killer cells protecting the metabolically healthy obese patient?
Lynch LA, O'Connell JM, Kwasnik AK, et al. · Obesity (Silver Spring) · 2009 · Background
PubMed: PMID 19238145 · NCT01847313 · Diabetes Mellitus
Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity.
Lynch L, O'Shea D, Winter DC, et al. · Eur J Immunol · 2009 · Background
PubMed: PMID 19585513 · NCT01847313 · Diabetes Mellitus
Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature.
Liu Z, Liu J, Jahn LA, et al. · J Clin Endocrinol Metab · 2009 · Background
PubMed: PMID 19567533 · NCT03883412 (ZQL007)
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.
Liu H, Dear AE, Knudsen LB, et al. · J Endocrinol · 2009 · Background
PubMed: PMID 19136619 · NCT02001363 · Reperfusion Injury
Limb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severity.
Lindner JR, Womack L, Barrett EJ, et al. · JACC Cardiovasc Imaging · 2009 · Background
PubMed: PMID 19356447 · NCT03883412 (ZQL007)
Diabetes is an independent risk factor for severe nocturnal hypoxemia in obese patients. A case-control study.
Lecube A, Sampol G, Lloberes P, et al. · PLoS One · 2009 · Background
PubMed: PMID 19262746 · NCT02889510 · Diabetes Mellitus, Type 2
Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes.
Kilpatrick ES, Rigby AS, Atkin SL, et al. · Diabetes Care · 2009 · Background
PubMed: PMID 19549736 · NCT02879409 · Diabetes Mellitus, Type 2
Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome.
Jungheim ES, Lanzendorf SE, Odem RR, et al. · Fertil Steril · 2009 · Background
PubMed: PMID 18692801 · NCT03034941 · Obesity
Intensive pharmacologic treatment in patients with acute non ST-segment elevation myocardial infarction who did not undergo percutaneous coronary intervention.
Jeong HC, Ahn YK, Jeong MH, et al. · Circ J · 2009 · Background
PubMed: PMID 18724013 · NCT02490176 · Heart Failure
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary.
Grundy SM, Cleeman JI, Daniels SR, et al. · Crit Pathw Cardiol · 2009 · Background
PubMed: PMID 18340209 · NCT03038620 · Obesity
Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W, Abraira C, Moritz T, et al. · N Engl J Med · 2009 · Background
PubMed: PMID 19092145 · NCT02879409 · Diabetes Mellitus, Type 2
American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults.
Donnelly JE, Blair SN, Jakicic JM, et al. · Med Sci Sports Exerc · 2009 · Background
PubMed: PMID 19127177 · NCT04122716 (S-LITE) · Obesity
Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment.
Dimou E, Booij J, Rodrigues M, et al. · Curr Alzheimer Res · 2009 · Background
PubMed: PMID 19519314 · NCT01469351 · Alzheimer Disease
Development of a semi-quantitative food frequency questionnaire for use in United Arab Emirates and Kuwait based on local foods.
Dehghan M, Al Hamad N, Yusufali A, et al. · Nutr J · 2009 · Background
PubMed: PMID 15921524 · NCT02879409 · Diabetes Mellitus, Type 2
Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.
Buchwald H, Estok R, Fahrbach K, et al. · Am J Med · 2009 · Background
PubMed: PMID 19272486 · NCT01597531 · Diabetes Mellitus, Type 2
The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action.
Barrett EJ, Eggleston EM, Inyard AC, et al. · Diabetologia · 2009 · Background
PubMed: PMID 19283361 · NCT03883412 (ZQL007)
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
Alberti KG, Eckel RH, Grundy SM, et al. · Circulation · 2009 · Background
PubMed: PMID 19805654 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2

2008 (31 papers)

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
Vilsbøll T, Brock B, Perrild H, et al. · Diabet Med · 2008 · Trial result
PubMed: PMID 18201212 · NCT00154401 · Diabetes Mellitus, Type 2
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
Seino Y, Rasmussen MF, Zdravkovic M, et al. · Diabetes Res Clin Pract · 2008 · Trial result
PubMed: PMID 18495285 · NCT00154414 · Diabetes Mellitus, Type 2
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D, Farmakiotis D, Rousso D, et al. · Fertil Steril · 2008 · Trial result
PubMed: PMID 17980364 · NCT05952882 · Obesity
Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence.
Metwally M, Ong KJ, Ledger WL, et al. · Fertil Steril · 2008 · Trial result
PubMed: PMID 18068166 · NCT05952882 · Obesity
Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
Irie S, Matsumura Y, Zdravkovic M, et al. · Int J Clin Pharmacol Ther · 2008 · Trial result
PubMed: PMID 18541123 · NCT01515592 · Diabetes Mellitus, Type 2
Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.
Horowitz M, Vilsbøll T, Zdravkovic M, et al. · Diabetes Obes Metab · 2008 · Trial result
PubMed: PMID 18435773 · NCT00154401 · Diabetes Mellitus, Type 2
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Dunaif A · Nat Clin Pract Endocrinol Metab · 2008 · Trial result
PubMed: PMID 18364705 · NCT05952882 · Obesity
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Ban K, Noyan-Ashraf MH, Hoefer J, et al. · Circulation · 2008 · Trial result
PubMed: PMID 18427132 · NCT02602600 (GAP) · Microvascular Angina
Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study.
Yeh HC, Punjabi NM, Wang NY, et al. · Diabetes Care · 2008 · Background
PubMed: PMID 18056886 · NCT02889510 · Diabetes Mellitus, Type 2
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.
Yamada C, Yamada Y, Tsukiyama K, et al. · Endocrinology · 2008 · Background
PubMed: PMID 18039776 · NCT02473809 (LIRABONE) · Diabetes Complications
Weight loss therapy improves pancreatic endocrine function in obese older adults.
Villareal DT, Banks MR, Patterson BW, et al. · Obesity (Silver Spring) · 2008 · Background
PubMed: PMID 18388888 · NCT02488057 · Glucose Intolerance
Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension.
van Heerebeek L, Hamdani N, Handoko ML, et al. · Circulation · 2008 · Background
PubMed: PMID 18071071 · NCT02655770 · Diabetes Mellitus, Type 2
Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men.
van der Meer RW, Hammer S, Lamb HJ, et al. · J Clin Endocrinol Metab · 2008 · Background
PubMed: PMID 18430773 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.
Sonne DP, Engstrøm T, Treiman M, et al. · Regul Pept · 2008 · Background
PubMed: PMID 17976835 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis.
McLaughlin T, Sherman A, Tsao P, et al. · Diabetologia · 2008 · Background
PubMed: PMID 17549449 · NCT03038620 · Obesity
Relationship between beta-cell mass and diabetes onset.
Matveyenko AV, Butler PC · Diabetes Obes Metab · 2008 · Background
PubMed: PMID 18834430 · NCT02488057 · Glucose Intolerance
Effects of Bulbus allii macrostemi on clinical outcomes and oxidized low-density lipoprotein and plasminogen in unstable angina/non-ST-segment elevation myocardial infarction patients.
Liu Y, Zhang L, Liu YF, et al. · Phytother Res · 2008 · Background
PubMed: PMID 18688814 · NCT02490176 · Heart Failure
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.
Krauss RM, Mangravite LM, Smith JD, et al. · Circulation · 2008 · Background
PubMed: PMID 18332269 · NCT02488057 · Glucose Intolerance
Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes.
Kilpatrick ES, Rigby AS, Atkin SL, et al. · Diabetologia · 2008 · Background
PubMed: PMID 18040661 · NCT02879409 · Diabetes Mellitus, Type 2
Effect of exercise on 24-month weight loss maintenance in overweight women.
Jakicic JM, Marcus BH, Lang W, et al. · Arch Intern Med · 2008 · Background
PubMed: PMID 18663167 · NCT04122716 (S-LITE) · Obesity
Glucagon-like peptide-1, glucose homeostasis and diabetes.
Holst JJ, Deacon CF, Vilsbøll T, et al. · Trends Mol Med · 2008 · Background
PubMed: PMID 18353723 · NCT04122716 (S-LITE) · Obesity
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
Holman RR, Paul SK, Bethel MA, et al. · N Engl J Med · 2008 · Background
PubMed: PMID 18784091 · NCT02879409 · Diabetes Mellitus, Type 2
Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men.
Hammer S, van der Meer RW, Lamb HJ, et al. · J Clin Endocrinol Metab · 2008 · Background
PubMed: PMID 18029455 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus.
Hammer S, van der Meer RW, Lamb HJ, et al. · Am J Physiol Endocrinol Metab · 2008 · Background
PubMed: PMID 18628354 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function.
Hammer S, Snel M, Lamb HJ, et al. · J Am Coll Cardiol · 2008 · Background
PubMed: PMID 18786482 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.
Green BD, Hand KV, Dougan JE, et al. · Arch Biochem Biophys · 2008 · Background
PubMed: PMID 18708025 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance.
Fernández-Real JM, Chico B, Shiratori M, et al. · Diabetes Care · 2008 · Background
PubMed: PMID 18285549 · NCT02889510 · Diabetes Mellitus, Type 2
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
Després JP, Lemieux I, Bergeron J, et al. · Arterioscler Thromb Vasc Biol · 2008 · Background
PubMed: PMID 18356555 · NCT03038620 · Obesity
Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1.
Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, et al. · J Mol Endocrinol · 2008 · Background
PubMed: PMID 18487229 · NCT01847313 · Diabetes Mellitus
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. · N Engl J Med · 2008 · Background
PubMed: PMID 18539916 · NCT02879409 · Diabetes Mellitus, Type 2
Effects of intensive glucose lowering in type 2 diabetes.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. · N Engl J Med · 2008 · Background
PubMed: PMID 18539917 · NCT02879409 · Diabetes Mellitus, Type 2

2007 (26 papers)

Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms.
Zhang Y, Guo K, LeBlanc RE, et al. · Diabetes · 2007 · Trial result
PubMed: PMID 17360978 · NCT02616003 · Obesity, Morbid
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Vilsbøll T, Zdravkovic M, Le-Thi T, et al. · Diabetes Care · 2007 · Trial result
PubMed: PMID 17372153 · NCT00154401 · Diabetes Mellitus, Type 2
Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study.
Johnson BD, Shaw LJ, Pepine CJ, et al. · Eur Heart J · 2007 · Trial result
PubMed: PMID 16720691 · NCT02602600 (GAP) · Microvascular Angina
Coronary microvascular dysfunction.
Camici PG, Crea F · N Engl J Med · 2007 · Trial result
PubMed: PMID 17314342 · NCT02602600 (GAP) · Microvascular Angina
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis.
Vestergaard P · Osteoporos Int · 2007 · Background
PubMed: PMID 17068657 · NCT02473809 (LIRABONE) · Diabetes Complications
Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers.
van der Meer RW, Doornbos J, Kozerke S, et al. · Radiology · 2007 · Background
PubMed: PMID 17885193 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
Sokos GG, Nikolaidis LA, Mankad S, et al. · J Card Fail · 2007 · Background
PubMed: PMID 17174230 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.
Sokos GG, Bolukoglu H, German J, et al. · Am J Cardiol · 2007 · Background
PubMed: PMID 17719327 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Exercise for overweight or obesity.
Shaw K, Gennat H, O'Rourke P, et al. · Cochrane Database Syst Rev · 2007 · Background
PubMed: PMID 17054187 · NCT04122716 (S-LITE) · Obesity
The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study.
See R, Abdullah SM, McGuire DK, et al. · J Am Coll Cardiol · 2007 · Background
PubMed: PMID 17707180 · NCT03038620 · Obesity
Diabetes, fracture, and bone fragility.
Schwartz AV, Sellmeyer DE · Curr Osteoporos Rep · 2007 · Background
PubMed: PMID 17925191 · NCT02473809 (LIRABONE) · Diabetes Complications
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Navarro JF, Milena FJ, Mora C, et al. · Am J Nephrol · 2007 · Background
PubMed: PMID 17167242 · NCT01847313 · Diabetes Mellitus
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study.
McGavock JM, Lingvay I, Zib I, et al. · Circulation · 2007 · Background
PubMed: PMID 17698735 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
Mari A, Degn K, Brock B, et al. · Diabetes Care · 2007 · Background
PubMed: PMID 17468345 · NCT02488057 · Glucose Intolerance
Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy.
Kanamori H, Matsubara T, Mima A, et al. · Biochem Biophys Res Commun · 2007 · Background
PubMed: PMID 17631861 · NCT01847313 · Diabetes Mellitus
Contraction stimulates nitric oxide independent microvascular recruitment and increases muscle insulin uptake.
Inyard AC, Clerk LH, Vincent MA, et al. · Diabetes · 2007 · Background
PubMed: PMID 17563063 · NCT04575844 (ZQL008) · Metabolic Syndrome
Hypothesis: the 'metabolic memory', the new challenge of diabetes.
Ihnat MA, Thorpe JE, Ceriello A, et al. · Diabet Med · 2007 · Background
PubMed: PMID 17490424 · NCT02879409 · Diabetes Mellitus, Type 2
The physiology of glucagon-like peptide 1.
Holst JJ · Physiol Rev · 2007 · Background
PubMed: PMID 17928588 · NCT01795248 · Diabetes Mellitus, Type 2
Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S, Dokun AO, Li Y, et al. · Circ Res · 2007 · Background
PubMed: PMID 17823371 · NCT04575844 (ZQL008) · Metabolic Syndrome
Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts.
Goodarzi MO, Taylor KD, Scheuner MT, et al. · Pharmacogenomics J · 2007 · Background
PubMed: PMID 16755277 · NCT02488057 · Glucose Intolerance
Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects.
Ghanim H, Aljada A, Daoud N, et al. · Diabetologia · 2007 · Background
PubMed: PMID 17180352 · NCT01722266 · Diabetes Mellitus, Type 1
Hyperinsulinemia rapidly increases human muscle microvascular perfusion but fails to increase muscle insulin clearance: evidence that a saturable process mediates muscle insulin uptake.
Eggleston EM, Jahn LA, Barrett EJ, et al. · Diabetes · 2007 · Background
PubMed: PMID 17720897 · NCT04575844 (ZQL008) · Metabolic Syndrome
Molecular connexions between dementia and diabetes.
Cole AR, Astell A, Green C, et al. · Neurosci Biobehav Rev · 2007 · Background
PubMed: PMID 17544131 · NCT01469351 · Alzheimer Disease
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB, Klonoff DC, Nielsen LL, et al. · Clin Ther · 2007 · Background
PubMed: PMID 17379054 · NCT01722266 · Diabetes Mellitus, Type 1
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L, Klein EJ, Han J, et al. · Diabetes Obes Metab · 2007 · Background
PubMed: PMID 16776751 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.
Basu A, Charkoudian N, Schrage W, et al. · Am J Physiol Endocrinol Metab · 2007 · Background
PubMed: PMID 17711996 · NCT04575844 (ZQL008) · Metabolic Syndrome

2006 (19 papers)

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Nauck MA, Hompesch M, Filipczak R, et al. · Exp Clin Endocrinol Diabetes · 2006 · Trial result
PubMed: PMID 17039422 · NCT01511172 · Diabetes Mellitus, Type 2
An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.
Damholt B, Golor G, Wierich W, et al. · J Clin Pharmacol · 2006 · Trial result
PubMed: PMID 16707410 · NCT01507337 · Diabetes Mellitus
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.
Zhao T, Parikh P, Bhashyam S, et al. · J Pharmacol Exp Ther · 2006 · Background
PubMed: PMID 16489128 · NCT04575844 (ZQL008) · Metabolic Syndrome
Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions.
Yozai K, Shikata K, Sasaki M, et al. · J Am Soc Nephrol · 2006 · Background
PubMed: PMID 16177002 · NCT01847313 · Diabetes Mellitus
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.
Yancy CW, Lopatin M, Stevenson LW, et al. · J Am Coll Cardiol · 2006 · Background
PubMed: PMID 16386668 · NCT02655770 · Diabetes Mellitus, Type 2
Mixed meal and light exercise each recruit muscle capillaries in healthy humans.
Vincent MA, Clerk LH, Lindner JR, et al. · Am J Physiol Endocrinol Metab · 2006 · Background
PubMed: PMID 16682488 · NCT04575844 (ZQL008) · Metabolic Syndrome
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll T · Dan Med Bull · 2006 · Background
PubMed: PMID 16009062 · NCT01795248 · Diabetes Mellitus, Type 2
Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats.
Tone A, Shikata K, Sasaki M, et al. · Diabetologia · 2006 · Background
PubMed: PMID 16231067 · NCT01847313 · Diabetes Mellitus
The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss.
Stiegler P, Cunliffe A · Sports Med · 2006 · Background
PubMed: PMID 16526835 · NCT04122716 (S-LITE) · Obesity
The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study.
Panagiotakos DB, Pitsavos C, Yannakoulia M, et al. · Atherosclerosis · 2006 · Background
PubMed: PMID 16285994 · NCT04122716 (S-LITE) · Obesity
VEGF receptor signalling - in control of vascular function.
Olsson AK, Dimberg A, Kreuger J, et al. · Nat Rev Mol Cell Biol · 2006 · Background
PubMed: PMID 16633338 · NCT04575844 (ZQL008) · Metabolic Syndrome
Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials.
Nordmann AJ, Nordmann A, Briel M, et al. · Arch Intern Med · 2006 · Background
PubMed: PMID 16476868 · NCT04122716 (S-LITE) · Obesity
Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.
Kim JA, Montagnani M, Koh KK, et al. · Circulation · 2006 · Background
PubMed: PMID 16618833 · NCT03883412 (ZQL007)
The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.
Kilpatrick ES, Rigby AS, Atkin SL, et al. · Diabetes Care · 2006 · Background
PubMed: PMID 16801566 · NCT02879409 · Diabetes Mellitus, Type 2
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Ding X, Saxena NK, Lin S, et al. · Hepatology · 2006 · Background
PubMed: PMID 16374859 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Long-term weight loss after diet and exercise: a systematic review.
Curioni CC, Lourenço PM · Int J Obes (Lond) · 2006 · Background
PubMed: PMID 15925949 · NCT04122716 (S-LITE) · Obesity
Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle.
Clerk LH, Vincent MA, Jahn LA, et al. · Diabetes · 2006 · Background
PubMed: PMID 16644702 · NCT03883412 (ZQL007)
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.
Chow FY, Nikolic-Paterson DJ, Ozols E, et al. · Kidney Int · 2006 · Background
PubMed: PMID 16374426 · NCT01847313 · Diabetes Mellitus
Endurance training in obese humans improves glucose tolerance and mitochondrial fatty acid oxidation and alters muscle lipid content.
Bruce CR, Thrush AB, Mertz VA, et al. · Am J Physiol Endocrinol Metab · 2006 · Background
PubMed: PMID 16464906 · NCT04122716 (S-LITE) · Obesity

2005 (21 papers)

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Nikolaidis LA, Elahi D, Hentosz T, et al. · Circulation · 2005 · Trial result
PubMed: PMID 15313949 · NCT02602600 (GAP) · Microvascular Angina
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S, Schmitz O, Ranstam J, et al. · Diabetes Care · 2005 · Trial result
PubMed: PMID 15161785 · NCT01509755 · Diabetes Mellitus, Type 2
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
Harder H, Nielsen L, Tu DT, et al. · Diabetes Care · 2005 · Trial result
PubMed: PMID 15277417 · NCT01508949 · Diabetes Mellitus, Type 2
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Feinglos MN, Saad MF, Pi-Sunyer FX, et al. · Diabet Med · 2005 · Trial result
PubMed: PMID 16026367 · NCT01511198 · Diabetes Mellitus, Type 2
Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
Workgroup on Hypoglycemia, American Diabetes Association · Diabetes Care · 2005 · Background
PubMed: PMID 15855602 · NCT02113332 · Diabetes Mellitus, Type 2
Long-term weight loss maintenance.
Wing RR, Phelan S · Am J Clin Nutr · 2005 · Background
PubMed: PMID 16002825 · NCT04122716 (S-LITE) · Obesity
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.
Thrainsdottir I, Malmberg K, Olsson A, et al. · Diab Vasc Dis Res · 2005 · Background
PubMed: PMID 16305055 · NCT02655770 · Diabetes Mellitus, Type 2
Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study.
Thomas EL, Hamilton G, Patel N, et al. · Gut · 2005 · Background
PubMed: PMID 15591516 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
The burden of mortality attributable to diabetes: realistic estimates for the year 2000.
Roglic G, Unwin N, Bennett PH, et al. · Diabetes Care · 2005 · Background
PubMed: PMID 16123478 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.
Potenza MA, Marasciulo FL, Chieppa DM, et al. · Am J Physiol Heart Circ Physiol · 2005 · Background
PubMed: PMID 15792994 · NCT03883412 (ZQL007)
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.
Nyström T, Gonon AT, Sjöholm A, et al. · Regul Pept · 2005 · Background
PubMed: PMID 15582729 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Chronic kidney disease: the global challenge.
Meguid El Nahas A, Bello AK · Lancet · 2005 · Background
PubMed: PMID 15664230 · NCT01847313 · Diabetes Mellitus
The union of vascular and metabolic actions of insulin in sickness and in health.
Kim JA, Koh KK, Quon MJ, et al. · Arterioscler Thromb Vasc Biol · 2005 · Background
PubMed: PMID 15863720 · NCT03883412 (ZQL007)
Human energy requirements: report of a joint FAO/ WHO/UNU Expert Consultation.
Food Nutr Bull · 2005 · Background
PubMed: PMID 15810802 · NCT03038620 · Obesity
Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes.
Home P · Curr Med Res Opin · 2005 · Background
PubMed: PMID 16004665 · NCT02879409 · Diabetes Mellitus, Type 2
Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study.
Hernández C, Francisco G, Chacón P, et al. · Diabetes Care · 2005 · Background
PubMed: PMID 15793200 · NCT02501850 (EGLIPA) · Diabetes Mellitus, Type 2
Lower capillary density but no difference in VEGF expression in obese vs. lean young skeletal muscle in humans.
Gavin TP, Stallings HW, Zwetsloot KA, et al. · J Appl Physiol (1985) · 2005 · Background
PubMed: PMID 15298982 · NCT03883412 (ZQL007)
Diversity of the human intestinal microbial flora.
Eckburg PB, Bik EM, Bernstein CN, et al. · Science · 2005 · Background
PubMed: PMID 15831718 · NCT04046822 · Obesity
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model.
Bose AK, Mocanu MM, Carr RD, et al. · Cardiovasc Drugs Ther · 2005 · Background
PubMed: PMID 15883751 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Bose AK, Mocanu MM, Carr RD, et al. · Diabetes · 2005 · Background
PubMed: PMID 15616022 · NCT04575844 (ZQL008) · Metabolic Syndrome
The metabolic syndrome--a new worldwide definition.
Alberti KG, Zimmet P, Shaw J, et al. · Lancet · 2005 · Background
PubMed: PMID 16182882 · NCT03038620 · Obesity

2004 (22 papers)

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group · Hum Reprod · 2004 · Trial result
PubMed: PMID 14688154 · NCT05952882 · Obesity
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Nikolaidis LA, Mankad S, Sokos GG, et al. · Circulation · 2004 · Trial result
PubMed: PMID 14981009 · NCT02602600 (GAP) · Microvascular Angina
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB, Juhl CB, Sturis J, et al. · Diabetes · 2004 · Trial result
PubMed: PMID 15111485 · NCT01508923 · Diabetes Mellitus, Type 2
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
Agersø H, Vicini P · Eur J Pharm Sci · 2004 · Trial result
PubMed: PMID 12791417 · NCT01507272 · Diabetes Mellitus
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.
Wild S, Roglic G, Green A, et al. · Diabetes Care · 2004 · Background
PubMed: PMID 15111519 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Skeletal muscle contraction stimulates capillary recruitment and glucose uptake in insulin-resistant obese Zucker rats.
Wheatley CM, Rattigan S, Richards SM, et al. · Am J Physiol Endocrinol Metab · 2004 · Background
PubMed: PMID 15213062 · NCT03883412 (ZQL007)
Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo.
Vincent MA, Clerk LH, Lindner JR, et al. · Diabetes · 2004 · Background
PubMed: PMID 15161743 · NCT03883412 (ZQL007)
Incretins, insulin secretion and Type 2 diabetes mellitus.
Vilsbøll T, Holst JJ · Diabetologia · 2004 · Background
PubMed: PMID 14968296 · NCT01795248 · Diabetes Mellitus, Type 2
Capillary regression in vascular endothelial growth factor-deficient skeletal muscle.
Tang K, Breen EC, Gerber HP, et al. · Physiol Genomics · 2004 · Background
PubMed: PMID 15084712 · NCT03883412 (ZQL007)
Lipotoxicity: when tissues overeat.
Schaffer JE · Curr Opin Lipidol · 2004 · Background
PubMed: PMID 12840659 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Nyström T, Gutniak MK, Zhang Q, et al. · Am J Physiol Endocrinol Metab · 2004 · Background
PubMed: PMID 15353407 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Pulmonary involvement in diabetes mellitus.
Nicolaie T, Zăvoianu C, Nuţă P, et al. · Rom J Intern Med · 2004 · Background
PubMed: PMID 15526520 · NCT02889510 · Diabetes Mellitus, Type 2
Intramyocellular lipids and insulin resistance.
Machann J, Häring H, Schick F, et al. · Diabetes Obes Metab · 2004 · Background
PubMed: PMID 15171747 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population.
Lauenborg J, Hansen T, Jensen DM, et al. · Diabetes Care · 2004 · Background
PubMed: PMID 15111544 · NCT01795248 · Diabetes Mellitus, Type 2
Design and analysis of pilot studies: recommendations for good practice.
Lancaster GA, Dodd S, Williamson PR, et al. · J Eval Clin Pract · 2004 · Background
PubMed: PMID 15189396 · NCT02879409 · Diabetes Mellitus, Type 2
Insulin induced increase in coronary flow reserve is abolished by dexamethasone in young men with uncomplicated type 1 diabetes.
Laine H, Sundell J, Nuutila P, et al. · Heart · 2004 · Background
PubMed: PMID 14966043 · NCT04575844 (ZQL008) · Metabolic Syndrome
The biological variation of sex hormone-binding globulin in type 2 diabetes: implications for sex hormone-binding globulin as a surrogate marker of insulin resistance.
Jayagopal V, Kilpatrick ES, Jennings PE, et al. · Diabetes Care · 2004 · Background
PubMed: PMID 14694008 · NCT02879409 · Diabetes Mellitus, Type 2
Biological variation of lipoprotein(a) in a diabetic population. Analysis of the causes and clinical implications.
Hernández C, Francisco G, Chacón P, et al. · Clin Chem Lab Med · 2004 · Background
PubMed: PMID 12964817 · NCT02501850 (EGLIPA) · Diabetes Mellitus, Type 2
Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium.
Eringa EC, Stehouwer CD, van Nieuw Amerongen GP, et al. · Am J Physiol Heart Circ Physiol · 2004 · Background
PubMed: PMID 15059773 · NCT03883412 (ZQL007)
Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study.
Davis WA, Knuiman M, Kendall P, et al. · Diabetes Care · 2004 · Background
PubMed: PMID 14988297 · NCT02889510 · Diabetes Mellitus, Type 2
Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.
Chow F, Ozols E, Nikolic-Paterson DJ, et al. · Kidney Int · 2004 · Background
PubMed: PMID 14675042 · NCT01847313 · Diabetes Mellitus
The gut microbiota as an environmental factor that regulates fat storage.
Bäckhed F, Ding H, Wang T, et al. · Proc Natl Acad Sci U S A · 2004 · Background
PubMed: PMID 15505215 · NCT04046822 · Obesity

2003 (13 papers)

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
Elbrønd B, Jakobsen G, Larsen S, et al. · Diabetes Care · 2003 · Trial result
PubMed: PMID 12145241 · NCT01507272 · Diabetes Mellitus
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
Chang AM, Jakobsen G, Sturis J, et al. · Diabetes · 2003 · Trial result
PubMed: PMID 12829647 · NCT01511185 · Diabetes Mellitus, Type 2
Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin.
Vincent MA, Barrett EJ, Lindner JR, et al. · Am J Physiol Endocrinol Metab · 2003 · Background
PubMed: PMID 12791603 · NCT04575844 (ZQL008) · Metabolic Syndrome
The effects of insulin and short-term hyperglycaemia on myocardial blood flow in young men with uncomplicated Type I diabetes.
Sundell J, Laine H, Nuutila P, et al. · Diabetologia · 2003 · Background
PubMed: PMID 12107720 · NCT04575844 (ZQL008) · Metabolic Syndrome
Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans.
Starkie R, Ostrowski SR, Jauffred S, et al. · FASEB J · 2003 · Background
PubMed: PMID 12626436 · NCT04122716 (S-LITE) · Obesity
Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
Kernan WN, Inzucchi SE, Viscoli CM, et al. · Stroke · 2003 · Background
PubMed: PMID 12730556 · NCT02765399 · Diabetes Mellitus, Type 2
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
Keeley EC, Boura JA, Grines CL, et al. · Lancet · 2003 · Background
PubMed: PMID 12517460 · NCT02507128 · ST Elevation Myocardial Infarction
Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study.
Jensen DM, Mølsted-Pedersen L, Beck-Nielsen H, et al. · Am J Obstet Gynecol · 2003 · Background
PubMed: PMID 14634573 · NCT01795248 · Diabetes Mellitus, Type 2
Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles.
Eringa EC, Stehouwer CD, Merlijn T, et al. · Cardiovasc Res · 2003 · Background
PubMed: PMID 12445887 · NCT03883412 (ZQL007)
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
During MJ, Cao L, Zuzga DS, et al. · Nat Med · 2003 · Background
PubMed: PMID 12925848 · NCT01469351 · Alzheimer Disease
Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study.
Duncan BB, Schmidt MI, Pankow JS, et al. · Diabetes · 2003 · Background
PubMed: PMID 12829649 · NCT04122716 (S-LITE) · Obesity
Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus.
Diamant M, Lamb HJ, Groeneveld Y, et al. · J Am Coll Cardiol · 2003 · Background
PubMed: PMID 12875772 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Accurate assessment of beta-cell function: the hyperbolic correction.
Bergman RN, Ader M, Huecking K, et al. · Diabetes · 2003 · Background
PubMed: PMID 11815482 · NCT02488057 · Glucose Intolerance

2002 (12 papers)

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB, Hollingdal M, Sturis J, et al. · Diabetes · 2002 · Trial result
PubMed: PMID 11812750 · NCT01507311 · Diabetes Mellitus, Type 2
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
Agersø H, Jensen LB, Elbrønd B, et al. · Diabetologia · 2002 · Trial result
PubMed: PMID 11935150 · NCT01507285 · Diabetes Mellitus, Type 2
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
Zander M, Madsbad S, Madsen JL, et al. · Lancet · 2002 · Background
PubMed: PMID 11897280 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group · JAMA · 2002 · Background
PubMed: PMID 12020338 · NCT02879409 · Diabetes Mellitus, Type 2
Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats.
Wallis MG, Wheatley CM, Rattigan S, et al. · Diabetes · 2002 · Background
PubMed: PMID 12453905 · NCT03883412 (ZQL007)
High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes.
Vozarova B, Weyer C, Lindsay RS, et al. · Diabetes · 2002 · Background
PubMed: PMID 11812755 · NCT04122716 (S-LITE) · Obesity
Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow.
Sundell J, Nuutila P, Laine H, et al. · Diabetes · 2002 · Background
PubMed: PMID 11916935 · NCT04575844 (ZQL008) · Metabolic Syndrome
Screening for gestational diabetes; past, present and future.
Hanna FW, Peters JR · Diabet Med · 2002 · Background
PubMed: PMID 12027921 · NCT01795248 · Diabetes Mellitus, Type 2
Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction.
Gibson CM, Cannon CP, Murphy SA, et al. · Circulation · 2002 · Background
PubMed: PMID 11997276 · NCT02507128 · ST Elevation Myocardial Infarction
Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo.
Clerk LH, Rattigan S, Clark MG, et al. · Diabetes · 2002 · Background
PubMed: PMID 11916937 · NCT03883412 (ZQL007)
Risk factors for development of diabetes mellitus in women with a history of gestational diabetes mellitus.
Bian X, Gao P, Xiong X, et al. · Chin Med J (Engl) · 2002 · Background
PubMed: PMID 11776065 · NCT01795248 · Diabetes Mellitus, Type 2
Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study.
Bella JN, Palmieri V, Roman MJ, et al. · Circulation · 2002 · Background
PubMed: PMID 11997279 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2

2001 (7 papers)

Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study.
Reis SE, Holubkov R, Conrad Smith AJ, et al. · Am Heart J · 2001 · Trial result
PubMed: PMID 11320360 · NCT02602600 (GAP) · Microvascular Angina
Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.
Norman RJ, Masters L, Milner CR, et al. · Hum Reprod · 2001 · Trial result
PubMed: PMID 11527911 · NCT05952882 · Obesity
Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes.
Vara E, Arias-Díaz J, Garcia C, et al. · Am J Respir Crit Care Med · 2001 · Background
PubMed: PMID 11282754 · NCT02889510 · Diabetes Mellitus, Type 2
Obesity: preventing and managing the global epidemic. Report of a WHO consultation.
World Health Organ Tech Rep Ser · 2001 · Background
PubMed: PMID 11234459 · NCT04122716 (S-LITE) · Obesity
Dietary treatment and long-term weight loss and maintenance in type 2 diabetes.
Hensrud DD · Obes Res · 2001 · Background
PubMed: PMID 11707564 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease.
Brendle DC, Joseph LJ, Corretti MC, et al. · Am J Cardiol · 2001 · Background
PubMed: PMID 11165969 · NCT03883412 (ZQL007)
Long-term weight-loss maintenance: a meta-analysis of US studies.
Anderson JW, Konz EC, Frederich RC, et al. · Am J Clin Nutr · 2001 · Background
PubMed: PMID 11684524 · NCT04122716 (S-LITE) · Obesity

2000 (7 papers)

Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha.
Youd JM, Rattigan S, Clark MG, et al. · Diabetes · 2000 · Background
PubMed: PMID 11078458 · NCT03883412 (ZQL007)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
Stratton IM, Adler AI, Neil HA, et al. · BMJ · 2000 · Background
PubMed: PMID 10938048 · NCT02879409 · Diabetes Mellitus, Type 2
Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction.
Porte D · Ann N Y Acad Sci · 2000 · Background
PubMed: PMID 10842653 · NCT01795248 · Diabetes Mellitus, Type 2
Insulin-induced increment of coronary flow reserve is not abolished by dexamethasone in healthy young men.
Laine H, Nuutila P, Luotolahti M, et al. · J Clin Endocrinol Metab · 2000 · Background
PubMed: PMID 10843167 · NCT04575844 (ZQL008) · Metabolic Syndrome
Role of capillaries in determining CBF reserve: new insights using myocardial contrast echocardiography.
Jayaweera AR, Wei K, Coggins M, et al. · Am J Physiol · 2000 · Background
PubMed: PMID 10600857 · NCT04575844 (ZQL008) · Metabolic Syndrome
Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies.
Flint A, Raben A, Blundell JE, et al. · Int J Obes Relat Metab Disord · 2000 · Background
PubMed: PMID 10702749 · NCT01795248 · Diabetes Mellitus, Type 2
Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study.
Davis TM, Knuiman M, Kendall P, et al. · Diabetes Res Clin Pract · 2000 · Background
PubMed: PMID 10960726 · NCT02889510 · Diabetes Mellitus, Type 2

1999 (4 papers)

Acute vasoconstriction-induced insulin resistance in rat muscle in vivo.
Rattigan S, Clark MG, Barrett EJ, et al. · Diabetes · 1999 · Background
PubMed: PMID 10078557 · NCT03883412 (ZQL007)
Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT.
Molyneaux LM, Constantino MI, McGill M, et al. · Diabetes Res Clin Pract · 1999 · Background
PubMed: PMID 9886743 · NCT02879409 · Diabetes Mellitus, Type 2
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.
Matsuda M, DeFronzo RA · Diabetes Care · 1999 · Background
PubMed: PMID 10480510 · NCT02765399 · Diabetes Mellitus, Type 2
Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats.
Jiang ZY, Lin YW, Clemont A, et al. · J Clin Invest · 1999 · Background
PubMed: PMID 10449437 · NCT03883412 (ZQL007)

1998 (7 papers)

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group · BMJ · 1998 · Background
PubMed: PMID 9732337 · NCT02879409 · Diabetes Mellitus, Type 2
Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors.
Nitenberg A, Paycha F, Ledoux S, et al. · Circulation · 1998 · Background
PubMed: PMID 9498536 · NCT02655770 · Diabetes Mellitus, Type 2
Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee.
Metzger BE, Coustan DR · Diabetes Care · 1998 · Background
PubMed: PMID 9704245 · NCT01795248 · Diabetes Mellitus, Type 2
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet · 1998 · Background
PubMed: PMID 9742976 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2
The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.
Gerich JE · Endocr Rev · 1998 · Background
PubMed: PMID 9715377 · NCT01795248 · Diabetes Mellitus, Type 2
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint A, Raben A, Astrup A, et al. · J Clin Invest · 1998 · Background
PubMed: PMID 9449682 · NCT04122716 (S-LITE) · Obesity
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet · 1998 · Background
PubMed: PMID 9742977 · NCT02879409 · Diabetes Mellitus, Type 2

1996 (1 paper)

Impaired insulin-stimulated nonoxidative glucose metabolism in glucose-tolerant women with previous gestational diabetes.
Damm P, Vestergaard H, Kühl C, et al. · Am J Obstet Gynecol · 1996 · Background
PubMed: PMID 8623813 · NCT01795248 · Diabetes Mellitus, Type 2

1995 (4 papers)

Testing for baseline balance in clinical trials.
Senn S · Stat Med · 1995 · Background
PubMed: PMID 7997705 · NCT02879409 · Diabetes Mellitus, Type 2
Changes in energy expenditure resulting from altered body weight.
Leibel RL, Rosenbaum M, Hirsch J, et al. · N Engl J Med · 1995 · Background
PubMed: PMID 7632212 · NCT04122716 (S-LITE) · Obesity
The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.
Fehmann HC, Hering BJ, Wolf MJ, et al. · Pancreas · 1995 · Background
PubMed: PMID 7479679 · NCT02473809 (LIRABONE) · Diabetes Complications
Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance.
Celentano A, Vaccaro O, Tammaro P, et al. · Am J Cardiol · 1995 · Background
PubMed: PMID 7484905 · NCT01761318 (MAGNA VICTORIA) · Diabetes Mellitus, Type 2

1994 (1 paper)

Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response.
Hiatt WR, Wolfel EE, Meier RH, et al. · Circulation · 1994 · Background
PubMed: PMID 7923674 · NCT03883412 (ZQL007)

1993 (3 papers)

The diabetic heart: metabolic causes for the development of a cardiomyopathy.
Rodrigues B, McNeill JH · Cardiovasc Res · 1993 · Background
PubMed: PMID 1486584 · NCT02655770 · Diabetes Mellitus, Type 2
Baseline analysis of renal function in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group [corrected].
Molitch ME, Steffes MW, Cleary PA, et al. · Kidney Int · 1993 · Background
PubMed: PMID 8455366 · NCT02879409 · Diabetes Mellitus, Type 2
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. · N Engl J Med · 1993 · Background
PubMed: PMID 8366922 · NCT02879409 · Diabetes Mellitus, Type 2

1990 (1 paper)

Analysis of serial measurements in medical research.
Matthews JN, Altman DG, Campbell MJ, et al. · BMJ · 1990 · Background
PubMed: PMID 2106931 · NCT02879409 · Diabetes Mellitus, Type 2

1989 (1 paper)

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.
Dunaif A, Segal KR, Futterweit W, et al. · Diabetes · 1989 · Trial result
PubMed: PMID 2670645 · NCT05952882 · Obesity

1987 (2 papers)

Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man.
Lillioja S, Young AA, Culter CL, et al. · J Clin Invest · 1987 · Background
PubMed: PMID 3301899 · NCT03883412 (ZQL007)
Intermittent claudication, exercise, and blood rheology.
Ernst EE, Matrai A · Circulation · 1987 · Background
PubMed: PMID 3499255 · NCT03883412 (ZQL007)

1982 (1 paper)

Active and passive capillary control in red muscle at rest and in exercise.
Honig CR, Odoroff CL, Frierson JL, et al. · Am J Physiol · 1982 · Background
PubMed: PMID 7114231 · NCT03883412 (ZQL007)

1980 (1 paper)

Capillary microaneurysms in the human diabetic heart.
Factor SM, Okun EM, Minase T, et al. · N Engl J Med · 1980 · Background
PubMed: PMID 7351930 · NCT02655770 · Diabetes Mellitus, Type 2

1979 (1 paper)

Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects.
Zech LA, Grundy SM, Steinberg D, et al. · J Clin Invest · 1979 · Background
PubMed: PMID 221537 · NCT02765399 · Diabetes Mellitus, Type 2

1974 (1 paper)

Role of diabetes in congestive heart failure: the Framingham study.
Kannel WB, Hjortland M, Castelli WP, et al. · Am J Cardiol · 1974 · Background
PubMed: PMID 4835750 · NCT02655770 · Diabetes Mellitus, Type 2

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Fri, 08 May 2026 19:01:49 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).